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Hypoplastic left heart syndrome (HLHS) is a rare congenital heart defect in 
which the left side structures of the heart are severely underdeveloped and 
major, repeated surgeries throughout childhood are required for survival. 
Although the specific features can vary considerably, a series of abnormalities 
involving a diminutive left ventricle, a narrow ascending aorta and atretic or 
stenotic mitral and aortic valves, are always noted.  Based on inheritance of 
HLHS in families, a strong genetic component to HLHS has been suggested. 
Despite this, genetic studies have failed to reveal mutated genes that cause 
HLHS. A novel approach was taken in this study where it was hypothesised 
that there might be distinct anatomical subgroups of HLHS that differed from 
the current clinical classification. Thus, performing analyses on specific and 
homogeneous subgroups might be more amenable to understand which 
defects in HLHS are potentially primary and which secondary, and ultimately 
finding the causative gene(s) for HLHS. To accomplish this, archival formalin-
fixed HLHS hearts, obtained from Birmingham Children's Hospital, were 
carefully phenotyped and re-classified based on their ventricular morphology. 
It was suggested that genomic analysis of these hearts might reveal causative 
mutations for HLHS, but it is also recognised that formalin fixation causes 
damage to DNA. Consequently, a method was developed for extracting high 
quality DNA from formalin fixed tissue that could be used for PCR or Next 
Generation Sequencing (NGS). Through comparison of NGS whole exome 
sequencing data from formalin-fixed DNA with blood derived DNA, it was 
possible to determine bioinformatics processes to maximise the detection of 
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genomic variants with high specificity and moderate sensitivity from formalin-
fixed tissue. 
Finally, as a prelude to future genomic studies, the expression patterns of 
genes previously implicated in HLHS genes were analysed, focussing on the 
structures affected by HLHS and considering how they might link to the 
previously identified HLHS phenotypic subgroups. Although some HLHS-
implicated genes, including Gja1 and Sap130, showed very broad expression 
patterns, and thus it was hard to associate them with the HLHS phenotypes, 
other genes showed specific expression within the structures affected by 
HLHS. It was speculated that Notch3, Hand1, Foxc2, and Pcdha9 would be 
more likely to correlate with, based on their expression patterns, the 
abnormalities associated with various subgroups of HLHS. 
Together, these data suggest that the broad clinical spectrum of HLHS is made 
up of distinctive anatomical subgroups. DNA obtained from archival hearts 
should not be used for primary variant detection but could be used for 
corroboration of findings for example from family studies. Some postulated 
genes appear to be expressed in structures affected in HLHS and are more 
interesting candidates for the malformations, whilst others are more broadly 
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1.1 Overview  
Hypoplastic left heart syndrome (HLHS) is a rare congenital heart defect that 
without intervention leads to death in the first months of life. It is characterized 
by an underdeveloped and functionally insufficient left-side structure of heart, 
including non-apex forming hypoplastic left ventricle with atretic (imperforate) 
or stenotic (narrowed) mitral and aortic valves, and hypoplastic aorta (Figure 
1.1) (Crucean and Alqahtani et al., 2017).  
 
Figure 1.1: Diagrammatic sketches of a normal heart (A) and a hypoplastic 
left heart (B). 
HLHS is characterised by hypoplasia of left ventricle and aorta, stenosis and 
atresia of aortic and mitral valves, atrial septal defect and patent ductus 
arteriosus (red labelled). 
 
The underdevelopment of the left side of the heart is detectable antenatally 
and can be diagnosed as early as 15 weeks of gestation using routine 
sonographic scans (Andrews et. al., 2004; Galindo et al., 2009). Upon 
diagnosis of HLHS, parents are challenged with two options: termination or 
continuation of pregnancy. If continuation of pregnancy is chosen, the infant 
will have to either undergo an emergency three-step surgical procedure 
A) B) 
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(staged palliation) and/or a heart transplantation or go for comfort palliative 
care when the baby is born (Yabrodi et al., 2017). The staged palliation 
consists of three procedures: Norwood Procedure1 or Hybrid procedure2 
(performed as emergency operations shortly after birth), Bi-directional Glenn 
Operation (six months after first surgery), and Fontan Operation (approx. 18 
to 36 months after the second surgery). Thereafter, HLHS patients will require 
a life-long cardiac care and medications including anticoagulation and anti-
arrhythmics (Karbassi et al., 2017). Unfortunately, even when the staged 
palliation is initially successful, there is a significant risk of requiring a heart 
transplant in later life. Despite improvements in the medical and surgical 
management of HLHS and the usually good surgical results, this remains a 
very complex and life-threatening clinical problem.  
Remarkably, the knowledge of HLHS pathology remains limited and its causes 
remain unknown. Therefore, this section intends to review what is known about 
early heart development in order to try to understand the developmental 
origins of HLHS, and will outline the historical perspectives, epidemiology, and 






1 Norwood procedure involves atrial septectomy, joining the aorta to the pulmonary artery and inserting a shunt 
between the two branching pulmonary arteries and either the right ventricle or the branch of aorta to provide blood 
flow to the lungs. 
2 Hybrid procedure involves balloon atrial septectomy, placement of a stent to patent ductus arterious and banding 
the branching pulmonary arteries.  
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1.2 Formation of a normal heart 
The heart is one of the earliest organs to differentiate and function. Generally, 
the heart begins to beat at around 22-23 days in human embryos (Moore et. 
al., 2015). The development of the heart is highly similar between different 
species, but it has been intensively studied in mice (Vincent and Buckingham, 
2010). Therefore, this section will look at heart development from the 
standpoint of mouse cardiogenesis, highlighting relevant aspects of human 
development (Figure 1.2). 
 
 
Figure 1.2: Development of heart in human Carnegie stages (CS) and mouse 
Embryonic days (E). 
CS is a standardised and universal system for staging embryonic development. 
In human, there are 23 stages (first 60 days of development) and after that the 
term changes from embryo to fetus.  
 
 Overview of mouse heart development  
The development of the heart in mice begins at embryonic day 6.5 (E6.5), 
when the cardiac progenitor cells, derived from the epiblast and located lateral 
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to the primitive streak, undergo an epithelial to mesenchymal transition (EMT) 
and enter the primitive streak (Tam et al., 1997). These cells then migrate to 
form clusters in the ventro-lateral region of the embryo, in the new 
mesenchymal layer. By E7.5, the merged clusters are located under the head 
folds and establish the cardiac crescent, which is a horseshoe-shaped 
structure (Vincent and Buckingham, 2010). Through several signals from the 
underlying endoderm, including fibroblast growth factor (FGF), WNT signals 
and bone morphogenetic protein (BMPs), expression of cardiac transcription 
factors such as GATA binding protein 4 (Gata4) and Tbx5 are induced and 
differentiation of cardiac myoblasts begins (Kelly and Buckingham, 2002). As 
the embryo grows, it starts to fold laterally, the two ends of the cardiac crescent 
come together at the midline, and fuse to form a single primitive cardiac tube, 
which swiftly begins to pump blood (Moorman et al., 2003, Vincent and 
Buckingham, 2010). By E8, the cardiac tube is composed of an outer 
myocardial layer surrounded by an inner endocardial cell layer, and in between 
an extracellular matrix-filled cardiac jelly (Figure 1.3) (de Vlaming et al., 2012). 
The dorsal mesocardium, a mesenchymal fold, keeps connection between the 
posterior pericardial wall of the growing embryo and the cardiac tube. As 
embryonic development progresses, however, this attachment disappears and 
the heart tube suspends in the developing pericardial cavity through its 
connections at the venous and arterial poles (Kelly et al., 2014). At 
approximately E8.5, the cardiac tube undergoes a rightward looping process, 
which causes the developing chambers to be placed into their adult positions. 
The process of looping is still not fully understood although there are thoughts 
of cell additions that lead to elongation of the cardiac tube and extracellular 
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matrix irregular depositions (Taber et al., 1995) and buckling through gradual 
breakdown of dorsal mesocardium while growing of the heart tube between 
fixed poles (Garrec et al., 2017). The looping process as well as expansion of 
myocardium result in the formation of recognisable heart chambers 
(Buckingham et al., 2005). By E10.5, the heart has developed four-
recognisable chambers, but is still a tube until E14.0-E16.5 when the 
chambers and outflow tract are separated by the fusion of myocardial and 
membranous septa (Figure 1.3) (Buckingham et al., 2005).    
  




Figure 1.3: Development of the heart tube.  
At E6.5, cardiac progenitor cells, located lateral to the primitive streak, undergo 
an epithelial to mesenchymal transition (EMT) to enter the primitive streak. At 
E7.0 to E7.5, cells migrate to form cardiac crescent in which the two ends of the 
cardiac crescent fuse to form a single primitive cardiac tube. At E8.0, cardiac 
tube is formed by an outer myocardial layer surrounded by an inner endocardial 
cell layer, and in between an extracellular matrix-fil led cardiac jelly. Between 
E8.5 to E9.5, the cardiac tube undergoes a rightward looping and ballooning 
processes. By E10.5, the heart has developed four-recognisable chambers and 
at E14.5 the chambers and outflow tract are separated. CC, Cardiac crescent; 
SHF, second heart field (Dark green: myocardium and pale green: vascular 
endothelial cells); FHF, first heart field (Orange); MC, Myocardium/myocardial 
cells; EndoC, endocardium/endocardial cells; CJ, cardiac jelly; LV, left ventricle, 
RV, Right ventricle; LA, left atrium; RA, right atrium; OFT, outflow tract; Ao, 
aorta; Pul, pulmonary artery. 
  
Chapter 1: Introduction to HLHS 
8 
 
 Myocardial progenitor cells and regulatory genes 
Myocardial specification and differentiation are initiated in the splanchnic 
mesoderm, and in mouse, they continue for a 3 day period during the phases 
of cardiac tube elongation and heart looping (Kelly et al., 2014). The addition 
of cells at the end of the heart tube initiates cardiac tube growth. As mentioned 
previously, after the suspension of heart tube in the pericardial cavity, the 
mesodermal cells maintain connection with the heart tube through posterior 
venous and anterior arterial poles of the heart (Buckingham et al., 2005; Kelly, 
2012). Retrospective lineage analysis and genetic tracing studies have shown 
that myocardium originates from two distinctive cell lineages: the first heart 
field (FHF) and the second heart field (SHF).  
 The first heart field (FHF) 
The early wave of mesodermal cells that give rise to the initial heart tube and 
express muscle-specific proteins is referred to the first heart field (FHF), which 
originates from the cardiac crescent (Buckingham et al., 2005). The FHF cells 
provide a scaffold for later growth and have mainly a left ventricular identity, 
although they also contribute to the atria (Kelly et al., 2014).  
1.2.2.1.1 Genes involved in FHF regulations 
There are several transcription factors expressed in the FHF, including Nkx2.5, 
Gata4, Tbx5 and Mesp1. Although Nkx2.5 is an essential transcription factor 
for the FHF, it is also expressed in the SHF, which indicates a central 
regulatory role for Nkx2.5 during cardiac development and losing Nkx2.5 
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function causes impairment of cardiogenesis (reviewed in Colombo et al., 
2018). Likewise, knockout the transcription factor GATA binding protein 4, 
Gata4, caused cell migration failure and eventually led to cardiac bifida where 
two independent hearts started to form on either side of the embryo (reviewed 
in Zaffran et al., 2004; Buckingham, 2016). Furthermore, identification of 
transgenic genes such as Tbx5 specific to FHF has opened the way to 
functional analysis not only to the FHF but also to SHF (Vincent and 
Buckingham, 2010). 
 The second heart field (SHF) 
The SHF cells are detected initially lying medially and extending posteriorly to 
the cardiac crescent (the FHF; Hami et al., 2011). However, upon fusion of the 
cardiac crescent, the SHF cells relocate behind the heart tube, anteriorly 
adjacent to the outflow tract, and posteriorly adjacent to the sinus venosus and 
venous pole (reviewed in Buckingham, 2016). As the heart tube is in continuity 
with the dorsal mesocardium, this allows addition of undifferentiated cells from 
the SHF. Even after the dorsal mesocardial connection disappears, the SHF 
cells continue to add to the heart poles forming myocardium through the 
venous and arterial poles of the heart (Felker et al., 2018). This addition of 
SHF cells lasts for several days in mouse embryos, as myocardium of the 
caval veins and pulmonary is not fully formed until E12.5 or 40 days of human 
development (Buckingham, 2016). The SHF delivers a pool of cardiac 
progenitor cells that are conserved as a population of proliferating and non-
differentiated cells. The behaviour of these cells is largely controlled by 
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transcription factors and signalling molecules, which have been identified as 
markers for these cells (Vincent and Buckingham, 2010).  
1.2.2.2.1 Genes involved in SHF regulations 
The progenitor cell population of the SHF has several genes that are 
specifically expressed in these cells. These genes have been considered as 
the key markers for the SHF population. Islet1, for example, has long been 
known to be the major marker for the SHF cells (reviewed in Vincent and 
Buckingham, 2010; Kelly, 2012). However, it was reported that Islet1 was also 
expressed in the FHF progenitors, although transiently and at a low level, 
suggesting less sensitivity of this marker (Vincent and Buckingham, 2010). 
Therefore, other gene markers for the SHF progenitors have been identified 
including genes encoding for transcription factors such as Foxc2, Mef2c-AHF-
Cre, Nkx2-5-Cre, Tbx1, and the chromatin remodelling protein SWI-/SNF-
related, matrix-associated, actin-dependent regulator of chromatin, subfamily 
D, member 3 (Smarcd3) (Buckingham, 2016). All these genes are expressed 
in the SHF and also involved in myocardial differentiation.  
Although the transcription factors and components of signalling pathways 
described above show essential roles in cardiogenesis, they are not 
necessarily cardiac specific (Buckingham and Rigby, 2014). Loss of cardiac 
regulatory genes can lead to embryonic lethality at early stages or cause 
multiple defects such as those seen in syndromes where the heart is affected, 
but other organ systems are also disturbed. This is the case for Tbx1, which 
in humans is associated with DiGeorge syndrome. This syndrome not only 
Chapter 1: Introduction to HLHS 
11 
 
causes cardiac defects including persistent truncus arteriosus / common 
arterial trunk, but also craniofacial abnormalities (Papangeli and Scambler, 
2013). This is because Tbx1 is involved in development of the endoderm and 
ectoderm of the pharyngeal region that is fundamental for both cardiac and 
cranial neural crest, as well as its role in the SHF (Buckingham, 2016). 
Therefore, genes that are specific to the SHF with no expression outside of 
this progenitor population, are the best candidates for malformations that are 
restricted to SHF-derived regions of the heart.  
 Development of the left ventricle  
The left ventricle originates from the first heart field (FHF) and can first be seen 
after heart looping, as the primary heart tube elongates and bends to show an 
inner and outer curvature. The outer curvature gives rise to the main chamber 
and the apical parts of the left and right ventricles through a ballooning process 
(Moorman et al., 2007) (Figure 1.3). Eventually with remodelling, the inner 
curvature is very small and observed as the area between the left atrial wall 
and the root of the aortic valve (Crucean and Alqahtani et al., 2017).  
The earliest phases of ventricular growth and development begin during the 
looping process (Moorman et al., 2003) as ventricular trabeculations appear. 
It is presumed the trabeculare network of myocardial muscle strands develop 
and functions to increase myocardial oxygen delivery whilst the coronary 
circulation is not yet established (Samsa et al. 2013), but it may also act as a 
preferential network for electrical activity prior to the establishment of the 
mature conduction system (Hatcher and Basson, 2009). Whilst the trabeculae 
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are forming the underlying compact myocardium also thickens, the 
trabeculated myocardium has a distinctive programme of gene expression that 
varies from that of the compact ventricular wall myocardium (Qi et al., 2007). 
In this section, the remodelling events that lead to formation of trabecula as 
well as the formation of ventricular septum will be discussed.   
 Left ventricular trabeculae 
The initial formation of the trabeculae starts in the mouse at E9.5 and in the 
humans at CS12 (by the end of the fourth gestational week) (Figure 1.2). 
Because trabeculation occurs prior to ventricular septation, most of the 
myocardial mass and ventricular wall thickness in the embryonic heart is 
formed by the trabeculae (Wessels and Sedmera, 2003). In fact, the 
trabeculated myocardium has a distinctive programme of gene expression that 
varies from that of the ventricular wall myocardium (Qi et al., 2007). During 
cardiac development, the trabeculae undergo remodelling events that 
influence their arrangement and density. These remodelling events have been 
suggested to associate with formation of different cardiac structures, including 
delineation of papillary muscles, conduction system, and the coronary 
vasculature (Liu et al. 2010). Several genetic manipulation studies, primarily 
in mouse, have shown that disruptions of the normal meshwork of the 
trabeculae arrangement leads to severe consequences, such as an immature 
ventricular conduction system, dysfunctional myocardial contractility or even 
to embryonic lethality (Samsa et al., 2013; Liu et al. 2010).  
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As ventricular septation occurs, between E10.5 to E14.5 in mouse, the 
trabecular meshwork becomes more complex and thickly packed, with no 
great differences in complexity between the left and the right ventricles (Captur 
et al., 2016; Moorman et al., 2003). At E12.5, the left and right ventricular free 
walls are thickened along with the interventricular septal wall. From E14.5, this 
thickening in the septal and free walls is continued while the complexity of the 
trabeculae is reduced. Strikingly, at E14.5, the arrangement of the trabecular 
meshwork becomes noticeably aligned illustrating an “apex-to-base” 
orientation. Also, the trabecular strands now merge together providing the 
base for the developing papillary muscles (Towbin et al., 2015; Captur et al., 
2016). At this stage, in the mouse and human, differences between left and 
right ventricles can be seen. For example, the surface of the left ventricular 
septal wall is trabeculated, whereas the surface of the right ventricular septal 
wall is relatively smooth. Also, in the humans, the left ventricular myocardium 
usually has more trabecular compaction compared to the right ventricular 
myocardium, with trabeculae much more obvious in the mature right ventricle 
than in the left (Towbin et al., 2015).   
The trabeculations of myocardium in the developing heart to form the inner 
ventricular walls, and aggregation to generate the compact myocardium of the 
ventricular free walls in the mature heart, remain poorly understood. There 
have been, however, two models to explain the potential consolidation of 
myocardium from a trabecular layer to compact muscle (Figure 1.4). The first 
model proposed the expansion of the fetal compact myocardium into the 
trabecular layer to form the mature inner myocardial wall (Kirby, 2007). The 
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second model proposed merging the fetal trabeculated myocardium together 
to form the mature inner myocardial wall (Wessels and Sedmera, 2003). Both 
models suggested that the expansion of compact myocardium leads to the 
development of the outer myocardial wall/ventricular free wall. However, they 
both suggested a different mechanism for transformation of the trabeculated 
layer into the inner myocardial wall. Recently, a fate mapping study has 
proposed a new model that combines the two previous models, as well as 
adding a new component by identifying a middle hybrid myocardial zone 
(Figure 1.5). The new proposed model suggests that expansion of the 
embryonic compact myocardium into the trabecular layer in an epicardial-to-
endocardial orientation causes condensation of the trabeculated myocardium, 
subsequently closing the spaces within the trabecular meshwork, which 
eventually forms the inner myocardial wall (Tian et al., 2017). In this model, 
the contribution of the compact myocardium to the trabecular layer that forms 
the inner myocardial wall is limited to the hybrid myocardial zone. The high 
proliferation rate of the fetal compact myocardium compared to the 
trabeculated myocardium allows inward expansion of compact myocardium 
rather than outward expansion of the trabeculated myocardium. Altogether, 
although there are several models that have been proposed to explain the 
postnatal transformation of trabeculated myocardium into compact 
myocardium, the cellular process of trabecular compaction remains 
controversial.  
  




Figure 1.4: The two proposed models for myocardium compaction 
transformation in developing heart. 
Model 1 indicated expansion of the compact myocardium from the outer wall into 
the intertrabcular space forming the inner myocardial wall in postnatal heart. 
Model 2 indicated the compact myocardium fused together to form the inner 
myocardial wall. IMW, inner myocardial wall; OMW, outer myocardial wall (Image 
obtained from Tian et al., 2017). 
 
 
Figure 1.5: The recent model for myocardium compaction.   
This model combines the two previously reported models with a novel 
identification of a hybrid myocardial zone that contains the contribution of 
compacted myocardium into the trabecular layer (image obtained from Tian et 
al., 2017).   
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 Formation of the ventricular septum  
The initial appearance of the ventricular septum observed is at E10.5 in 
mouse, and at CS12 in human (by the end of the fourth gestational week) 
(Figure 1.2). As the heart tube undergoes the looping and ballooning process, 
the formation of the muscular ventricular septum begins at the interventricular 
groove (Anderson et al., 2014), whereas the membranous region of the 
ventricular septum develops at the atrioventricular groove by the endocardial 
cushions (Wiegering et al. 2017) (Figure 1.6 A-C). In parallel with ventricular 
growth, at E10.5 to E11.5 in mouse, proliferation of cells located in the 
ventricular wall establishes the formation of the muscular region in the 
ventricular septum (Figure 1.6 C-D) (Franco et al. 2006). As trabecular 
meshwork develops and forms the inner ventricular wall, trabeculated 
myocardium fuse with the growing muscular ventricular septum and boost the 
septum growth (Figure 1.6 D-E) (Contreras-Ramos et al., 2008). Hence, this 
highlights the importance of the trabeculated myocardium and the normal 
development of the ventricular wall for the formation of the muscular 
ventricular septum (Wiegering et al. 2017). Because the ventricular septum 
forms between the left and right ventricles, it is composed of a combination of 
cardiomyocytes derived from both ventricles (Franco et al. 2006). As the 
muscular ventricular septum grows, the membranous ventricular septum 
originating from the atrioventricular endocardial cushion cells concomitantly 
grows to eventually fuse with the muscular ventricular septum in a yet 
unknown fashion (Figure 1.6 F-G) (Wiegering et al. 2017). 




Figure 1.6: Ventricular septum formation.  
(A-B) cardiac four-chambered shaped through looping and ballooning process. 
(C) Proliferation of myocardial cells (purple) from the ventricular wall causes 
outgrowth of the muscular region (dark blue) of the ventricular septum. (D) 
Trabeculated myocardium in the ventricular wall also contribute to the 
development of the septum. (E) In an unknown process, the membranous 
ventricular septum derived from the endocardial cushion cells (bright blue) 
develops and grows in the direction of the muscular ventricular septum. (F-G) 
Fusion of the muscular and membranous ventricular septa and development of 
the atrioventricular valves. OFT, outflow tract; RV, right ventricle; LV, left 
ventricle; RA, right atrium; LA, left atrium (Obtained and modified from Wiegering 
et al. 2017).  
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 Development of the aortic valve 
The aortic valve develops from the outflow tract cushions, which are 
expansions of cardiac jelly that are found in between an outer myocardial layer 
and an inner endocardial layer along the length of the unseptated outflow tract. 
The cardiac jelly is an acellular extracellular matrix; up-regulation of 
extracellular matrix secretion; transformation of endocardial cells to form 
mesenchyme and contribution of neural crest-derived mesenchymal cells 
leads to its expansion. SHF-derived endocardial cells undergo endothelial–
mesenchymal transformation (EndoMT) and invade into the cardiac jelly, 
particularly at the proximal outflow tract. This process occurs at E10.5 in 
mouse and 28 days post-fertilization in human (Figure 1.7) (Henderson et al., 
2018). At the same time, neural crest cells migrate into the distal part of the 
outflow tract to stimulate fusion of the left and right endocardial cushions and 
promote the septation of the outflow tract in a zipperlike fashion to form the 
aorta and pulmonary trunk. The aortic valve is formed at the distal part of the 
fused endocardial cushions, at the same level as the anterior and posterior 
intercalated cushions. The intercalated cushions primarily are first seen at 
E10.5 in mouse. Remodelling of these cushions to form the posterior (non-
coronary) and anterior leaflets of the arterial valves was first described in 1942 
by Kramer. Kramer also proposed that the left and right leaflets of the aortic 
and pulmonary valves developed from the main outflow cushions, and that 
these are different from the intercalated cushions. He suggested that the left 
leaflets of the aortic and pulmonary valves are formed by the superior main 
cushion, whereas the right leaflets for both valves are formed by the inferior 
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main cushions (Figure 1.8). This suggestion was supported and extended by 
Phillips et. al. (2013), who showed that neural crest cells and EndoMT-derived 
cells were observed in the left and right leaflets, but not in the posterior (non-
coronary) and anterior leaflets of the aortic and pulmonary valves. Recently, it 
was proposed that the intercalated cushions were originated from 
undifferentiated SHF-derived cells, which by a Notch-Jag dependent 
mechanism, these cells became differentiated (Figure 1.8) (Eley et al., 2018). 
Altogether this suggests that the anterior and posterior leaflets have a distinct 
origin to the left and right leaflets.  
 
 
Figure 1.7: Development of aortic valve.  
The endocardial cushions in the outflow tract undergo epithelial-to-mesenchymal 
transformation (EMT), generating the primitive valve at E9.5, and trigger 
proliferation of mesenchymal cells that remodel and mature into three thin valve 
leaflets. Image obtained from (Macgrogan et al., 2016). 
 
 
By E12.5, the primitive leaflets of the aortic and pulmonary valves are 
developed, and the aorta and pulmonary truck are separated. By E13.5, two 
free-standing arterial trunks are formed along with their respective three-leaflet 
valves that permit unidirectional blood flow. However, at these stages the 
arterial valve leaflets have not matured, as they resemble solid bulky 
structures with no valve sinuses formed. Subsequently the cushions remodel 
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by a lengthening/elongation process that sustains coaptation of valve 
components with growth and maturation into flat thinned structures, and the 
sinuses form, so that by postnatal day 2, the valves are completely formed. 
However, little is known about these latter stages of arterial valve remodelling. 
  
Figure 1.8: Development of aortic valve leaflets.  
(A) Cartoon based on (Kramer, 1942) showing the fusion of superior and inferior 
main cushions along with intercalated cushion (IC) forms the three leaflets of 
aortic valve (AoV) and pulmonary valve (PulV). (B) cartoon based on (Eley et 
al., 2018) il lustrating how the intercalated valve swelling, which found at E10.5 
within the outer wall of the outflow tract, expands at E11.5 and by E12.5 
separates from the wall remodelling the aortic and pulmonary valve leaflets. Ao 
IC: aortic valve intercalated cushions, Pul IC: pulmonary vavle intercalated 
cushions. Colour scheme summarised the contributions of cardiomyocytes 
(green), endothelium and EndMT-derived cells (red), neural crest cells (purple) 
and second heart fields (light green) in the leaflets of aortic and pulmonary 
valves. Image obtained from Eley et al., 2018. 
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 Development of the mitral valve 
Similar to the aortic valve, the mitral valve develops between the left atrium 
and left ventricle from endocardial cushions, although in this case in the 
atrioventricular canal (Figure 1.9). However, there are key points where 
development of the atrioventricular canal cushions differs from that of the 
outflow tract cushions. Unlike the outflow tract cushions, the atrioventricular 
canal endocardium is not derived from the second heart field (SHF). Lineage 
tracing studies have shown that only the outflow tract cushion mesenchymal 
cells express the SHF-specific markers: Mef2c-AHF-Cre and Isl1-Cre 
(Wessels and Sedmera, 2003). Moreover, the aortic valve received a large 
contribution of neural crest cells to the outflow cushions, whereas the mitral 
valve received small/no contributions from these cells. Also, the maturation 
process of the aortic valve and mitral valve are different, as the mature leaflets 
have distinct structure; the aortic valve has free edged leaflets, whereas the 
mitral valve retains tendinous chords leaflets (Butcher and Markwald, 2007). 
  





Figure 1.9: Development of the mitral valve.  
Similar to the development of the aortic valve, the endocardial cells undergo 
endothelial-to-mesenchymal transition (EndMT) and migrate into the cardiac 
cushion of the atrioventricular canal to proliferate and secrete extracellular 
matrix proteins that lead to bend the valve leaflets along the blood flow. Further 
remodelling occurs as the valve develops, including formation of fibrous chordae 
tendineae that distinguish the mitral valve from the aortic valve. 
  
The initial formation of the mitral valve begins by the two major endocardial 
cushions that develop opposite to each other at the wall of the atrioventricular 
canal. These two major cushions are known as the inferior cushion and 
superior cushion (Figure 1.9) (Wessels et al., 2012). As heart development 
proceeds, the two major cushions fuse and thus the atrioventricular canal 
separates into a left and right atrioventricular orifice. Also, fusion of the major 
cushions, particularly the inferior cushion, leads to the formation of the septal 
leaflet in the tricuspid (right) valve and the aortic leaflet of the mitral valve. 
Whereas fusion of the superior major cushion contributes only to the formation 
of the aortic leaflet of the mitral valve (Wessels and Sedmera, 2003; Lamers 
et al., 1995). At the same time, an additional set of endocardial cushions, 
originating from mesenchymal protrusions, begin to form on the left and right 
lateral aspects of the atrioventricular canal. These cushions are known by the 
left and right lateral cushions and composed of epicardial-derived cells that 
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replaced the endocardial-derived cells (Wessels and Sedmera, 2003; Butcher 
and Markwald, 2007). Both the left and right lateral cushions play a role in the 
valve morphogenesis, as the left lateral cushion contributes to the formation 
of the mural leaflet of the mitral valve, whereas the right lateral cushion is 
responsible for the formation of anterosuperior leaflet of the tricuspid valve. 
However, the mechanisms in which these cushions develop and differentiate 
remain poorly understood (Butcher and Markwald, 2007; Wessels et al., 2012).   
Remodelling event occurs to form the free-moveable leaflets of the mitral and 
tricuspid valves through myocardial delamination. During this process, the 
inferior atrioventricular cushions connected to the myocardial layer separate 
from the myocardial wall of ventricle, whilst retaining attachment at the cranial 
and caudal edges, forming the papillary muscles (Figure 1.10) (Markwald et 
al., 1977; Nowak et. al., 2011). As development progresses, the leaflets 
gradually lose the myocardium at their ventricular side and develop 
mesenchymal tissue strands, which eventually progress to generate the 
tendinous chords (Chesler et. al., 1971; Wessels and Sedmera, 2003). 
However, these processes remain poorly understood.  
 




Figure 1.10: Remodelling of the atrioventricular cushions to form the 
atrioventricular valve.  
Atr, atrium; epi, epicardium; AV-myo, atrioventricular myocardium; vent, 
ventricle; tendon, tendinous chords. Image obtained from (Wessels and 
Sedmera, 2003).   
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 Formation of atrial septum 
The atrioventricular cushions contribute to the process of atrial septation.  After 
fusion of the major atrioventricular cushions (AVC), a large mesenchymal 
“bridge” is formed linking the atrioventricular canal posterior wall to the cardiac 
anterior wall. The mesenchymal component located posteroinferiorly connects 
to the endocardial cushions, and to the dorsal mesocardial projection and the 
mesenchymal cap (cap) on the leading edge of the primary interatrial septum 
(IAS) (Figure 1.11) (Wessels and Sedmera, 2003). At this stage, the primary 
interatrial foramen between left and right atrium has not closed, thus the 
mesenchymal bridge (cap) covers the atrial foramen between the fused major 
cushions (AVC) (Figure 1.11). 
 
Figure 1.11: Contribution of the major atrioventricular cushions and the 
primary atrial septum along with the mesenchymal cap to the atrial 
septation at E10.5.  
IAS, interatrial septum, “cap” mesenchymal cap; sAVC, superior atrioventricular 
cushions; iAVC, inferior atrioventricular cushions; IVS, interventricular septum; 
LV, left ventricle; RV, right ventricle; LA, left atrium; RA, right atrium. Image 
obtained from (Wessels and Sedmera, 2003). 
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As development continues, the atrial foramen closes by fusion of the 
atrioventricular major cushions and the mesenchymal cap located on the 
primary interatrial septum (Wessels and Sedmera, 2003; Kramer, 1942). Such 
remodelling eventually leads to the formation of the membranous 
atrioventricular septum, as it occurs between the muscular interventricular 
septum and the interatrial septum.  
  




Throughout human life, the circulatory system changes and adapts to be 
compatible with the needs of the body. The foetal circulation is different from 
the adult circulation because of the placenta, the presence of foramen ovale, 
and the ductus arteriosus (Kiserud and Acharya, 2004; Whitaker, 2001). The 
following section will look at the foetal circulation with respect to the changes 
that occur after birth and how these changes are important for cardiac 
malformations.  
 Physiology of foetal, transitional and post-natal circulations 
Since the lungs in the foetus are not completely developed, the foetal 
circulatory system relies mainly on the placental circulation and other 
supporting structures, including the foramen ovale and ductus arterious, and 
the ductus venosus (Kiserud and Acharya, 2004) (Figure 1.12).  
 




Figure 1.12: diagram shows the foetal circulation.  
Modified from Murphy (2005). 
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In the foetus, the placenta delivers oxygenated blood through the umbilical 
vein to the inferior vena cava and ductus venosus in the liver. In return, a mixed 
of oxygenated/deoxygenated blood goes through the two umbilical arteries of 
the umbilical cord back to the placenta (Whitaker, 2001). Consequently, gas 
exchange occurs in the placenta without direct contact between the mother 
and fetal blood flows (Kiserud and Acharya, 2004). When the oxygenated 
blood from the placenta enters the right atrium through the inferior vena cava, 
a large stream of the blood passes to the left atrium via the patent foramen 
ovale. Then, it flows from the left atrium to the left ventricle into the ascending 
aorta to the upper regions of the foetus. Therefore, the most oxygenated blood 
passes mainly to the brain and upper extremities. However, the other stream 
of blood that enters the right atrium through the inferior vena cava joins the 
blood stream that comes from the superior vena cava, which is blood returning 
from the upper regions of the foetus. Hence, this blood stream has limited 
oxygen levels compared to the blood that passes to the left atrium (Whitaker, 
2001). This limited oxygenated blood then passes into the right ventricle where 
it bypasses the lungs, shunts via the ductus arteriosus directly to the 
descending aorta, and finally goes to the lower part of the body (Kiserud and 
Acharya, 2004). The ductus arteriosus is a blood vessel connecting the 
pulmonary trunk to the descending aorta and it is a unique feature of the foetal 
circulation. At this stage, the diameter of the ductus arteriosus is comparable 
to that of the ascending aorta and hence the blood predominantly flows into 
the aorta and only a small stream goes to the lungs (Whitaker, 2001; Kiserud 
and Acharya, 2004). 
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At birth, closure of the umbilical cord eliminates the umbilical vessels, causing 
a dramatic drop in the blood flow through the ductus venosus and inferior vena 
cava (Kiserud and Acharya, 2004). This subsequently causes a passive 
closure of the ductus venosus within 3 to 10 days of birth.  It also leads to 
increased blood flow in the pulmonary arteries and consequently in the 
pulmonary veins that direct blood to the left atrium. This therefore results in 
the left atrial pressure exceeding the right atrial pressure, and eventually 
causes the flap of the foramen ovale, located between the two atria, to push 
against the atrial septum (Whitaker, 2001). This effectively causes the initial 
closure of the foramen ovale, which occurs within a few minutes to hours of 
birth. Although the closure of the foramen ovale happens in the majority of 
babies, there are around 25% of the adult population have a patent foramen 
ovale (Almekhlafi et al., 2009). The permanent closure of foramen ovale 
occurs a few days after birth where the septum primum fuses with the septum 
secundum closing the foramen ovale and leaving a thin fibrous layer, termed 
the fossa ovalis (Kiserud and Acharya, 2004; Whitaker, 2001). As a result, the 
blood entering the right atrium can only flow into the right ventricle. The ductus 
arteriosus closes within two days of birth through a complicated process 
involving removal of prostaglandins (relaxation hormone) and a rise in blood 
oxygen tension (Coceani and Baragatti, 2012).  
Overall, although there are several aspects where the foetal circulation differs 
from the neonatal circulation, and the foetal circulation is essential for normal   
foetal development. However, a healthy foetal circulation does not guarantee 
a normal foetal heart as the foetus with a malformed heart can survive 
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pregnancy by relying on the foetal aspects of the circulation, such as the 
ductus arteriosus. Thus, babies with severe heart malformations such as 
Hypoplastic Left Heart Syndrome (HLHS) can survive pregnancy and birth 
without problems, as long as the ductus arteriosus is open. However, after 
birth, when the ductus arteriosus closes, the baby can become acutely ill, and 
will die if untreated, as there is no systemic circulation (Murphy, 2005).     
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1.4 Hypoplastic left heart syndrome  
Hypoplastic left heart syndrome (HLHS) is a rare congenital heart defect that 
without intervention leads to death in the first months of life. It is characterized 
by an underdeveloped and functionally insufficient left heart-aorta complex, 
including hypoplastic aorta and none-apex forming hypoplastic left ventricle 
with atretic or stenotic mitral and aortic valves (Crucean and Alqahtani et al., 
2017). In this section, HLHS will be described taking a historical and 
nomenclature perspective. In addition, epidemiology, potential causes, and 
main genes implicated in HLHS will be discussed. 
 Nomenclature and historical perspectives of HLHS 
Hypoplastic left heart syndrome (HLHS) was described by Lev in 1952, as 
underdevelopment of the aortic arch with a small ascending aorta and small 
left atrial and ventricular chambers. At that time, HLHS was known as 
“hypoplasia of the aortic tract complexes” (Lev, 1952). However, in 1958, it 
was recognised as a syndrome by Noonan and Nadas. They broadly defined 
HLHS to include a range of lesions that included vestigial left ventricle with 
aortic and mitral atresia and hypoplasia or atresia of the aortic arch (Noonan 
and Nadas, 1958). Henceforth, several other definitions have been suggested 
to describe HLHS, which eventually made the specific definition of this 
syndrome complicated. For example, Feinstein and colleagues described 
HLHS as “genetically inherited abnormalities in the valves, such as aortic valve 
atresia and mitral valve regurgitation, accompanied by dilated left atrium and 
a hypoplastic and fibrotic left ventricle, and usually a small patent foreman 
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ovale” (Feinstein et. al., 2012). However, Nemes and colleagues defined 
HLHS as “defects during cardiogenesis causing enlargement of the right 
ventricle and atrium, pulmonary venous hypertension, atrial septal defect, 
hypoplastic left ventricle and ascending aorta, and stenotic or atretic valves” 
(Nemes et. al., 2014). These two definitions differ based on the author’s 
ideological theory of HLHS; the Nemes’s theory was mainly about defects in 
the right-sided structures that lead to defects in the left-side of the heart, 
whereas in Feinstein’s theory the defects were predominantly in the left-sided 
structures of the heart. Therefore, there was no clear agreement as to how 
precisely HLHS should be described, although recently the term “classical 
HLHS” had gained some recognition. Classical HLHS was defined as a 
spectrum of cardiac structural anomalies with a common obstructive lesion 
including atresia or stenosis of the left-sided heart structures (Simpson, 2000). 
According to Simpson, the term “classical HLHS” should only be used to 
describe two cases: (1) atresia of mitral and aortic valves with indemonstrable 
or slit-like left ventricular cavity, and (2) atresia of the aortic valve with patent 
mitral valve and detectable hypoplastic left ventricle. Other instances, where 
hypoplastic left ventricle was accompanied with severe aorta coarctation, 
critical aortic stenosis, or unbalanced atrioventricular septal defect, should be 
termed HLHS variants (Simpson, 2000). Additionally, Tchervenkov and 
colleagues referred to the mild degree of left ventricle hypoplasia with small 
mitral and aortic valves, but without core valve stenosis, as hypoplastic left 
heart complex (HLHC) (Tchervenkov et al, 2000). Most recently, the Eleventh 
Iteration of the International Classification of Diseases (ICD-11) (Franklin et al. 
2017), which has gained a globally accepted nomenclature tree for CHD and 
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recognised by the international nomenclature committee, has defined HLHS 
as a spectrum of heart malformations that involve a small non-apex-forming 
left ventricle with atresia, stenosis or reduction in size of the mitral and aortic 
valves, and hypoplasia of the aorta. This definition required normally aligned 
great arteries without atrioventricular septal defect (Franklin et al. 2017). 
Therefore, the ICD-11 has provided the most definitive definition for HLHS. 
Although there have been various suggested definitions for HLHS, they all 
shared a common approach which reflected clinical approaches to treatment. 
As a result, HLHS has for many years been clinically classified into four 
subgroups: aortic and mitral atresia (AA/MA), aortic atresia and mitral stenosis 
(AA/MS), aortic stenosis and mitral atresia (AS/MA), and aortic and mitral 
stenosis (AS/MS) (Tchervenkov et al, 2000). However, there have not been 
any attempts to classify HLHS into discrete subtypes based on the anatomical 
features of the hypoplastic ventricle or its developmental origin. Hence, this 
study intends to evaluate HLHS based on its anatomical features, ignoring 
approaches to treatment, and thereby to attempt to shed light on whether it is 
a spectrum of abnormalities or falls into discrete subtypes. In order to do this, 
HLHS was characterised according to the ICD-11 definition. The hypoplasia 
of the left heart causes malformation of the left-sided structures, leading to 
non-apex forming left ventricle, a combination of the mitral and aortic valve 
atresia or stenosis, hypoplasia of the ascending aorta, and atrial septal defects 
(Franklin et al. 2017). Other HLHS variants, double outlet right ventricle, 
atrioventricular septal defects, ventricular septal defect, transposition of the 
great arteries, and common arterial trunk were excluded (Franklin et al. 2017).  




Epidemiology is the study of how and when diseases or conditions occur and 
is often used to suggest causative factors, through incidence rate and the 
outcome of relevant managements as survival or mortality rate. In this section, 
the incidence, and survival and mortality of HLHS will be discussed with 
emphasis on any suggested aetiological factors. 
 Incidence 
Several studies have reported the frequency of HLHS over the last 40 years 
(Figure 1.13 and Appendix Table 1). Some have reported the incidence within 
the whole population, whereas others have indicated the frequency within 
patients with congenital heart defects (CHD). According to Hoffman (2002), 
the population incidence of CHDs is 0.8% and this therefore was used as a 
basis for comparing these studies. Whilst no studies have specifically sought 
to determine variations in the incidence of HLHS, or CHD in general, between 
countries or over time, the incidence of HLHS in European-based studies has 
remained at approximately 2-3% of all CHD or 4/100,000 live births since 1980 
(Grech, 1999).  




Figure 1.13: the line chart shows the incidence percentage of HLHS of all 
CHD between 1977 and 2006.  
Colour scheme represents the population-based region: green, Europe; yellow, 
USA and Canada. 
 
There are many factors that can influence the incidence rate of HLHS including 
gender, twinning, and association with chromosomal abnormalities. Based on 
clinical and population studies, HLHS is predominantly found in males and has 
an approximate ratio of male to female (1.5:1) (Karamlou et.al, 2010; Ohye et. 
al., 2010). The overall reported incidence of HLHS in all CHD was 7% 
according to a population-based study, with 1% prevalence of HLHS (Lopriore 
et.al., 2007). Of interest, HLHS has been reported in monozygotic twins in 
which both foetuses had HLHS diagnosed at week 15 of gestation (Andrews 
et. al., 2004). Another study also reported monozygotic twins in which only one 
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regurgitation (Negishi et.al., 1995). These studies not only suggest the 
possibility of a genetic explanation, but also showed that HLHS incidence is 
relatively affected by twinning particularly when they are affected with other 
CHDs (see section 1.4.3.2.2). In addition, it has been reported that 20% of 
CHDs are associated with chromosomal abnormality, where HLHS accounted 
for 2.4% of all CHDs that are associated with chromosomal abnormalities; 
such as Turner, DiGeorge, and Downs syndromes (Brenner and Kuehl, 2011). 
Overall, although all these factors suggest a genetic aetiology for HLHS, they 
also play a major role in conflicting the incidence rate for HLHS.  
 Survival and mortality  
Currently, the three to five-year survival rates for infants undergone the stage 
I repair of HLHS is estimated at 70%, whereas around 90% for of children (up 
to 12 months) survive the stage II repair (Siffel et al 2015). However, it is 
generally accepted that HLHS is a severe form of CHD and is the leading 
cause of cardiac death in the first month of life (Surmiak et al, 2015). In 
general, the mortality rate of HLHS without surgical intervention accounts for 
25% to 40% of death from all CHDs, whereas it accounts for whilst 4% -16% 
of HLHS death occur during the surgical interstage period (Siffel et al., 2015; 
Simsic et al., 2005). Since there are different clinical subgroups of HLHS, the 
frequency of each HLHS subgroup could be related to the mortality rate. The 
frequency of the clinical subgroup with aortic atresia and mitral atresia 
(AA/MA) has been suggested to account for 50% of HLHS patients, whereas 
the subgroups with aortic atresia and mitral stenosis (AA/MS) and aortic 
stenosis and mitral stenosis (AS/MS) are found in 26% and 23% of HLHS 
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patients, respectively (Glatz et. al., 2008). Strikingly, the mortality rate of the 
AA/MS subgroup during the surgical interstage period was suggested to be 
higher (21%) than that for other HLHS subgroups (6% for AA/MA and 0% for 
AS/MS) (Glatz et. al., 2008). Similarly, another study had also shown a high 
mortality rate (29%) for the AA/MS subgroup compared to the other HLHS 
subgroups (7.9% for AA/MA and AS/MS) (Vida et. al., 2008). The high 
mortality rate in this specific subgroup (AA/MS) of HLHS has been investigated 
and some possible causes were suggested. This involved the presence of 
pathological abnormalities within the left ventricle, such as interstitial fibrosis, 
calcifications, and myocardial necrosis (Sugiyama et al., 1999). Also, 
angiographic and pathologic studies have suggested the appearance of 
abnormal left ventricle–subepicardial coronary artery communications causing 
the failure in HLHS treatment management (Baffa et al., 1992). Overall, 
although the mortality rate of HLHS varies based on the HLHS clinical 
subgroups, the overall mortality rate for all HLHS subgroups remains high 
compared to the other CHDs.  
 The causes of HLHS 
Two factors have been considered to influence the occurrence of HLHS: 
environmental and genetic (Gladki et al., 2015; Hinton et al., 2007).  The 
following section will discuss these factors and how they may influence HLHS. 
 Environmental factors 
Several studies have suggested associations of HLHS with various 
environmental factors including ambient air pollution, viral infections, 
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consumption of medications and alcohol, and teratogens (Gładki et al., 2015; 
Agay-Shay et al., 2013). Although there have been intensive studies to 
investigate the association between maternal exposure to air pollution, such 
as sulphur-dioxide, carbon monoxide, ozone, and nitrogen-dioxide, these 
studies could not link the air pollution to a specific form of CHD (Dadvand et 
al., 2011; Agay-Shay et al., 2013; Dolk et al.,2010; Gilboa et. al., 2005; Hansen 
et al., 2009). A recent study based on analysing 100 infants with HLHS 
compared to 100 new-borns without CHD showed no association between the 
occurrence of HLHS and other factors including marital status, consumption 
of tobacco, medications and alcohol, or parent’s age (Gladki et al., 2015). 
However, the Towbin group suggested an association between viral infections 
and the occurrence of endocardial fibroelastosis, which is frequently reported 
in HLHS (Ni et al., 1997). The study was based on analysing 29 samples from 
patients with diverse CHDs and autopsy-proven endocardial fibroelastosis, to 
detect the presence of various viral genomes. Interestingly, 70% of the 
samples were positive for mumps virus, whereas 28% were positive for 
adenovirus. This therefore indicated a connection between maternal viral 
infection, particularly mumps virus, and occurrence of endocardial 
fibroelastosis (Ni et al., 1997). It was suggested that transplacental mumps 
infection was a significant cause of endocardial fibroelastosis (Lurie, 2010). 
However, there was no report of decreasing the incidence of HLHS after 
vaccination, and thus no direct links to HLHS was concluded (Lurie, 2010; St. 
Geme et al 1966). Overall, there is insufficient evidence to decisively conclude 
that HLHS can be caused by specific environmental factors.  
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 Genetic factors  
There have been several studies that link HLHS to genetic factors (Brenner et. 
al., 1989; Hinton et al., 2007; Kelle et al., 2015). The original thought that 
genetic factors influence the aetiology of HLHS was in 1974 by Bjornstad and 
Michalsen. Based on analysing previous study cases of HLHS, they found that 
64% of the analysed cases (102/160 cases) were boys, suggesting a strong 
sex-linked aetiology for HLHS. Interestingly, when they analysed specific 
subgroup of HLHS (aortic and mitral atresia), they found that 50% (11/22 
cases) were boys, indicating a lower importance of gender in this group 
(Bjornstad and Michalsen, 1974). In 1976, a survey of HLHS infants (64 cases) 
and their pedigree (42 families) information indicated an increased recurrence 
of HLHS in later siblings, which gave rise to the conclusion of HLHS caused 
through polygenic inheritance (Brownell and Shokeir, 1976). Thereafter, the 
idea of a genetic aetiology for HLHS has been widely accepted. In 1989, a 
pilot study was carried out on 41 first-degree relatives of 11 HLHS probands. 
This showed that 5/41 relatives of the HLHS probands had confirmed cardiac 
defects. This study not only suggested a high risk of cardiac defects in the first-
degree relatives of HLHS patients, but also proposed a high frequency of 
HLHS recurrence in siblings, compared to the earlier model of polygenic 
inheritance (Brenner et al., 1989). In 2005, a familial study of left ventricular 
outflow tract obstruction (LVOTO), including a family with HLHS and aortic 
coarctation, suggested a male to male inheritance for HLHS as two male family 
members (father and brother) had mild aortic stenosis (Wessels et al., 2005). 
Furthermore, examination of 38 HLHS probands with a three-generation family 
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history showed that 55% (21/38) of families had at least one or more family 
members affected by cardiac defects, with an 8% recurrence risk for HLHS in 
siblings suggesting heritability of HLHS (Hinton et al., 2007). According to 
Leary’s group (2015), the familial incidence in first-degree members of HLHS 
probands was approximately 11.2%, as it was based on screening 152 first-
degree family members of 52 HLHS probands, including 55 siblings and 97 
parents (Kelle et al., 2015). Consequently, there has been increased evidence 
to support a genetic element underpinning HLHS.  
1.4.3.2.1 Transmission patterns of HLHS 
Although all of these studies had implied the genetic causes of HLHS, the 
proposed models for HLHS transmission pattern remains debatable. The 
suggested sex-linked aetiology for HLHS, for example, was based on the 
studies that included aortic atresia cases, which were not necessarily HLHS 
cases. Moreover, when HLHS was limited to a specific phenotype (aortic and 
mitral atresia), the sex-linked aetiology for HLHS became less significant. In 
addition, the polygenic inheritance was suggested through analysis of 42 
families in which no phenotype for the HLHS cases was provided. Hence, it 
was not possible to determine the accuracy of the suggested inheritance 
model. The autosomal dominant inheritance model was based on analysis of 
a familial study of left ventricular outflow tract obstruction (LVOTO) and was 
not limited to HLHS. Therefore, it was difficult to conclude whether this 
inheritance model was applied specifically to HLHS or to LVOTO cases. 
Altogether, these studies had provided possible models to explain the genetic 
transmission patterns for HLHS, but further investigation particularly using a 
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specific subgroup of HLHS can provide a better insight into the genetic 
mechanisms of HLHS.  
1.4.3.2.2 Twin study of HLHS 
The study of twins in HLHS can provide an insight to further understand the 
genetic origin of HLHS. In the case of a birth defect such as HLHS, twin studies 
are a valuable source of information to explore individuals with identical 
genotypes. Although twin pregnancies have a higher risk of structural heart 
disease than singleton pregnancies, the concordance rate between twins has 
been revealed to be relatively low (Andrews et al., 2003).  
Comparisons between monozygotic and dizygotic twins can assess the 
degree of genetic and environmental influence on HLHS. Monozygotic twins 
share 100% of their genes and have the same sex, whereas dizygotic twins 
share around 50% of their genes and can be either gender. Therefore, when 
monozygotic twins reveal a significant concordance of HLHS compared to 
dizygotic twins, this suggests that genes largely influence HLHS. However, 
when monozygotic twins and dizygotic twins share similar or equal 
concordance of HLHS, this provides evidence for a large influence of the 
environment rather than genetic factors. Analysing HLHS twin case reports, 
between 1973 to 2018, showed that concordance for HLHS (i.e. both twins 
had HLHS) was significantly higher in monozygotic twins than in dizygotic 
twins, (Figure 1.14, Table 1.1). This therefore suggets a strong influence of 
genetic factors.  




Figure 1.14: HLHS cases reported in monozygotic and dizygotic twins.  
There were not any dizygotic twin cases reported where both twins had HLHS, 
whereas there were two cases for monozygotic twins. Both monozygotic and 
dizygotic twins had equal cases of one twin with HLHS and a healthy co-twin. 
However, there were double cases in monozygotic twins, where one twin had 
HLHS and co-twin had other congenital heart defect (see table1.1), compared to 
dizygotic twins. The error bars represented the standard error.    
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Table 1.1: case reports for HLHS in mono/dizygotic twins between 1973 to 2018. 
Twin types Twin 1 Twin 2 Reference 
Dizygotic twin HLHS Brain death Blitzer et al., 
2016 








Dawson et al., 
2016 
Monozygotic diamniotic twin HLHS HLHS Andrew et al., 
2003 










HLHS TTTS del Río et al., 
2005 
Monozygotic twin HLHS BAV Mu et al., 2005 
Monozygotic twin HLHS OEIS Mathew et al., 
2009 
Monozygotic diamniotic twin HLHS, 
TGA, PA, 
sirenomelia 
Healthy Al Yaqoubi et 
al., 2018 






AlRais et al., 
2011 
Not specified  HLHS HLHS Leake et 
al.,1973 
Not specified  HLHS AVSD Digilio et al., 
1999 
 
Key: HLHS: hypoplastic left heart syndrome; AVSD: atrioventricular septal 
defect, PA: pulmonary atresia; TGA: transposition of the great arteries; BAV: 
bicuspid aortic valve; TTTS: twin-twin transfusion syndrome; OEIS: 
omphalocele-exstrophy-imperforate anus-spinal defects; HRHS: hypoplastic 
right heart syndrome. 
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 Candidate genes for HLHS 
As there are a growing body of evidences to show genetic causes for HLHS, 
several genes have been suggested to associate with HLHS. This includes 
GJA1 (Dasgupta et al., 2001), NKX2.5 (Elliott et al., 2003; McElhinney et al., 
2003), NOTCH1/NOTCH3/NOTCH4 (Garg et al., 2005; Yang et al., 2017; 
Durbin et al., 2017), HAND1 (Reamon-Buettner et al., 2008), FOXC2/FOXL1 
(Iascone et al., 2012; Yu et al., 2010; Finegold et al., 2001), SMAD3 (Fitzgerald 
et al., 2014), TBX5 (McCulley and Black, 2012), ETS1 (Ye et al., 2010), 
RBFOX2 (verma et al., 2016) and PCDHA9/SAP130 (Liu et al., 2017). This 
section will briefly discuss the HLHS suggested genes and further discussion 
will be in chapter 4.  
Since the above suggested genes were proposed to cause HLHS, some of 
these genes, such as HAND1, NKX2.5, GJA1 and PCDHA9/SAP103, were 
used to generate experimental animal models for HLHS. The reported HAND1 
frameshift mutation (Hand1A126fs), which was originally identified in 24 of 31 
formalin-fixed hypoplastic left ventricles, was modelled in mice (Reamon-
Buettner et al., 2008). Although the Hand1A126fs mice showed abnormal 
cardiac development including a thin ventricular myocardium, defects in the 
outflow tract, and ventricular septal defect, the size of the left ventricle in these 
mice was normal and eventually this mutation caused embryonic lethality 
(Firulli et al., 2017). In addition, generating a mouse model for a ventricular-
restricted knockout of Nkx2.5 exhibited no structural defects or HLHS, but had 
overgrowth of the trabecular muscle (hypertrabeculation) of the left ventricle 
and complete heart block (Pashmforoush et al., 2004). Similarly, another study 
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had used a semi-automatic software to study the effect of the Nkx2.5 deletion 
on the trabeculated mass of mice model. This study showed that inducing the 
Nkx2.5 mutation during early embryonic development led to dramatically 
increased trabeculation but not HLHS (Frandon et al., 2016). Furthermore, 
targeted mutagenesis of GJA1 revealed that its presence was essential for 
survival of mouse embryos. The mutant embryos of GJA1 displayed several 
heart defects including blockage of the right ventricular outflow tract and 
eventually caused embryonic death at birth (Reaume et al, 1995). The fact that 
GJA1 caused decreased flow in the developing ventricles through blocking the 
pulmonary venous connections was compatible with the flow theory (Wessels 
et al., 2005). Altogether this finding indicated an important role of GJA1 during 
heart development, it did not exhibit classic symptoms of HLHS. More recently, 
the digenetic interactions between Pcdha9 and Sap130 was proposed to 
cause HLHS in mice (Liu et al., 2017). It was also suggested that mutations in 
Pcdha9 were responsible for causing aortic valve abnormalities, whereas 
mutations in Sap130 caused hypoplasia in the left ventricle. Therefore, 
combination of both genes together was required to produce HLHS features 
(Liu et al., 2017). Linking this finding to human HLHS patients revealed that 
one patient out of 68 HLHS patients had rare mutations in SAP130 and in 
PCDHA13, which was proposed to be homologous to Pcdha9 identified in 
HLHS mice (Liu et al., 2017). Although a digenic model for HLHS was 
proposed, the interaction between these two genes was not necessarily 
causing HLHS (Discussed further in chapter 5). Overall, all the generated 
animal models for HLHS revealed a weak association between the implicated 
genes and HLHS, and eventually led to either embryonic lethality or generating 
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other complex cardiac defects. Therefore, further investigations are required 
in order to find the causative gene(s) for HLHS.  
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1.5 Hypothesis and aims 
Whilst several studies have supported a genetic aetiology for HLHS, there 
have been many unsuccessful attempts to find the specific gene(s) that cause 
this defect. This could be because the majority of genomic studies, which 
aimed to find HLHS genes, had investigated a wide variety of heart defects 
without limiting their study to a specific subgroup of HLHS. Although the clinical 
subgrouping of HLHS is broadly accepted in clinical diagnosis, for genomic 
studies these subgroups provide a wide range of valvular morphological 
malformations, which can be difficult to accurately phenotype, but ignore the 
ventricular phenotype. Therefore, this study hypothesises that there are 
distinct subgroups of HLHS, which can be identified based on the left 
ventricular morphology. Analysis of a discrete well-characterised subgroup of 
HLHS using archival formalin-fixed tissues may aid in understanding the 
genetic aspect behind it, and ultimately finding the causative gene(s) of HLHS. 
Also, since archival formalin-fixed tissues are used in characterising HLHS 
subgroups, it is hypothesised that DNA samples can be extracted from these 
samples at high quality and used in genomic downstream applications. Finally, 
evaluation of the expression patterns of the currently implicated genes for 
HLHS may provide good understanding of how these genes contribute to 
HLHS. 
This study has several aims including: (1) to establish on morphological 
grounds, using archival specimens, whether there is evidence for different 
subtypes of HLHS; (2) to establish an improved method to extract high quality 
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DNA with reliable and reproducible sequence information from formalin-fixed 
tissues, and (3) to investigate the expression of HLHS proposed genes at 
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Over the years, there has been much discussion about whether hypoplastic 
left heart syndrome (HLHS) is caused by environmental factors, inherited 
genetic factors, or a combination of genetic and environmental factors 
together. Further, if there are genetic factors, there is controversy about 
whether it is caused by disruption of a single gene, or several genes (Banner 
and Kuehl, 2011). Although these arguments have been going on for a long 
time with no definitive conclusion, there is now a greater preference for HLHS 
being a hereditary defect (Connor and Thiagarajan, 2007; Hinton et al., 2007; 
Liu et al., 2017). Analysis of published studies about HLHS revealed that the 
majority of these studies were not specific in their criteria for identifying and 
sub-classifying HLHS (Appendices Table 8.1). Some studies characterized 
HLHS patients according to the conventional clinical (functional) classification, 
which is based on the functional capacity of the valves located on the left side 
of the heart. Other studies either included other morphological defects such as 
atrial/ventricular septal defect (A/VSD) and hypertrophy of the right-sided 
cardiac structures, or linked HLHS to other syndromes including Down 
syndrome (Colquitt et al., 2016). As a result, these studies incorporated a 
variety of malformations affecting the relevant cardiac regions in HLHS and 
combined them into one group to eventually use them for genetic analysis 
studies (Appendix Table 8.1). This could be a reason for the delay in revealing 
the aetiology of HLHS. Therefore, this chapter will suggest a new way to 
understand and investigate HLHS. To achieve this, an alternative classification 
based on the anatomical abnormalities rather than the clinical functionality was 
Chapter 2: HLHS Subtypes Morphological Analysis 
52 
 
explored. The clinical classification is essential for correct surgical 
management. However, the new suggested classification in this chapter is 
particularly important for genetic and developmental studies, as it provides a 
well-defined and accurately characterised subgroup of HLHS that is ultimately 
critical for aetiology studies.  Evaluation of the overall appearance and main 
structures affected in HLHS resulted in a classification based on the ventricular 
phenotype. Below, an overview of the developmental processes that underpin 
formation of the main anatomical segments implicated in HLHS is presented.    
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2.2 Main structures involved in HLHS 
HLHS is a congenital heart condition that leads to underdevelopment of the 
left-sided structures of the heart, causing obstruction to the normal blood flow 
through the left ventricular outflow tract. It not only affects the left ventricle but 
also the valves that modulate flow into and out of the left ventricle (mitral and 
aortic valves) and aorta (Schoenwolf et al., 2009). Although HLHS is caused 
by perturbation during heart development, the main underlying processes 
remain unclear. Classifying HLHS subtypes according to their valvar 
malformation suggests that HLHS is initiated, at least in part, by perturbation 
during valve formation. However, it is still unclear to what extent defects in the 
valves can be considered as the primary cause of HLHS, as they may be 
secondary to malformations in the left ventricle. Therefore, this section will look 
at the normal development of left cardiac structures; with emphasis on the 
development of the left ventricle, aortic and mitral valves, and aorta, as these 
are the fundamental segments involved in HLHS. The knowledge of the normal 
heart structures allows the assessment of abnormalities associated with HLHS 
hearts.  
2.2.1 Left ventricle 
The left ventricle is one of four chambers in the heart. It functions to pump 
blood from the heart to most of the body. The position, form and proportion of 
the infant heart differs from that in adult and older children. Infant hearts tend 
to have a more horizontal position compared to that in adults. This is because 
of the large abdomen and high diaphragm in infants (Jour, 1950). In addition, 
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the form of infant hearts varies in several aspects. The new-born heart is 
broader and rounder than adult hearts. Also, the morphological right 
ventricular wall of the infant heart is slightly larger than the morphological left 
ventricular wall. Moreover, the left and right ventricles are cardiac apex forming 
(Jour, 1950; Huelke, 1998). At this stage, no individual features have 
developed in the left and right sides and hence the heart has a symmetrical 
structure (Jour, 1950) (Figure 2.1). 
 
Figure 2.1: Infant Left ventricle structure.  
In the infant heart the LV wall thickness is relatively similar to that in the RV. 
Both ventricles have the same length and are apex forming (modified from 
Schoenwolf et al., 2009). 
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2.2.2 Mitral valve  
The mitral valve (or bileaflet valve) is located between the left ventricle and the 
left atrium and is composed of two leaflets: the anteromedial and posterolateral 
leaflets (Hinton et. al., 2008). These leaflets are formed from the 
atrioventricular (AV) cushions. The superior AV cushion develops to form the 
aortic leaflet, whereas the left lateral AV cushion forms the mural leaflet of the 
mitral valve (Snarr et. Al., 2008). The mitral valve leaflets are protected from 
prolapsing during blood flow by chordae tendineae located in the left ventricle. 
The chordae tendineae form a supportive bridge that attaches to papillary 
muscles at one end and to valve leaflets at the other end. There is some 
variability with the points of attachment on the valve leaflet and some attaching 
to the ventricular wall rather than the papillary muscles. The mitral annulus is 
a non-continuous fibrous circle surrounding the mitral valve (Hinton et. al., 
2008) (Figure 2.2). It is attached to the mitral valve leaflets and helps in 
maintaining a complete closure of the leaflets during contraction or systole 
(Playford and Weyman, 2001).  
 




Figure 2.2: Mitral valve structure.  
Mitral valve contains two leaflets known as anteromedial leaflet, which is in 
fibrous continuity with the aortic valve, and posterolateral leaflet. These leaflets 
are supported by chordae tendineae that connect to the LV wall, the leaflets and 
the papillary muscles that attach to the left ventricular inner wall. Abbreviations: 
LA: left atrium, LV: left ventricle, AoV: aortic valve (Modified from Schoenwolf et 
al., 2009) 
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2.2.3 Aortic valve  
The aortic valve is located in the junction between the ascending portion of the 
aorta and outlet of the left ventricle. It functions to regulate blood flow from the 
left ventricle to the aorta and then to rest of the body (Reid, 1970). The aortic 
valve is composed of three leaflets which have been described in several 
ways. For example, the right coronary leaflet can be known as the anterior 
leaflet, the left coronary leaflet, can be described as the left posterior, and non-
coronary leaflet can be known as the right posterior (Ho, 2009; Charitos and 
Sievers, 2012). However, the most common clinical terms are the left 
coronary, right coronary and non-coronary cusps (Ho, 2009). The left coronary 
leaflet and non-coronary leaflet are in fibrous continuity with the mitral valve. 
The aortic valve and its leaflets are all part of a complex structure called the 
aortic root. The aortic root joins the heart to the systemic circulation (Ho, 2009; 
Charitos and Sievers, 2012).  In addition to aortic valve leaflets, the aortic root 
consists of leaflet attachments, the sinotubular junction, the ventriculo-aortic 
junction, the interleaflet triangles/trigones, and the sinuses of valsalva 
(Charitos and Sievers, 2012) (Figure 2.3).   











Figure 2.3: Aortic valve structure.  
The aortic valve has three leaflets: left coronary leaflet (L), posterior leaflet (P) 
and right coronary leaflet (R). Structures between the sinutubular junction and 
the ventriculo-aortic junction form the aortic root. The grey area indicated the 
fibrous continuity between aortic valve and mitral valve. Abbreviations: LA: left 
atrium, LV: left ventricle, AoV: aortic valve, Ao: aorta, MV: mitral valve, FM: 
fibrous membrane, S: Sinus of valsalva, asterisk: inter leaflet triangle or trigone 
(Modified from Schoenwolf et al., 2009). 
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2.2.4 Aorta  
The aorta is the largest artery in the body, originating from the left ventricle, to 
carry oxygenated blood away from the heart to the body through the aortic 
valve. In adults, the diameter ratio of pulmonary artery (PA) to ascending aorta 
(AA) is 1:1, whereas this ratio is slightly increased to 1.09:1 in the infant 
(Compton et. al., 2015). The aorta is normally considered to consist of three 
segments: the ascending aorta, the aortic arch and associated arteries, and 
the descending aorta. The ascending aorta is found superior to the heart 
exiting from the left ventricle. The transverse segment of the aorta gives rise 
to the brachiocephalic artery, which branches in turn to give the right common 
carotid artery and right subclavian artery, left common carotid artery, and left 
subclavian artery (Figure 2.4). The descending aorta is distal to the isthmus 
and has both thoracic and abdominal components. 
One major difference between adult hearts and newborn hearts is the closure 
of the ductus arteriosus to form the ligamentum arteriosum (arterial ligament) 
a few days after birth. The ductus arteriosus arises from the left 6th pharyngeal 
arch artery, which remodels to join the pulmonary trunk (formed from the 
septated outflow tract) to the descending aorta (Walmsley and Monkhouse, 
1988) (Figure 2.4). However, the form, length and diameter of the ductus 
arteriosus varies between infant hearts (Edwards, 1960). The region between 
the ductus arteriosus junction and the left subclavian artery is termed the 
isthmus (Evans, 1964). Although pathological changes in the isthmus have 
been described (Ho and Anderson, 1979; Bremer, 1948), the cause of these 
changes and origin of the isthmus remains unclear (Figure 2.4).  




Figure 2.4: Structure of the aorta.  
Three segments of aorta: Ascending aorta, aortic arch, and descending aorta. 
The ductus arteriosus is indicated in black. Abbreviation: LA: left atrium, LV: left 
ventricle, AoV: aortic valve, MV: mitral valve, RV: right ventricle, RA: right 
atrium, RSCA: right subclavian artery, RCCA: right common carotid artery, BCA: 
Brachiocephalic artery, LCCA: left common carotid artery, LSCA: left subclavian 
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2.3 Hypothesis and aim of this chapter  
This chapter hypothesises that an anatomical analysis of HLHS will create 
subgroups that can be useful for genetic and developmental studies, designed 
to investigate the aetiology of HLHS. 
The focus of this chapter is to undertake a novel approach to understanding 
and analysing hearts with HLHS. Therefore, this chapter aims: 
• To establish on morphological grounds whether there are different 
subtypes of HLHS through using human archival hearts obtained from 
Birmingham Children’s Hospital. 
• To describe the morphological structure of each segment affected in 
HLHS.  
• To correlate the various characteristics of HLHS according to a 
morphological classification. 
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2.4 Materials and Methods  
2.4.1 Archival HLHS hearts  
The human congenitally malformed archival heart collection based at 
Birmingham Children’s Hospital, contains a collection of approximately 2000 
specimens collected since 1939 (the storage time for each heart was not 
available). Permission to perform the analysis on the HLHS heart collection 
was obtained from the Guardian Committee of the collection and the R&D 
department at Birmingham Children’s Hospital NHS Foundation Trust. The 
collection of 183 HLHS hearts were initially analysed by Professor R. H. 
Anderson and Dr A. Crucean to confirm the diagnosis of HLHS. A second 
analysis including measurements and photography was made by A. M. S. 
Alqahtani and Dr. B. Chaudhry. The specimens were described according to 
the method of sequential segmental analysis (Anderson and Shirali, 2009) and 
physical measurements and analysis were performed using digital calipers, 
microscopic examination, and probe patency. This measurement method was 
novel and has not been described before. Photographs of the selected 
specimens were taken using either a Leica microscope (MZ16, Leica, 
Germany) or a digital SLR camera (Nikon 3100, Nikon, Japan). 
The archival collection of 183 hearts was already prosected and fixed in 
formalin, no further prosection was permitted. The HLHS hearts included in 
this study were carefully categorised according to specific criteria. Firstly, it 
was important to include only non-operated hearts in good condition because 
only these hearts can provide a true and correct morphological description of 
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affected regions. Secondly, the selected hearts had to conform to the classic 
definition of HLHS as defined by Tchervenkov et.al, 2006 and the WHO 
International Classification of Diseases (ICD-11). This included a hypoplastic 
left ventricle with significant hypoplasia of the ascending aorta, aortic arch and 
at least one of the main left-sided valves; aortic and mitral. Moreover, the great 
arteries had to be normally aligned and there had to be a fully formed 
atrioventricular septum. Finally, the right-sided structures of the hearts had to 
be well formed with normally connected valves. Due to the original cardiac 
explant, it was not possible to examine the pulmonary veins or to identify the 
connections with the superior caval veins. The information about the gender 
and age of the selected hearts were not available for confidentiality reasons. 
Therefore, all the obtained measurements were normalised to the well-formed 
right-sided structure of each heart.  
Therefore, in total 78 hearts (out of 183) were selected for analysis on the 
basis of the criteria above. These hearts were further analysed through 
measuring the left ventricular length and wall thickness, ascending aorta size 
and the distance between the left subclavian artery and ductus arteriosus 
(Figure 2.5.1 and Appendix Table 8.2). In addition, a morphological analysis 
of the overall external shape of the left ventricle in terms of hypertrophic left 
ventricles and the presence of endocardial fibroelastosis (EFE) was carried 
out (Appendix Table 8.2). Furthermore, the aortic and mitral valves were 
always small in HLHS hearts but with different ranges in size (no measurement 
were made). To accurately classify the different mitral valvar phenotypes, a 
semi-quantitative method was devised, describing the leaflets, papillary 
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muscles and chordae tendineae. Similarly, the aortic valve was 
morphologically evaluated based on the presence or absence of leaflets and 
a semi-quantitative method was devised (Appendix Table 8.2).  
 
Figure 2.5.1: The measurement approach for the main characteristics of 
HLHS. 
(A) Perpendicular measurement of LV to RV free-wall ratio and the size of EFE. 
(B) LV to RV length ratio, LV length starts from the atrioventricular groove and 
ends at the coronary artery, whereas the RV ends at the apex. (C) LV 
hypertrophy (arrow). (D) Non-hypertrophy LV (arrow’s head). (E) Isthmus starts 
from the LCCA to the ductus arteriosus, AAo to PT ratio. All measurements were 
in millimetre (mm). Key: LV: left ventricle, RV: right ventricle, MV: mitral valve, 
TV: tricuspid valve, EFE: endocardium fibrosis, BCA: Brachiocephalic artery, 
LCCA: left common carotid artery, LSCA: left subclavian artery, DAo: descending 
aorta, i: Isthmus, PT: pulmonary trunk, AAo: Ascending aorta. Scale bar = 2mm. 
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2.4.2 Statistical analysis 
All the statistical calculations were performed using SPSS (Version 22, IBM) 
software for Windows. Analysis was carried out using ANOVA and Tukey’s 
multiple comparison test assuming non-parametric distributions. The statistical 
significance of differences between the various HLHS subgroups was 
assessed and only p-values less than 0.05 were considered significant.  
  
Chapter 2: HLHS Subtypes Morphological Analysis 
66 
 
2.5 Results  
2.5.1 Selection of hearts  
In total 78 hearts (out of 183) were selected for analysis on the basis of the 
criteria above. No additional data was collected for the excluded hearts. As a 
preliminary analysis, the selected hearts were initially sub-categorised 
according to the conventional clinical categories. This categorisation involved 
sub-classifying hearts on the basis of aortic and mitral valve patency using the 
description terms: atresia (non-patent to probe entry) and stenosis 
(slightly/fully patent to probe entry) (Figure 2.5).  
 
Figure 2.5: Schematic diagram showing the selection of HLHS hearts and 
the conventional classification of these hearts.  
A total of 78 hearts were included in the study and further sub-classified 
according to the conventional clinical classification. Other cardiac defects 
associated with a relatively small or dysfunctional left ventricle were excluded. 
The selected hearts (n=78) maintained (A) a normal morphologically right 
ventricle, normal appearance of (B) pulmonary valve, (C) tricuspid valve, (D) 
Patent foramen ovale PFO. One heart (E) had a large coronary sinus.   




2.5.2 Left ventricle  
Examination of 78 hearts revealed that the morphological right ventricle was 
clearly apex forming in all the examined hearts. In contrast, the morphological 
left ventricle was not an apex-forming ventricle and showed three distinctly 
different appearances. A unique subset was identified by absence of the left 
ventricular cavity that located in the left-posterior aspect of the ventricular 
mass. This subset was referred to as “slit-like ventricle” (SLV) and was found 
in 19/78 hearts. A cross-sectional view of all of these 19 hearts exposed a thin 
parietal left ventricular wall with a fissure-like cavity that was identified by 
delimiting coronary vessels found on the surface of the hearts (Figure 2.6 
G,H). All of these hearts presented with no valvular connections as non-patent 
probe entry was found, and hence were previously diagnosed as aortic atresia 
and mitral atresia (AA/MA) (Figure 2.6 I). A second subset had a small left 
ventricular cavity with a remarkably thick left ventricular wall (Figure 2.6 D,E). 
This group was referred to as “thick-walled ventricle” (TWV) and was seen in 
the majority of cases; 54/78 hearts (Figure 2.6 F). Of this subset, 35/54 hearts 
were identified with non-patent probe entry to the aortic valve and narrow 
patent probe entry to the mitral valve, and thus were representative of aortic 
atresia and mitral stenosis (AA/MS). The remaining 19/54 hearts had limited 
probe entry to both the aortic and mitral valves and thus were classified as 
having aortic stenosis and mitral stenosis (AS/MS), The final subset, which 
was found to be the smallest group with 5/78 hearts, had an almost normal 
sized left ventricular cavity and wall thickness, yet the left ventricle was not 
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apex-forming (Figure 2.6 A,B). While these hearts had morphologically 
normal-looking mitral and aortic valves with limited probe patency, they were 
smaller in size compared to their respective right-sided valves (Figure 2.6 C). 
Thus, these hearts were classified as exhibiting aortic stenosis and mitral 
stenosis (AS/MS) as flow would have been limited through these valves. As it 
is probable that these hearts could have been repaired by a biventricular 
surgical procedure, they were previously recognised as “hypoplastic left heart 
complex” (Tchervenkov 1998). Nevertheless, for the purpose of this study, 
these hearts were termed “miniaturised ventricle” (MinV).  
Thus, examination of the ventricular morphology revealed three distinct 
groups; the slit-like ventricles, thick-walled ventricles and miniaturised 
ventricles. The ventricular-based classification provided well-defined and 
obvious characterised subgroups for HLHS. It also showed that the AS/MS 
and AA/MS groups, which have been previously considered as distinct HLHS 
subgroups, had in fact extremely similar morphological structures and they 
could be included into one group based on their ventricular morphology. 
Altogether, the AA/MA clinical group always have SLV and vice versa. 
Nevertheless, that is not the case for the other clinical/ventricular groups. 
Hence, this may be important for further analytical and aetiological studies.  




Figure 2.6: Three different left ventricular phenotypes of HLHS hearts. 
Examination of HLHS hearts revealed three distinctive phenotypes of ventricles: 
(A) slit-l ike ventricle detected by coronary vessels (black arrows) with no cavity 
(white arrow) and (B) a thin free-wall (White arrow), (C) overview of non-apex 
forming left ventricle (black arrow) and the apex forming right ventricle (white 
arrow) in the slit-like ventricles. (D) Thick-walled ventricles (white arrow) with 
small cavity and non-apex forming LV (black arrow). (E) Endocardial 
fibroelastosis (EFE) asterisk. (F) Overview of non-apex forming the left ventricle 
(black arrow) and the apex forming right ventricle (white arrow) in the thick-
walled ventricles. (G) Miniaturised ventricle with a small cavity (black arrows) 
and (H) thin wall (white arrow). (I) overview of non-apex forming the left ventricle 
(black arrow) and the apex forming right ventricle (white arrow) in the 
miniaturised ventricles. Scale bar = 2mm. 
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2.5.2.1 Length and wall thickness of the three ventricular 
morphology groups 
For further analysis of the three distinctive ventricular morphology groups, the 
length and wall thickness of the left ventricle were measured and compared 
between groups. The length of left ventricle was obtained by defining the 
anterior and posterior epicardial coronary arteries located in the inter-
ventricular groove (Figure 2.7 A, B). The measurement of the coronary arteries 
was acquired starting from the atrioventricular groove and ending at the heart 
apex for both the right and left ventricles. Since demographic data (e.g. age 
and body size) for this heart collection were not available, the length of the left 
ventricle was related to the right ventricle producing a ratio-metric index that 
represented a normalised length value for the left ventricular size (Figure 2.7 
A). Likewise, a ratio of left ventricular wall to right ventricular wall thickness 
was utilised to illustrate the wall-thickness of left ventricle (Figure 2.7 B).  
Comparing the length of left ventricle between HLHS groups based on the 
usual clinical classification revealed no significant differences in left ventricular 
length between these groups (Figure 2.7 C). However, analysing the left 
ventricular length using the ventricular phenotype groups of SVL, TWV and 
MinV showed differences in the length between these groups (Table 8.2). The 
miniaturised ventricles (n=5, mean 28.4mm) were relatively longer than those 
with slit-like ventricles (n=19, mean 25.6mm) or thick-walled ventricle (n=54, 
mean 24.8mm). However, the slit-like ventricle (AA/MA) and thick-walled 
ventricle (which was described as AA/MS and AS/MS) groups, showed 
overlapping ventricular length values indicating no differences in relative 
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length between these groups of ventricular phenotypes (Figure 2.7 E). 
Therefore, this suggested that the various degree of hypoplasia presented by 
the relative ventricular cavity length in HLHS did not relate to the condition of 
the mitral/aortic valves. Thus, although both the thick-walled and miniaturised 
ventricular phenotypes included AS/MS cases, the length of ventricle varied. 
Hence, as in the conventional grouping, this parameter of relative LV length 
was not correlated with the valve status.  
Normal development of ventricles results in equal wall-thickness of both left 
and right ventricles at the time of birth (Daimei et al., 2014). In the current 
study, based on the clinical classification groups, the ratio of the left and right 
ventricular wall thickness (LV/RV ratio) was significantly lower in the 
conventional AA/MA group compared to the AA/MS and AS/MS groups (Figure 
2.7 D). However, based on the ventricular morphology grouping, the ratio of 
LV/RV wall thickness suggested equal wall thickness in the miniaturised 
ventricles (n=5, mean 4.5mm). Conversely, the LV/RV wall thickness ratio for 
the thick-walled ventricles (n=54, mean 7.2mm), including AA/MS and AS/MS, 
was increased indicating hypertrophy of the LV wall. A significant decrease in 
the LV/RV ratio for the slit-like ventricles (n=19, mean 2.9mm) confirmed the 
thin wall of LV in this group (Figure 2.7 F). Therefore, the wall thickness LV/RV 
ratio suggested that although LV wall thickness did not relate to the 
conventional grouping based on stenosis or atresia of the mitral and aortic 
valves, it entirely correlated with the ventricular phenotypes. Hence, this 
implied the possibility of an alternative classification of HLHS based on the 
ventricular morphology: slit-like ventricle with no sign of hypertrophy and 
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reduced relative LV length, the thick-walled ventricle with hypertrophied LV 
and a reduced relative LV length, and miniaturised ventricles with no 
hypertrophy and reduced LV length.  
  




Figure 2.7: Comparison of LV length and wall thickness.  
(A) A diagram showing the measurements of LV length in relation to RV length 
(measuring from the left coronary artery to the left anterior descending coronary 
artery). (B) A diagram showing LV free wall thickness in relation to RV free wall 
thickness. (C) The chart showed the LV length in the clinical classification group, 
as the left ventricular length was the same in all the different clinical groups. (D) 
the wall-thickness of left ventricle in the clinical classification groups, where only 
the AA/MA group revealed a significant difference in the thickness of LV wall. 
Other clinical groups showed similar wall-thickness. (E) The left ventricular 
length index in the ventricular morphology groups. The LV length of slit-l ike 
ventricles was the same as that of thick-walled ventricles (mean 25.6mm and 
24.8mm). However, the miniature ventricle group had longer LV lengths (mean 
28.4mm). (F) Left ventricular free wall thickness in HLHS grouped based on 
ventricular morphology. LV wall thickness in miniaturised ventricles was the 
same as in RV (mean 4.50mm). However, the walls of the slit-like ventricle were 
thin (mean 2.9mm), and the walls of thick-walled ventricles demonstrated 
remarkable thickening in keeping with the morphological observations (mean 
7.2mm). Black markers indicated no EFE. Bars indicate median and interquartile 
range; *p<0.05, **p<0.01, ****p<0.0001). 
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2.5.2.2 Endocardial fibroelastosis  
Further examination of HLHS hearts revealed the presence of endocardial 
fibroelastosis (EFE). The EFE appears as a firm and smooth layer on the 
endocardial surface of the LV. In this collection, EFE was found in the thick-
walled ventricular phenotype, specifically in 50/54 thick-walled ventricle hearts 
(Figure 2.6 E,F). Of the remaining four hearts in the thick-walled ventricle 
group that did not show EFE under microscopic investigation, three hearts 
were clinically classified as AS/MS and one was AA/MS (Figure 2.7 C,D black 
dots). Strikingly, no EFE was found in any of the slit-like ventricle or 
miniaturised ventricle hearts (Figure 2.7 E,F). Histological examination (i.e. 
preparation of histological sections to look for EFE microscopically) for further 
analysis was not possible on these hearts, as these hearts were set up for 
morphological analysis only. The aetiology of EFE in HLHS remains unknown. 
However, it has been suggested to be caused by a primary stimulus on the 
endothelial layer leading to fibro-elastic thickening of the ventricular 
endocardium (Krenning et al., 2010). Although EFE was found in almost all of 
the thick-walled ventricular hearts, no relationship was drawn between the 
thickness in LV wall or length of LV and the presence of EFE (Figure 2.7 E,F 
all dots in the thick-walled ventricles excluding the black dots).  
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2.5.3 Aortic valve  
The aortic valve was next examined for all 78 HLHS hearts within the 
collection.  Aortic valve patency was correlated with valve appearances and 
ventricle morphology. Assessments of the aortic valve were made either from 
the ventricular aspect, proximal aorta view, or entire outflow tract view based 
on the condition and screening possibility of the examined hearts.  
There were 24 hearts identified with aortic stenosis. In 12/24 hearts, the 
morphological structure of the aortic valve exhibited three thin leaflets (Figure 
2.8 A, B). Relating these hearts to the ventricle phenotypes revealed 5/12 
hearts had the miniaturised ventricular phenotype, with the remaining 7/12 
hearts having a thick-walled left ventricular phenotype. The remaining 12/24 
hearts belonged to the thick-walled ventricle group and they exhibited different 
appearances of the aortic valve. Of these 12 hearts, 10 hearts had dysplastic 
valves with thickened leaflets (Figure 2.8 C, E, F) and the remaining 2/12 
hearts showed bicuspid or unicuspid leaflets (Figure 2.8 D). The size and form 
of valvar leaflets was proportional to the overall appearance of the aortic root. 
Thus, the dysplastic leaflets were found in hypoplastic aortic roots, whereas 
small and thin leaflets were observed within well-formed aortic roots.  
There were 54 hearts identified with aortic atresia. Of the 54 hearts, 32 hearts 
presented with non-identifiable aortic valve structures (Figure 2.8 G,H). 
Referring this to the ventricular morphology grouping, there were 15/32 hearts 
identified with thick-walled ventricular morphology, whereas 17/32 had a slit-
like ventricular phenotype. Due to their ventricular morphology (i.e. no 
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ventricular cavity), it was not possible to examine the outflow tract from the 
ventricular aspect. However, examination of some cases with previous 
dissected proximal aorta revealed no aortic valve tissue in the region between 
the coronary artery ostia. Thus, histological sectioning, although not allowed 
here, could be a useful for further studies. The remaining 22/54 hearts had 
either a slit-like (2/22) or a thick-walled (20/22) ventricular phenotype. Of the 
two cases with the slit-like ventricular phenotype, one case exhibited the aortic 
valve as dysplastic with thickened leaflets and the other case as fused valvular 
leaflets. In the thick-walled ventricular phenotype hearts, the aortic valve 
(13/20) was found as a lump of white fibrous tissues with non-distinguishable 
leaflets (Figure 2.8 G,H). In the remaining (7/20) hearts, the aortic valve was 
presented as dysplastic with thickened leaflets or with bicuspid or unicuspid 
leaflets (Figure 2.8 D,E,F).   
A summary of the different valvar phenotypes correlating to the clinical 
conventional classification and to the ventricular morphology groups is 
presented in the following graph (Figure 2.9).   




Figure 2.8: Morphological structures of aortic valve.  
(A-B) small well-formed aortic valve with three leaflets (black arrows) identified 
in both miniaturised and thick-walled ventricles, also in AS/MS clinical grouping. 
(C) bobbly leaflets (D) bicuspid leaflets (E) dysplastic leaflets (F) thickened 
leaflets are the phenotypes seen in thick-wall ventricles and both AS/MS and 
AA/MS clinical grouping. The aortic valve leaflets are indicated by black arrows. 
(G) fibrous-tissue leaflets blocking the aortic valve and (G) imperforate leaflets 
were seen in mostly all the slit-like ventricular phenotype and some thick-wall 
ventricular phenotype. Also, these valvar phenotypes were seen in AA/MS and 
AA/MA clinical classifications. Scale bars =2mm.  





Figure 2.9: Correlation of valvar phenotypes with the clinical conventional 
classification and the ventricular morphology groups.  
(A) The AA/MA and AA/MS groups presented with absent of aortic valve in most 
cases. Dysplastic valve and/or fused valve were seen across all clinical groups. 
In addition, the AS/MS group had moderate-size aortic valve. (B) The ventricular 
morphology classification, similarly, to the clinical classification, showed 
absence of aortic valve in most of the cases found in the slit-like ventricle and 
thick-walled ventricle. Also, dysplastic valve was observed across the slit-like 
and thick-walled ventricle. Moderate and well-form valve as well as small valves 
were mostly observed in the miniaturised ventricles.  
  
A B 
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2.5.4 Mitral valve  
The conventional clinical classification was based on correlation between the 
aortic valve and the mitral valve. Hence, examination of the mitral valve was 
performed to relate it to the ventricular phenotype.  
In 59/78 HLHS hearts, clinically classified as AS/MS or AA/MS, a range of 
characteristics was observed. In the thick-walled ventricle hearts with AS/MS 
(8/54), and the miniature ventricle hearts (3/5), the mitral valves were well-
formed, the leaflets were thin, the papillary muscles were prominent, and well-
formed separate chordae were apparent (Figure 2.10 A). In the remaining 2/5 
hearts of the miniature ventricle group, the mitral valves were of moderate size 
with chordae and absent papillary muscles (Figure 2.10 B). In addition, the 
thick-wall ventricles with AS/MS (11/54) and AA/MS (35/54) groups 
represented a spectrum of mitral valve abnormalities including small mitral 
valve, thickened leaflets, and dysplastic leaflets (Figure 2.10 B, C, D, E, F).  
Of the remaining 19/78 HLHS hearts, 15 of these hearts showed the mitral 
valve was either absent or existed as a small piece of non-patent fibrous tissue 
(Figure 2.10 G, H). All these 15 hearts had a slit-like ventricle and were 
clinically grouped as AA/MA. The remaining 4/19 hearts, which were also 
classified as AA/MA and slit-like ventricle, the mitral valve presented as 
dysplastic or small non-patent mitral valves (Figure 2.10 B, E, F, D). A 
summary of the different valvar phenotypes correlating to the clinical 
conventional classification and the ventricular phenotype grouping presented 
in the following graph (Figure 2.11).   
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Whilst there were similarities between the ranges of abnormalities observed in 
the mitral valve to that seen in aortic valve, correlation between both valves 
was limited. The miniaturized ventricle hearts were associated with the 
moderate to small valves that tended to have well-formed mitral and aortic 
valves, whereas the slit-like ventricles were associated with the most extreme 
abnormalities seen in both valves. Nevertheless, there was no clear 
associations between the appearances of the mitral valves in comparison to 
the aortic valves. In general, the aortic valve was more severely affected than 
the mitral valve. This could create an obstruction to the blood flow from the left 
ventricle with accompanying uncontrolled filling via the mitral valve.  




Figure 2.10: Various appearances of the mitral valve in HLHS hearts.  
(A) A moderate mitral valve with thin leaflets (black arrow), short chordae (white 
arrow) and papillary muscles (asterisks). (B) small valve with thin leaflets (black 
arrow) and short chordae (white arrow) with no papillary muscles. These 
phenotypes are observed in miniaturised hearts, MS/AS and MS/AA. A range of 
mitral valve abnormalities included (C) thickened leaflets (D) dysplastic valves 
(E-F) bobbly leaflets (G) absent (H) fibrous-tissue. These abnormalities were 
demonstrated in thick-walled ventricular phenotypes and both AS/MS and 
AA/MS. The slit-like ventricles and AA/MA showed either absent or fibrous 
tissue. Scale bars = 2mm. 
 








Figure 2.11: Correlation of the mitral valve phenotypes with clinical 
classification and ventricular phenotype groups.  
(A) In the clinical classification, absent of mitral valve was seen mostly in AA/MA 
and some cases in AA/MS. Small and dysplastic or fused leaflets were 
demonstrated in mostly in AA/MS and AS/MS groups. (B) The mitral valvular 
phenotypes observed in the ventricular morphological groups specifically the slit-
like and thick-wall ventricle groups were similar to that seen in the clinical 
classification. However, the miniaturised ventricles showed a specific 
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2.5.5 Ascending Aorta  
As previously mentioned, the normally functioning aorta serves to carry 
oxygenated blood from the left ventricle to the body through the aortic valve. 
Therefore, it has been suggested that normal aortic structure requires a fully 
formed aortic valve and left ventricle, as normal blood flow is required for the 
growth and functioning of the aorta (Chester et al., 2014). However, the 
counter-argument, that the abnormalities of the aorta are a primary defect that 
lead to malformation in related regions including the left ventricle and aortic 
valve, cannot be excluded (Sedmera et al., 2005).  
In the collection of HLHS hearts held at Birmingham Children’s Hospital, a 
general inspection of aorta dimension in HLHS hearts revealed a thin-looking 
aorta (Ao) compared to the pulmonary trunk (PT) in all the cases. This 
dimension did not differ throughout the ascending aorta segment (Figure 
2.12). Hence, a measurement of the proximal aortic diameter close to the root 
should provide a representative indication of the maximal aorta size (Figure 
2.12). The ascending aorta size was measured through gently flattening the 
aorta and taking the transverse dimension. Following the same principle, the 
pulmonary trunk was measured, and both measurements were expressed as 
the ratio of aorta: pulmonary trunk (Ao:PT) hemi circumference. This metric 
was sorted according to the conventional clinical groups and also to the 
ventricular morphological groups. All conventional clinical groups showed a 
significant reduction in the dimension of the ascending aorta compared to the 
pulmonary trunk. Upon analysis, three distinct appearances of the aorta were 
defined: thread-like, small and moderate aorta (Figure 2.13). The aorta size in 
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the AA/MA group (clinical classification), or the slit-like ventricle group 
(ventricular classification), which were previously labelled to represent the 
same group, was observed to have the smallest dimensions (Threadlike; mean 
Ao:PT ratio 0.2, n=19), followed by the AA/MS or AS/MS group that were part 
of the thick-walled ventricle group (small; mean Ao:PT ratio 0.4, n=54) and 
finally AS/MS that were part of the miniaturised groups (moderate; mean 
Ao:PT ratio 0.5, n=5) (Figure 2.14, Table 8.2). Although the relative dimension 
of ascending aorta varied between cases within the same ventricular 
phenotypic groups and conventional clinical classification, an overall increase 
in the ascending aorta size was observed and correlated with the expected 
blood flow through it (Figure 2.14). In AA/MA and the slit-like group, the 
forward flow through the aorta terminated early because of the atresia of both 
valves; this led to an extreme reduction in the ascending aorta size. However, 
in the AS/MS or miniaturised group, some forward flow was maintained as the 
aortic and mitral valve allowed flow into the left ventricle. Thus, it appeared 
that the more blood that was expected to enter into the aorta, the greater the 
size of the ascending aorta. Therefore, the observed differences in the 
ascending aorta dimensions suggested a flow-related feature that was 
secondary to abnormalities in the valves and possibly the small left ventricle.    




Figure 2.12: Measurement of the ascending aorta size. 
The dimension of the ascending aorta was measured through calculating the 
proximal aortic diameter and compared to the similar proximal region in the 






Figure 2.13: Aorta appearances in HLHS hearts. 
Three main phenotypes were observed in the HLHS hearts. The thread-like aorta 
that was mostly seen in slit-l ike ventricle and some cases with AA and thick-
walled ventricles. The small aorta was seen in thick-walled ventricles and cases 
with AA or AS. The moderate aorta was presented frequently with miniaturised 
ventricle, AS/MS, and AA/MS.  




Figure 2.14: Aorta size varies between different groups of HLHS. 
  Quantification of aorta dimension indicating significantly reduced aorta size 
between the conventional clinical groups and ventricular morphological groups 
of HLHS. All the subgroups represented a decrease in aorta size correlated with 
the valve severity. Black dots represent non-EFE hearts. One-way ANOVA test 
(turkey and Scheffe test) was used to calculate P values, ***p<0.001, ****p< 
0.0001. 
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2.5.6 Isthmus and ductus arteriosus  
The isthmus is the region of the aortic arch between the ductus arteriosus (DA) 
junction and the left subclavian artery (Figure 2.16 A). Narrowing and distortion 
of this region in HLHS has been reported (Gobergs et al., 2016). In the current 
collection, all the hearts were from new-born infants and thus the DA was 
patent, and the isthmus was wide in all cases. Normally, the left subclavian 
artery (LSCA) is found adjacent to the left common carotid artery (LCCA), and 
both arise from the outer curvature of the aortic arch, followed by the DA 
attached to the inner curvature at its boundary with the descending aorta 
(Figure 2.15 A). Strikingly, in this collection of HLHS hearts, several positions 
and points of attachments of the DA were observed. For example, some cases 
presented with the LSCA located opposite to the DA (Figure 2.15 B), whereas 
in other cases the DA was located proximal to the LSCA (Figure 2.15 C). 
Therefore, examination of the DA location in all of the 78 hearts in this 
collection was performed. The DA position was investigated and expressed as 
a ratio of the distance from the LSCA to the LCCA and the distance from the 
DA to the LCCA (Figure 2.16 A-C). This ratio indicated how far the DA was 
positioned from the LSCA, as when this ratio is 1:1 the DA is opposite the 
LSCA. However, if the value of the ratio fell, the DA was located far apart from 
the LSCA. 
Analysis of the DA position showed various points of attachments with no 
specific relationship to any sub-group of HLHS hearts (Figure 2.16). Hence, 
evaluation of the DA location according to the conventional clinical 
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classification or the ventricular phenotype revealed no relationship between 
these phenotypes (Figure 2.16 B).  
 
 
Figure 2.15: The ductus arteriosus position in relating to the left subclavian 
artery.  
(A) The DA located after the LSCA allowing the aortic isthmus to be wide. (B) 
The DA located opposite the LSCA limiting the isthmus region. (C) The DA 
located before the LSCA. Abbreviations: BCA: Brachiocephalic trunk, LCCA: left 
common carotid artery, LSCA: left subclavian artery, DA: ductus arteriosus, AAo: 
ascending aorta, DAo: descending aorta, Ao I: Aortic isthmus (red area).  
 
  





Figure 2.16: Position of ductus arteriosus.  
(A) The isthmus located in the region between the ductus arteriosus (DA) 
junction and the left subclavian artery, measurement of DA distance in relating 
to the LSCA was performed. (B) The relative position of DA compared to the 
LSCA showed a wide range of the point of attachment and revealed no direct 
correlation between the DA location and the clinical classification or the 
ventricular phenotypes. In this graph, both MS/AS and MS/AA groups represent 
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2.6 Discussion  
Hypoplastic left heart syndrome (HLHS) has been used to describe a 
heterogeneous spectrum of cardiac defects that includes various degrees of 
left heart-aorta complex underdevelopment (Chervenkov et al., 2000). 
Treating HLHS once it has been diagnosed prenatally is remarkably 
challenging, particularly due to the left ventricle’s involvement in the systemic 
circulation. The placental circulation supplies essential oxygen and nutrition to 
the developing foetus, meaning that it is much less dependent on the function 
of the heart and systemic circulation in utero, than it is after birth (Ferreira et 
al., 2014). Therefore, signs of heart failure are not normally detected in 
foetuses as an abnormality affecting one side of the heart is compensated by 
the other normal side.  Heart failure is detected after birth when the infants 
become entirely dependent on the systemic circulation.   
HLHS was initially described by Maurice Lev in 1952, based on babies in which 
hypoplasia of the left heart and hypertrophy of the right cardiac structures were 
observed (Lev, 1952). However, in 1958, Noonan and Nadas narrowed the 
classification of HLHS to include a spectrum of left ventricular hypoplasia, 
ranging from atretic aortic and mitral valves with a vestigial left ventricle, to a 
mild form of left ventricular underdevelopment (Noonan and Nadas, 1958). 
Based on their classification, five groups of HLHS were proposed; (1) atresia 
of aortic valve, (2) atresia of mitral valve, (3) stenosis of mitral valve, (4) atresia 
of aortic arch, and (5) hypoplasia of the aortic arch. In 1996, the 
characterisation of HLHS was altered to take into account the varying degree 
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of valvar abnormalities that associate with hypoplastic development of the left 
ventricle (Lev, 1996; Ferreira et al., 2014). Of the different proposed 
classifications, the valvar abnormality-based classification that focused on 
mitral and aortic valves conditions has become accepted and widely used. 
This was predominantly due to the clinical use of this classification in the early 
surgical reports and by surgeons working to find a surgical solution for HLHS 
(Norwood et al., 1980; Doty et al., 1980). Therefore, despite the lack of 
specificity and difficulty in precise diagnosis, the valvular based classification 
has gained widespread acceptance.   
Despite several HLHS genomic studies that have investigated the clinical 
valvular morphology, the aetiology of HLHS remains unknown. Therefore, in 
order to facilitate genomic and developmental studies on HLHS, this study has 
suggested a novel classification method based on ventricular morphology. The 
ventricular morphological classification presents three groups of left ventricular 
hypoplasia, ranging from the severest form with slit-like ventricle with atretic 
aortic and mitral valves, to thick-walled ventricle with EFE and mitral stenosis 
and either atresia or stenosis of the aortic valve, to a mild form with a 
miniaturised ventricle characterised by stenotic aortic and mitral valves. This 
classification has also showed some overlap with the clinical classification, 
specifically the slit-like ventricles with AA/MA, thick-walled ventricles with 
AA/MS and severe AS/MS, and miniaturised ventricles with AS/MS. The fact 
that the thick-walled ventricular group has resulted in categorising the AA/MS 
and severe AS/MS clinical groups together comes in agreement with Bharati 
and Lev study. It was proposed by Bharati and Lev in 1984, as they analysed 
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230 surgical hearts with HLHS and noticed almost identical anatomical 
features between AA/MS hearts and the severe AS/MS hearts (Bharati and 
Lev, 1984). Although they did not suggest the ventricular-based classification, 
they recommended considering the AA/MS and severe AS/MS groups as one 
group. The various presented parameters in this chapter including the left 
ventricular wall thickness, left ventricular cavity length and detection of EFE 
supported the alternative ventricular-based grouping. This supports the 
importance of the ventricular classification in developmental and genetic 
studies of HLHS, as this classification provides essential parameters, which 
are useful for detecting and proposing causes of HLHS from a developmental 
point of view.  
Although the clinical classification is based on the functionality of the valves, 
from a morphological point of view this classification does not accurately 
describe the valve appearances. Thus, describing the valve appearances with 
respect to the left ventricular phenotypes provides additional information that 
might be relevant to diagnosis and aetiology. For example, the slit-like 
ventricles always showed absent or severe aortic and mitral valve 
malformations, whereas the miniaturised ventricles showed mild aortic and 
mitral valve defects. This suggested a strong correlation between the valve 
malformation and the ventricular size. It also provided an easy and definitive 
classification for the complexity of HLHS. In addition, the association of valve 
appearances and ventricular size suggests there could be an initial factor 
controlling the primary formation of the left ventricle and/or the left 
atrioventricular junction, or its expansion, rather than the influence of blood 
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flow. In the cases where the valve tissue appeared to be completely absent, 
as was seen in the slit-like ventricle and in some cases of the thick-walled 
ventricles, a failure to form endocardial cushion/valve tissue might be the 
primary cause. However, in the mild valvular defects including that seen in the 
miniaturised ventricles and some cases of the thick-walled ventricles, a 
deficiency in the left ventricular growth could be the primary origin for rising 
the defects in these groups. 
The ascending aorta size was closely correlated with the severity of the 
abnormalities of the aortic valve, which also mapped perfectly to the ventricular 
phenotype classification. This correlation suggests that the hypoplasia of the 
aorta was secondary to a defect in the aortic valve that blocks the blood flow 
through the aorta and hence prevented its normal growth. This supports the 
hypothesis of no flow, no grow (Sedmera et al., 2005) in the hypoplastic aorta. 
However, the isthmus location showed no relationship to either the clinical or 
the ventricular phenotype classifications.  
The proposed ventricular phenotype classification may help in understanding 
the aetiology and genomic basis underlying HLHS (Figure 2.17). The 
arguments about whether HLHS results from syndromic or a sequence of 
events (Grossfeld et al. 2019) could be explained using the ventricular 
classification. For example, the SLV group that showed no valves and a very 
small ventricular cavity might be caused by a syndromic event of gene(s) 
specific for all of the affected regions in HLHS. This then could lead to defects 
in these regions at the same time. Hence, all of these regions were severely 
affected, as no features of developing valves and ventricle were observed. 
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Alternatively, the SLV group could be due to primary defect in the aortic and 
mitral valves caused by first/second heart field cushions, which led to 
secondary developmental defects in the left ventricle following the no flow, no 
grow hypothesis (Sedmera et al., 2005). Similarly, the MinLV group could be 
caused by a syndromic event of gene(s) that act at the same time and lead to 
underdevelopment of the affected regions in HLHS. Thus, all these regions 
were moderately affected allowing similar growth-rate for all of these regions. 
Alternatively, the MinLV group could be originally due to defects in the 
myocardium and first heart field endothelium of the left ventricle leading to 
secondary defect in the mitral valve and the aortic valve. The TWV group, on 
the other hand, could be primarily caused by second heart field derived 
endocardium in the aortic valve, which led to secondary defects in the left 
ventricle and the mitral valve. Alternatively, the TWV group with its various 
range of valvular morphology and thick wall with small ventricular cavity might 
be caused by a sequence of events due to ventricular specific gene(s). This 
then resulted in underdevelopment of the left ventricle and eventually led to 
the defects observed in the valves. Therefore, based on the ventricular 
severity, a different range of valvular morphological defects could be observed. 
Evaluation of the potential genes or HLHS will be discussed in more detail in 
chapter 5. A unique feature of the TWV group was the presence of EFE in the 
left ventricle, which was not found in the other SLV and MinLV subgroups. 
Although there have been several suggestions for the cause of EFE including 
viral infections, sub-myocardial ischaemia, and excessive endocardial to 
mesenchymal transformation (Tian and Morrisey, 2012; Baffa et al., 1992; Xu 
et al., 2015) it is still unclear what the main causes of EFE is and why it is 
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limited to the TWV subgroup. It is speculated that EFE is a secondary 
response to a condition of reduced but present blood flow in the left ventricle 
caused by defects in the valves. Together, this indicates that the ventricular 
classification provides new hypotheses for each subgroup that are informative 
of aetiology and feasibly investigable.  
 
 
Figure 2.17: Three different ventricular classification in relation to defects 
and progenitor linages.   
Purple represents high level of dexoxygenated blood with low level of 
oxygenated blood, while blue represents a mixture of oxygenated and 
deoxygenated blood. AV= Aortic valve, MV= mitral valve, LV= left ventricle, FHF 
= first heart field, SHF = second heart field.  
 
  




To summarise, HLHS affects multiple regions of the hearts in which these 
regions are disturbed to a varying degree. In this series of 78 hearts from the 
Birmingham Children’s Hospital, a novel classification method was proposed 
that was built on the basis of the ventricular phenotypes. Three distinctive 
ventricular morphologies were identified: slit-like ventricle, thick-walled 
ventricle and miniaturised ventricle (Figure 2.17). This method was not set to 
replace the clinical conventional classification, it was proposed to facilitate the 
genomic studies performed on HLHS cases as it suggested well-defined and 
specific anatomical subgroups of HLHS for investigating candidate genes for 
HLHS. The ventricular morphological classification also showed better 
correlation of the left ventricular wall thickness and length as well as valvular 
appearances, than the conventional clinical classification. This study not only 
suggests a novel classification of HLHS, it also shows the importance of 
archival heart collections in understanding the morphological appearances of 
HLHS in the different subgroups. The use of archival hearts made a close 
examination of HLHS possible and beneficial. This encourages the use of the 
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In the previous chapter, a collection of hypoplastic left heart syndrome (HLHS) 
archival hearts, which had different abnormalities associated with left-sided 
valvar and ventricular development leading to different subtypes, was 
presented. It might be difficult to fully identify the sub-types of HLHS during 
early heart development, but this could be easily achieved using HLHS 
archival hearts. Therefore, these archival hearts could, in theory, be used as 
a well-defined subgroup of HLHS for genetic studies. Archival hearts are 
normally fixed in a chemical preserving medium, formalin that maintains the 
biological structure of these hearts. Although the formalin-fixed hearts are 
excellent resources for morphological and histological analysis, their use in 
molecular studies is a challenge. This is due to the fact that formalin disrupts 
the chromosomal DNA in these tissues by cross-linking and cleaving, which 
eventually leads to corrupt and short sequencing reads from that DNA. 
However, owing to recent advances in molecular biology, these obstacles are 
no longer necessarily a limiting factor. Therefore, this chapter will discuss the 
detrimental effects of formalin fixative on DNA with a short review of the 
suggested solutions to overcome these effects; both through chemical and 
sequencing methodological approaches. Then, an optimal method for 
extracting DNA from formalin-fixed materials will be developed, based on DNA 
yield, purity, fragment size and amplification using polymerase chain reaction 
(PCR). Finally, assessment of DNA sequence produced from these tissues 
using the gold standard Sanger sequencing and the modern next-generation 
sequencing is presented.   
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3.2 The complications of formalin fixative in respect to DNA 
Fixation is the process of preserving cellular architecture and other bio-active 
moieties within non-living organisms with minimum alteration of their normal 
state (Thavarajah et. al., 2012). The use of formalin as a fixative was a 
fortuitous discovery by Blum in 1893, when he noticed the hardening of the 
skin on his fingers that had had a direct contact with diluted formaldehyde (Fox 
et al, 1985). Since then formalin has been universally approved as a biological 
preserving solution that has a convenient and consistent effect on tissues 
(Puchtler and Meloan, 1985; Fox et al, 1985). Although formalin is used to 
protect tissues from damage and decay, it penetrates into tissues through a 
physical process that unfortunately leads to several modifications and 
degradation of nucleic acids within the tissue (Thavarajah et. al., 2012). 
3.2.1 Physical process of formalin fixation 
Saturated formalin, or 100% formalin (CH2O), is a saturated solution 
containing 37%-40% formaldehyde with 10-20% methanol in distilled water. 
The addition of methanol is essential to provide stabilisation and prevent 
polymerisation (Pelco, 2016). Polymerisation of formaldehyde, although it is 
normally a gas, produces paraformaldehyde. Formalin, formaldehyde and 
paraformaldehyde are fundamentally all the same, with differences in the 
quantity of methanol present in the former (Pelco, 2016). Owing to the 
presence of methanol, the fixation process has two phases: an alcohol fixation 
phase to dehydrate and harden tissues, and a cross-linking phase regulated 
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by aldehyde (Thavarajah et. al., 2012; Fox et al, 1985). Tissue immersed in 
formalin is penetrated by formaldehyde and methylene glycol formed by 
hydrated formaldehyde (Kiernan, 2000). Whilst the covalent reaction is mainly 
mediated by formaldehyde cross-linking to tissue components, only a minor 
quantity of formaldehyde is present. Therefore, the majority of methylene 
glycol is dissociated to form more formaldehyde, allowing more cross-links to 
form (Mason and O'Leary, 1991; Thavarajah et. al., 2012; Fox et al, 1985).  
3.2.2 Cross linking of DNA 
The chemical reaction that leads to cross-linking of proteins and DNA by 
formalin is the fundamental process that maintains ultrastructural detail during 
formalin fixation (Hassell and Hand, 1974). However, formalin has several 
specific effects on DNA that lead to difficulties in DNA isolation and carrying 
out PCR.   
Formalin produces extensive aldehyde cross linking between complementary 
guanine (G), adenine (A), and cytosine (C) within double stranded or inter-
strand DNA. It also causes non-covalent linkages between adjacent 
nucleotides on the same strand with the typical reaction product being a 









In DNA-protein cross-linking, the covalent linkages formed by formalin 
between the amino groups, particularly within guanine moieties, contribute to 
the cross-linking with proteins to form a stable complex. The stability of this 
complex is due to the other guanine moiety found in the same strand binding 
to formalin via a strong hydrogen bond (Zeman et al., 1998). The formation of 
this protein-DNA cross-linking is considered as an initial genotoxic effect after 
exposure to formaldehyde. There are two pathways that can be responsible 
for the construction of protein-DNA cross-linking. (A) The first route involves 
formation of a formaldehyde-induced methylol adduct on the DNA molecule 
nucleophilic site, which leads to generation of a hydroxymethyl compound. 
Due to the instability of this compound, it is dehydrolysed to form a Schiff base 
that interacts with proteins to establish a methylene bridge. (B) The second 
route involves formation of a formaldehyde-induced methylol adduct on a 
protein nucleophilic site leading to a direct interaction with DNA bases to form 
a methylene bridge (Figure 3.2) (Lu et. al., 2010).  
Figure 3.1: Formalin-induced cross-linking between double stranded DNA. 
Formalin reacts with nucleotides by forming covalent linkages between inter-
strand (double stranded) and non-covalent linkages between nucleotides in the 
same strand (modified from Thavarajah et. al., 2012).  
  





Figure 3.2: The two routes for formaldehyde-induced protein DNA cross-
linking.  
(A) Formaldehyde-derived methylol adduct interacts with DNA on a nucleophilic 
site forming an unstable hydroxymethyl compound, which is quickly dehydrated 
to form a schiff base. A second interaction then occurs to generate a methylene 
bridge between the schiff base and protein with amide moiety. (B) Formaldehyde-
derived methylol adduct initially interacts with a protein in the nucleophilic site 
forming a hydroxymethyl compound, and then the compound interacts with DNA 
base to establish a methylene bridge. Abbreviations, MA: methylol adduct, H2C: 
schiff base.   
 
The cross-linking of DNA can be easily dissociated with heat, which indicates 
a reversible effect of formalin on DNA (Thavarajah et. al., 2012). However, 
within the PCR reaction this has the potential to interfere with the activity of 
polymerisation and incorporation of DNA debris into the template DNA. 
Consequently, this leads to the generation of new transcripts with non-specific 
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hybridization of DNA fragments to the template strand (Dietrich et.al. 2013). 
However, this is a rare event and does not lead to overall misreading (Quach 
et. al., 2004; Thavarajah et. al., 2012). Whilst these processes are known to 
occur, they are presumed to occur sporadically and at low level such that the 
overall sequence within the PCR product is maintained. There is no evidence 
to suggest that there are sequence-specific effects that would lead to a 
systematic artefact. Both the covalent complementary strand and the same 
strand non-covalent linkage are chemically reversible, but whether their effects 
of the sequence reads are reversible remains unclear (Thavarajah et. al., 
2012; Dietrich et.al. 2013; Tang, 2006). 
3.2.3 Covalent binding of protein 
Formalin creates covalent linkage of amino and imino groups to form a Schiff’s 
base or reacts with amides to generate hydroxymethyl compounds that 
contribute to a second linkage generating methylene bridges between amino 
acids or amides (Figure 3.3) (Schmiedeberg et. al., 2009; Thavarajah et. al., 
2012). The formation of methylene bridges facilities establishment of amino 
acids and single nucleoside cross-links. Interestingly, cross-links induced by 
methylene bridges have been reported between Lys, Cys, His and Trp with G, 
A and C, but not with T and not Arg, Gln, Tyr or Asn with G, A, and C (Lu et 
al., 2010). The formaldehyde-induced cross-linking between protein and DNA 
is found to be specific and normally unstable at room temperature, which 
indicates the reversibility of protein cross-linking (Schmiedeberg et. al., 2009; 
Toth and Biggin, 2000). In addition, it is most likely that formalin interacts with 
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proteins primarily either to generate protein-DNA cross-linking or protein-
protein cross-linking. Therefore, other molecules including nucleic acids, lipid 
and carbohydrates are considered to be entrapped within the complexity of 
protein cross-linking in a reversible manner (Ahmed, 2004).  
  
  
Figure 3.3: Formaldehyde-induced cross-linking between proteins.   
(A) Hydrated formaldehyde forms methylene glycol that reacts fast with amino 
or amide groups of a protein through dehydration. This leads to the formation 
of hydroxymethyl compound. (B) The hydroxymethyl group on that protein then 
reacts slowly with other reactive atom on other proteins generat ing a 
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3.2.4 Severing of DNA 
Whilst most of the formalin-induced genotoxic effects are reversible, there is 
also major irreversible damage caused by long term incubation in formalin, 
particularly with unbuffered formalin. The unbuffered formalin, or long-term 
incubation with buffered formalin, results in oxidation of formalin to formic acid, 
which has destabilizing properties. Formic acid de-purinates DNA such that 
the purine is lost from the DNA backbone through the cleavage of the N 
glycosidic link between the purine base and the deoxyribose in DNA (Kelly, 
2006). As a result, small fragments of DNA, less than 200bp, are found. These 
fragments produce a poor substrate for most polymorphism and mutation-
based genomic studies (Bonin et al., 2003; Tang, 2006).  
3.2.5 Reliability of sequence Information 
Although the reversibility of some formalin-induced DNA damage is 
encouraging, all the deleterious effects of formalin on DNA raise the question 
of whether the obtained sequence information is reproducible and reliable. 
Sequence modifications can occur during DNA replication, where DNA base 
damage is bridged by DNA polymerase by “crossover” to another strand or 
“fall off” its target leading to unreliable products (Pelt-Verkuil et. al., 2008; Tang 
et. al., 2006). Therefore, validation of sequence information is an important 
aspect that needs to be considered to avoid false positive or negative results.  
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3.3 Recommended solutions to overcome formalin 
complications 
Formalin causes modification and interactions that are essential for preventing 
DNA loss during tissue preservation, however at the same time it causes DNA 
degradation (Srinivasan et. al., 2002). In fact, most of the deleterious effects 
of formalin on DNA are not permanent; hence these effects can be reversed 
with some preparatory steps. Several studies have shown varying degrees of 
success in extracting high molecular weight DNA from formalin-fixed samples, 
with some additional steps needed to breakdown formalin cross-linking and 
release DNA (Diaz-Cano and Brady, 1997, Wang et. al., 2013). However, 
these steps may expose the DNA to increased risk of contamination from the 
harsh detergents used to extract the DNA, and eventually lead to DNA 
degradation during the extracting processes.   Therefore, this section will focus 
on the effective solutions that can be used to modify a standard DNA extraction 
method in order to minimise the detrimental complications of formalin while 
maintaining low levels of contamination, with emphasis on the impact of 
formalin on methodologies such as PCR. 
3.3.1 Removal of excessive formalin 
Tissues are normally immersed in a liquid form of formalin to ensure the 
hydration of tissue and efficient tissue fixation. The efficiency of fixation is 
mediated by formaldehyde cross-linking to the tissue components including 
proteins, lipids, and DNA (Kiernan, 2000). Therefore, in order to extract DNA, 
excessive formalin must first be removed to minimize the possibility of re-
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cross-linking by formalin when the breakdown of cross-linking begins. The 
Sarin group (Pandey et al., 2014) suggested the use of GTE buffer that 
contained Glycine, Tris, and ethylenediaminetetraacetic acid (EDTA) to wash 
off excessive formalin, whereas the Parmar group (Shrivastava et al, 2012) 
and Line group (Santo et al., 2008) favoured the use of TNE buffer containing 
Tris, sodium chloride (NaCl) and EDTA.  
The GTE buffer was recommended to use because it reduced the formation 
of methylene glycol, which was a source of formaldehyde, through the 
interactions between glycine (a component of GTE buffer) and formaldehyde. 
These interactions resulted in forming N-Methyleneglycine or Dimethylglycine 
rather than methylene glycol, which was the formaldehyde sources (Pandey 
et al., 2014). Moreover, the other component of the GTE buffer, Tris 
neutralised the DNA environment helping to reverse the DNA-protein cross-
linking (Pandey et al., 2014). EDTA, which was a shared component between 
GTE and TNE buffers, was mainly introduced to protect and prevent 
degradation of DNA through neutralising the activity of DNA by binding to 
metal ions, such as calcium and magnesium, and inactivates DNases 
(Shrivastava et. al., 2012; Santo et. al., 2008; Pandey et. al., 2014). Sodium 
chloride, which was used in the TNE buffer, was important for removing and 
precipitated proteins that were loosely bound to DNA (Shrivastava et. al., 
2012; Santo et. al., 2008). Thus, washing with either buffers were highly 
recommended for at least three days, with several changes every 6 to 12 hours 
or until the tissue became soft (Santo et. al., 2008; Pandey et al., 2014). 
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3.3.2 Digestion to remove formalin cross-linking 
It is essential to break down the cross-linking between formalin and DNA or 
formalin and protein, and even between protein and DNA, under non-
denaturing conditions and without disrupting the natural structure of DNA. 
Lysis buffer, which is used to digest tissue and extract cell components, allows 
the isolation processes of DNA, while preserving the nondenaturing conditions 
(Peach et. al., 2015). The constituents of lysis buffer can be altered depending 
on the molecule of interest, and source and type of tissue.  However, a 
standard lysis buffer contains salt solution, detergents, chelating agents and 
inhibitors.  
The majority of lysis buffers have Tris-HCl pH 8.0, HEPES, or sodium chloride 
as a salt solution to stabilize pH during the digestion process. Tris-HCl is the 
most widely accepted salt solution due to its ability to maintain stable pH and 
provide alkalinity to reverse the binding between proteins and DNA (Wang et. 
al., 2013; Coa et. al., 2003). In a study carried out on short-term formalin-fixed 
human liver specimens (Duval et al., 2010), it was suggested that a 
combination of Tris-HCl and sodium chloride was most effective, as NaCl 
removed proteins that are already unbound from DNA by Tris-HCl. In addition, 
NaCl enhances the ionic strength of lysis buffer, which leads to a high solute 
concentration outside cells, and hence increases diffusion of lysis buffer 
across the cell membrane (Lieb and Stein, 1968; Green and Sambrook, 2012).  
 
Chapter 3: Archival Tissues Extraction & Sequencing  
109 
 
Detergents in lysis buffer are then used to destroy the lipid barrier in cell 
membranes through protein stabilisation and disruption of interactions 
between lipid:lipid, protein:protein, and protein:lipid (Green and Sambrook, 
2012). Based on the nature of the detergent, they can be classified into three 
groups: ionic (anionic or cationic), non-ionic and zwitterionic (both a negative 
and a positive charge). Ionic detergents are favoured for their strong 
solubilizing ability and denaturing of proteins. Sodium dodecyl sulphate (SDS), 
is an anionic agent that is widely used for complete disruption of cell 
membranes and protein denaturing, as it adds a negative charge to all proteins 
leading to loss of protein functions. Similarly, sodium lauroyl sarcosinate or 
sarkosyl is an anionic agent that permeabilises cells and denatures proteins 
(Green and Sambrook, 2012).  
However, non-ionic agents are mostly used for protein non-denaturing buffer. 
Nonidet P40 and Triton-X100 are examples of non-ionic agents. Most of the 
non-ionic agents interfere with UV spectrophotometry, particularly Triton-
X100, as it absorbs UV light via its a phenyl ring (Lieb and Stein, 1968; Green 
and Sambrook, 2012). Tween 20 is also a non-ionic and polysorbate agent 
with lauric acid that it ideal for protein extraction as it does not affect the activity 
of proteins while maintaining its ability to permeabilise the cell membrane 
(Green and Sambrook, 2012).  
Although extracting DNA from formalin fixed tissues requires the addition of 
several chemical detergents, it is still important to consider their interactions 
and inhibitions of PCR amplification processes (Alaeddini, 2012). One 
recommended approach to eliminate PCR inhibitors was to use Chelex-100, 
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which provided alkaline conditions and helped in removing heavy metals (Idris 
and Goodwin, 2015). Chelex-100 is a chelating agent that has the ability to 
purify compounds through ion exchange. The use of Chelex-100 was mostly 
for isolating DNA from forensic-type samples, as it yielded high DNA quantity 
from small starting materials (Alaeddini, 2012). In addition, Chelex-100 was 
reported to protect DNA from high temperature treatments and chelated a 
large volume of divalent ions that could be found in the lysis buffer. Because 
it is easy to remove the Chelex-100 beads, it is normally recommended for use 
with PCR as it does not interfere with PCR amplification processes (Walsh et 
al., 1991).  
3.3.3 Reliable sequence information: Multiple clones or 
systematic comparison 
It is very important to ensure the obtained DNA sequence is indeed 
representative of the original specimen. Therefore, several suggestions have 
been proposed in order to reduce risk of faulty DNA products (Pelt-Verkuil et. 
al., 2008; Tang et. al., 2006).   
One approach to minimise the risk of having unreliable DNA sequence 
information is through cloning a DNA product extracted from a formalin fixed 
tissue, followed by performing a comparison between the different clones that 
are produced from the DNA product. This allows identification of the 
consensus sequence between the clones and thus reflects the original 
sequence (Pelt-Verkuil et. al., 2008). However, in the case of non-random and 
specific region alterations in DNA sequence, such as might arise following 
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fixation in formalin, another approach must be considered such as a 
comparison between a fixed sample and a fresh sample from the same 
individual (Tang et. al., 2006). However, fresh and fixed samples from the 
same individual are not always available, especially for archival studies, 
therefore a different methodology is required.  
More recently, the advances in sequencing technology have allowed genomic 
studies to be performed on formalin-fixed tissues. Next-generation sequencing 
(NGS) provides a solution for the problem of short DNA fragments, as it 
requires the DNA size to be between 100-200bp. Whilst NGS has opened the 
possibility for sequencing DNA extracted from formalin-fixed tissues (FFT), it 
is still unknown whether FFT will produce reliable sequencing reads using this 
NGS. Although it was recently reported that reliable NGS data was obtained 
from formalin-fixed paraffin-embedded (FFPE) tissues, short fixation ideally for 
one day with 10% buffered formalin was crucial to obtain reliable NGS data 
using the author’s protocol (Einaga et al., 2017). However, this was not the 
case when this protocol was used on FFPE samples that had been fixed in 
formalin for longer than one day. Therefore, whilst it has been shown that 
FFPE samples could produce reliable NGS data; but only if they were fixed for 
one day, it remains very important to validate DNA sequences generated by 
NGS from FF tissues particularly the ones that had been fixed in formalin for 
long periods.  
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3.4 Aims of this chapter 
The extraction of DNA from archival FFT provides rich sources of biomolecular 
information enabling gene expression analysis. The use of these tissues for 
gene expression analysis is fundamental for understanding challenging 
malformations such as HLHS. However, using archival FFT collections for 
genomic studies remains a challenge. Breakthroughs in technology have 
made the use of extracted genomic DNA (gDNA) from formalin-fixed materials 
possible. However, the methodological constraints and practical complications 
demand the optimisation of protocols to enhance the yield, purity and read 
length of extracted DNA.  Therefore, the main aim of the current chapter was 
to establish the most appropriate method to extract high quality DNA that will 
yield reliable and reproducible sequence information from FFT. The goal for 
the use of the optimised method is to identify genes causing HLHS using 
archival FFT collections of HLHS, such as those held at Birmingham Children’s 
Hospital investigated in Chapter 2. In order to achieve this, the following aims 
were established:  
• To establish a standard method that enables successful extraction of 
DNA from FFT, based on information from the published literature. 
• To assess the quality of extracted DNA by quantification of DNA yield 
and purity using NanoDrop/spectrophotometry; DNA fragment size 
distribution by gel electrophoresis; and successful amplification by 
PCR. 
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• To optimise conditions of the chosen method by systematically 
introducing changes to the main stages involved in the extraction 
procedure, such as the washing step and heat treatments.  
• To validate the efficiency of the optimised method by comparing the 
quality and quantity of extract DNA from this method to a commercial 
kit.  
• To assess the quality and reproducibility of sequence information 
generated by the isolated DNA from the optimised method and to 
compare its efficiency to a commercial kit. 
• To assess the possibility of extracting DNA from tissues with prolonged 
fixation period in formalin (up to 2 years). 
• To validate whether NGS particularly exome sequencing can produce 
reliable DNA data from formalin fixed tissues by comparing DNA 
isolated from a formalin-fixed tissue to that obtained from a fresh blood 
sample of the same individual.  
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3.5 Methods and materials 
3.5.1 Tissue samples and HTA ethics 
Archival formalin-fixed human lung artery specimen (approximately 4 g) from 
a healthy donor was obtained from the Royal Victoria Infirmary (RVI). 
Immediately upon removal of donor tissue, the sample was preserved in 10% 
neural buffered formalin at room temperature for almost 9 months. As for the 
comparison of NGS, DNA extracted from 10% buffered formalin-fixed 
explanted heart (right ventricular myocardium) preserved for two years and 
DNA extracted from blood sample were obtained from the same individual. 
Both samples were collected from the Department of Cellular Pathology, Royal 
Victoria Infirmary, Newcastle upon Tyne and analyses were approved by the 
Newcastle and North Tyneside 1, NRES Committee; REC Reference: 
15/NE/0311. 
Using a disposable sterile scalpel, 10mg (approximately 15mm2) tissue was 
placed on a plastic petri dish, chopped into small, equal pieces (approximately 
1mm2) and placed into a 60ml sterilin container using autoclaved forceps 
(Scientific laboratory supplement, CON7536, UK). To minimise risk of 
contamination, all used equipment were sterilised or autoclaved prior to use. 
The same amount of formalin-fixed tissue was used for all protocols performed 
in this study.  
Our DNA extraction method was developed following five main stages: wash, 
digest, heat treatment, elution, and clean-up and storage. The wash, digest 
and heat treatment stages were modified from Pandey et al., 2014; Cao et al., 
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2003; Idris and Goodwin, 2015; and Shi et al., 2002, followed by a traditional 
phenol: chloroform extraction (Green and Sambrook, 2012). The isolated DNA 
yield and purity were measured using a NanoDrop spectrophotometer; 
fragments and size range were determined by gel electrophoresis; suitability 
for amplification was determined based on polymerase chain reaction (PCR); 
and finally, reliability and reproducibility of sequence were established by a 
PCR-based cloning method.    
3.5.2 Standard protocol (ST-100) 
A modified protocol to extract DNA from formalin-fixed tissues was used as a 
control protocol (Pandey et al., 2014). This is described hereafter as the ST-
100 protocol. 
Wash: tissue was washed with GTE buffer (100mM glycine, 10mM Tris-HCL 
pH 8.0 and 1mM EDTA, Table 3.1) for three days at 37°C in a water bath 
shaker (800rpm) to remove excessive formalin.  Several short washes were 
carried out immediately after removal of tissue from formalin, followed by a 
fixed washing scheme performed every 12h using a disposable sterilised 
plastic pipette. Washing buffer was then removed and samples rinsed with 
0.5mL of the lysis buffer to equilibrate samples for the next step.  
Digest: samples were incubated in 3mL lysis buffer (1M Tris-HCl pH 8.0, 10% 
Sodium dodecyl sulphate (SDS), 0.5M EDTA) with 2mg/mL proteinase K 
(Sigma-Aldrich, P6556) at 55°C on a water bath shaker (Table 3.1) (Pandey 
et al., 2014: Duval et al., 2010). Following the Pandey protocol, fresh 
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proteinase K (to a final concentration of 2mg/mL) was added every 12h for two 
days. If tissue was not completely digested within this time, further addition of 
proteinase K (to a final concentration of 1mg/mL) was carried out every 12h 
until the tissue was fully digested (Farugia et al., 2010).  
Heat Treatment: digested samples were divided into three 1mL aliquots and 
transferred to 1.5mL microcentrifuge tubes. Following the protocol of Cao et 
al. 2003, the samples were heated at 100˚C using a heat block for 10 minutes 
to inactivate proteinase K. After cooling to room temperature, incubation with 
20µl of RNase A (final concentration of 40µg/mL, Sigma-Aldrich, R6513) for 5 
minutes at room temperature was performed (Green and Sambrook, 2012).  
Elution: samples were collected into sterilised 15mL tubes and an equal 
volume of phenol: chloroform: isoamyl alcohol solution (Sigma, P3803) was 
added and mixed gently on roller apparatus for 10 minutes. The samples were 
centrifuged for 15 minutes at 5000rpm (room temperature) and 0.75mL of the 
resulting upper aqueous layer was transferred into fresh, sterilized 1.5mL 
Eppendorf tubes (Green and Sambrook, 2012; Senguven et al., 2014). To 
ensure maximum recovery of DNA, 1mL 1x TE buffer pH 7.8 (Table 3.1) was 
added to the remaining phenol: chloroform: isoamyl alcohol solution and mixed 
gently for 10 minutes using the roller apparatus. Samples were then 
centrifuged for 15 minutes at 5000rpm and the upper aqueous layer 
transferred to fresh 1.5mL Eppendorf tubes. The final step was repeated to 
reduce risk of carryover contamination and to maximize DNA recovery (Green 
and Sambrook, 2012). 
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Clean-up and storage: one volume (0.75mL) isopropanol and 30μL sodium 
chloride (final concentration at 0.2M) were added to each tube to reduce the 
dielectric persistent of the solution, leading to DNA precipitation. The samples 
were inverted several times before chilling at −20°C overnight for DNA 
precipitation to occur. Subsequently, samples were incubated at minus 80oC 
for 2h (Green and Sambrook, 2012). Then, samples were centrifuged at 
13,000rpm for 30 minutes at 4°C. The supernatant was discarded and 500μL 
ice-cold 70% ethanol was added to the DNA pellet. The pellet was tapped 
gently before further centrifugation at 13,000rpm for 15 minutes. Supernatant 
was removed and the wash twice repeated. The pellet was air-dried and re-
suspended in 50μL 1× TE buffer, and stored at 4°C (Pandey et al., 2014).   
Table 3.1: List of reagents used and solution preparation. 
Reagent Preparation 
1x GTE buffer 
• 100 mM glycine 
• 10 mM Tris-HCL pH 8.0 
• 1 mM EDTA 
Lysis buffer 
• 0.5M EDTA, pH8.0 
• 1M Tris-HCl, pH8.5 
• 10% Sodium dodecyl sulphate (SDS) 
• 2mg/ml proteinase K 
1x TE buffer 
• 10 mM Tris-Cl (pH 7.5) 
• 1 mM EDTA (pH 8) 
• pH to either 7.8 or 8. 
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3.5.3 Simple heating protocol (ST-120)  
For the purpose of comparison, the ST-100 protocol was modified at the heat 
treatment stage. According to Shi et al. 2002, heating samples at 120˚C 
increased efficiency of DNA extraction. Therefore, samples were heated at 
120°C using an autoclave machine for 10 minutes. 
3.5.4  Chelex-100 at 100˚C protocol (CH-100) 
The ST-100 was modified according to Idris and Goodwin (2015). The ST-100 
protocol was followed with the exception of the heat treatment where, in 
addition, Chelex-100 was used. Briefly, the samples were treated with 200µl 
of 10% Chelex-100 (Bio-Rad laboratories) before subjecting to heat treatment 
at 100˚C for 10 minutes.  
3.5.5 Chelex-100 at 120˚C protocol (CH-120) 
The CH-120 protocol was designed to combine the techniques of Idris and 
Goodwin (2015) and Shi et al. (2002), along with the standard ST-100 protcol. 
Therefore, 200µl of 10% Chelex-100 (Bio-Rad laboratories) was added to the 
samples followed by heat treatment at 120˚C using an autoclave for 10 
minutes (Figure 3.4).     





Figure 3.4: Schematic diagram of DNA extraction procedures from formalin 
fixed tissues.   
The standard protocol involves a wash step for 72h with 1xGTE buffer at 37˚C, 
followed by a digestion step with lysis buffer with fresh additions of proteinase 
K every 12h for 72h at 55˚C. The heat treatment involves different conditions 
indicated by the colour scheme. The final step involves phenol/chloroform 
extraction and precipitation by ethanol.  
 
 
3.5.6 Introduced modifications to optimise protocol 
In order to improve and shorten the protocol, several alterations were 
introduced. The alterations were made to shorten duration period of the wash 
step, to reduce the concentration of proteinase K and to enhance the accuracy 
of sequence. Reducing proteinase K concentration was important because it 
would help in reducing the risk of DNA contamination and degradation, and in 
cutting the cost of proteinase K. The wash step was reduced to 24 hours at 
two different temperatures: 37˚C and 55˚C; proteinase K concentration was 
reduced to 1mg/mL instead of 2mg/mL; and 2U of Uracil-N-glycosylase (UNG) 
enzyme with 1x UNG buffer (New England BioLabs, Ipswich, MA) was added 
to samples and heated at 50˚C for 1 hour (Lui et al.,2013) (Figure 3.5).   





Figure 3.5: Schematic diagram of changes to the DNA extraction 
procedures.  
The initial step to improve and shorten duration of procedure was to reduce the 
period of wash incubation to 24 hours with changes to incubation temperature. 
Samples were incubated at 37˚C (blue box) or at 55˚C (green box) for 24 hours. 
The procedure was then performed as indicated in the white boxes. A second 
alteration was the reduction in proteinase K concentration from 2mg/mL twice a 
day to 1mg/mL twice a day. Again, the procedure was then carried out as 
indicated in white boxes. The final alteration was aimed to improve the reliability 
of sequence; therefore, an additional step was introduced after heat treatment 
and involving the addition of Uracil-N-glycosylase (UNG) at 50˚C for 1 hour.  
 
 
3.5.7 The DNA FFPE Kit 
The QIAgen GeneRead™ FFPE kit (Cat no.180134, Valencia, CA, USA) was 
used to isolate DNA from formalin fixed tissues and was compared to the final 
optimised method. The procedure was performed according to the 
manufacturer’s protocol (Figure 3.6). Briefly, 10mg of tissue was cut into small 
pieces and equally placed in two sterile 1.5mL microcentrifuge tubes. Then, a 
master mix of 25μl Buffer FTB, 55µL RNase-free water and 20μl proteinase K 
was added to each tube and incubated in a thermomixer for 1 hour at 56°C. 
Following a second incubation at 90°C for 1 hour, 115μL RNase-free water 
was added to each tube with 35μL Uracil-N-glycosylase (UNG), vortexed, and 
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heated for 1 hour at 50°C. After subsequent incubation with 2μL RNase A (100 
mg/ml) for 2 minutes at room temperature, 250μL Buffer AL was added, 
followed by 250μL absolute ethanol. Samples were vortexed and transferred 
to the QIAamp MinElute columns. The columns were centrifuged for 1 minute 
at 20,000 x g and the flow-through, discarded.  500μL Buffer AW1 was added 
to each column, centrifuged and the flow-through discarded. This was 
repeated with 500μL Buffer AW2 then 250μL absolute ethanol. To remove any 
residual liquid, columns were centrifuged for 1 minute and then placed into 
fresh 1.5mL collection tubes. Finally, 25μL Buffer ATE was added to the centre 
of each column membrane and incubated at room temperature for 5 minutes 
before centrifuging for 1 minute at 20,000xg. The resulting eluted DNA was 
stored at 4˚C. 
 




Figure 3.6: Schematic diagram showing the final optimal method and 
QIAgen commercial kit procedure to extract DNA from formalin fixed 
tissues.  
The optimal method started with a wash step using 1x GTE buffer for one day, 
followed by digestion with lysis buffer and fresh addition of proteinase K for three 
days at 55˚C. Then, samples were combined with Chelex-100 and subjected to 
heat treatment at 120˚C for 10 minutes before being treated with UNG buffer for 
1 hour at 50˚C. Finally, classical phenol/chloroform extraction was performed. 
The QIAgen commercial kit did not involve a wash step and samples were 
digested immediately after being removed from formalin. Samples were lysed 
using FTB buffer and proteinase K at 56˚C for 1 hour. After incubation for 1 hour 
at 90˚C, samples were treated with UNG buffer and incubated for 1 hour at 50˚C. 
Finally, a column-based protocol with intensive washes was performed to isolate 
the DNA. 
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3.5.8 Quantification of DNA 
The concentration and the purity of extracted DNA from all protocols were 
measured using a NanoDropTM spectrophotometry. The yield was 
automatically measured at a wavelength of 260nm and the ratio of the reading 
at 260/280nm provided an estimate of DNA purity. The quantity of extracted 
DNA was visualised on a 0.8% agarose gel electrophoresis (SeaKem LE 
agarose) and gDNA fragment size was analysed using a densitometry method 
in ImageJ using the analyse>gels option (1.52p java 1.8.0_172, USA). 
3.5.9 Polymerase chain reaction (PCR) 
To determine the fragment length of extracted DNA, PCR analysis was 
conducted. Four sets of primers specific to the human HAND1 gene were 
designed to generate amplicons of 200bp, 400bp, 600bp and 800bp when 
used in PCR. The reason for using HAND1 specific primer was that HAND1 is 
one of the most important associated genes in HLHS. These primers are listed 
in Table 3.1. All amplifications were performed using a Peliter Thermal cycler 
(PTC-200). Cycle conditions and primer suitability were optimised using 
genomic DNA extracted from fresh blood samples. 
Each 25μL PCR reaction contained 2μL extracted DNA (25ng/μL), 1.25μL of 
10μM each of primers, 0.5μL of 10μM each dNTPs, 2μL of 10mg/mL bovine 
serum albumin (final conc. 1μg/μL BSA), 5μL of 5X Q5 Reaction Buffer and 
5X Q5 High GC Enhancer, and 1U DNA Taq polymerase (Q5® High-Fidelity 
DNA Polymerase, NEB, Ipswich, MA). The thermal cycling conditions were as 
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follows: denaturation at 94°C for 5 minutes, followed by 40 cycles of 
denaturation at 94°C for 1 minute, annealing at 60°C for 30 seconds and 
extension at 72°C for 1 minute, and final extension at 72°C for 10 minutes. 
The PCR products were separated and visualised on 1% agarose gels stained 
with ethidium bromide. 





HAND1 200 GCCCTATCTCCATTTCCCTA CAGGAAGTGCAGCGACAAAA 
HAND1 400 CAACCACACACTTGGATCGC CAGGAAGTGCAGCGACAAAA 
HAND1 600 GCCCAGTCGAGAAGAGGATT CAGGAAGTGCAGCGACAAAA 
HAND1 800 ACCGGTAAGAAGACAGTGGG ACACAGCCTCCTTCGACTAC 
 
3.5.10 AT-cloning of HAND1 fragments from extracted DNA 
A PCR-based cloning method was used to generate colonies containing the 
maximum length of PCR-amplified DNA. After separation of PCR products on 
an agarose gel, the 200bp HAND1 gene fragment from the ST-100 protocol 
and 400bp HAND1 gene fragment from the Chelex-100 based protocol were 
extracted from gels using ISOLATE II PCR and GEL Kit (BioLine, BTP0812V1, 
USA). Then, a polyadenylation step was performed to create a suitable 
substrate for TA cloning by incubating samples at 72°C for 20 minutes with 
0.2mM dATP, 1X Taq buffer (1.5mM MgCl2), and 1U DNA Taq polymerase 
(Promega, Madison, WI, USA). 5µL of polyadenylated products were then 
ligated into 1 µL of 50ng pGEMT-easy vector (Thermo Fisher Scientific, Inc., 
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MA, USA) using 2X Rapid Ligation Buffer and T4 DNA Ligase (3 Weiss 
units/μl). After incubation for 90 minutes at room temperature, the mixture was 
transformed into JM109 competent cells (cat. M208CC85, AllianceBio) by heat 
shock at 42˚C for 45 seconds. Then, SOC medium was added and the newly 
transformed cells incubated for 1 h at 37°C with shaking at 225rpm before 
spreading on a LB agar plate containing 100μg/ml ampicillin, 100µL 100mM 
IPTG and 50µL 20mg/ml X-Gal. Following overnight incubation at 37°C, 
resulting white colonies were assessed by colony-PCR using identical 
conditions to those used for amplification of HAND1 from genomic DNA. Upon 
confirmation of correct HAND1 insert size, 20 selected colonies were cultured 
in LB broth overnight at 37°C with shaking in 225rpm.  
3.5.11 Isolation of DNA from gel agarose 
Isolation of DNA from gel was performed using ISOLATE II PCR and Gel Kit 
(Bioline, BIO-52058) following the manufacturer´s instructions. Briefly, the 
DNA fragment of interest was isolated using a disposable scalpel and 
incubated in an eppendrof tube. Based on the weight of the DNA fragment, 
200uL of binding buffer was added to every 100mg of 2% agarose gel. Then, 
the tube was incubated at 50°C for 10 minutes with vortexing the sample every 
3 minutes. After dissolving the gel into the binding buffer, the sample was 
loaded to a 2mL column and collection tube. Then, centrifuged for 1 minute at 
11,000xg and the flow-through was discarded. Next, 700uL of the wash buffer 
was added to the column, centrifuged for 1 minute at 11,000xg, and the flow-
through was discarded. The sample column was then centrifuged for 1 minute 
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at 11,000xg to remove excessive residual ethanol. Finally, the column was 
placed on a new tube and 30uL of elution buffer was added and incubated at 
room temperature for 5 minutes, before it was centrifuged for 1 minute at 
11,000xg. The final product was incubated at -20°C until needed.  
3.5.12 Plasmid Miniprepe purification  
Plasmid preparation was accomplished using QIAprep Spin Miniprep Kit (Cat 
No. 27104, QIAgen group, UK) according to the manufacturer´s instructions. 
The overnight growth bacterial cultures were centrifuged for 10min at 
1000rpm, room temperature. The pelleted bacterial cultures were then 
suspended in 250ul buffer P1 and transferred to Eppendorf tubes. Next, 250ul 
of buffer P2 was added and mixed through inverting the tube 7 times. After 
that, 350ul of buffer N3 was added, mixed thoroughly, and centrifuged for 
10min at 13,000rpm. The supernatant then was transferred into QIAprep spin 
columns by pipetting and centrifuged for 30sec. The flow through was 
discarded and the columns were washed with 500ul buffer PB. Then, the 
columns were centrifuged for 30secs at 13,000rpm, washed with 750ul buffer 
PE and centrifuged again. To remove the wash buffer from the columns, 
centrifuged for 1min at 13,000rpm. Using fresh 1.5ml Eppendorf tube, the 
columns were placed on tubes and DNA was eluted from columns by adding 
30ul buffer EB containing 10mM tris-HCl pH8.5 and left to stand for 5mins 
before centrifuged for 1min at 13,000rpm. The DNA samples were then stored 
at -20°C until needed.  
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3.5.13 Sanger sequencing  
Plasmid insert DNA was subjected to Sanger sequencing using both forward 
SP6 (Cat.no. Q5011, Promega, USA) and reverse T7 (Cat.no.Q5021, 
Promega, USA) direction primers to confirm reliability and reproducibility of 
inserted nucleotide sequence.  Sanger sequencing was performed by GATC 
biotech (Germany, https://www.gatc-biotech.com). The electropherogram was 
initially analyzed for good nucleotide peaks, followed by entire sequence 
analysis using ApE A Plasmid Editor (v2.07.47, California, USA) and Jalview 
(Waterhouse et al., 2009, http://www.jalview.org) to check accurate sequence 
of HAND1 desired size.  To ensure that no cross-contamination with other 
vectors had occurred, the flanking region of the insert was tested for vector-
specific sequences (Figure 3.6.1). 
 
 




Figure 3.6.1: Diagram showing regional localization of exon 2 in HAND1 
gene with markers indicating the length of cloned regions.  
HAND1 is mapped to chromosome 5 (5q33.2) and consists of two exons: exon 1 
is 799bp in length and exon 2 is 939bp in length. The panel shows the relative 
position of HAND1 gene exons on cDNA (ensemble.org). Small regions on exon 
2 are used in this study to allow determination of correct sequence read 
produced by the different methods of DNA extraction. The region from 1057bp 
to 1464bp is used to generate a 400bp PCR amplicon and the region from 1254bp 
to 1464bp is used to produce a 200bp PCR amplicon. The primers used to 
generate these fragments are indicated in Table 3.2.  
 
3.5.14 Extraction of DNA from blood samples 
Extraction of DNA from blood samples was carried out using BACC2 kit 
(RPN8502, GE healthcare) following the manufacturer´s instructions. The 
blood samples were collected in sodium EDTA tubes and 4 times the volume 
of the blood sample, reagent A was added. Then, the samples were rotated at 
room temperature for 4 minutes before it was centrifuged at 1,300xg for 5 
minutes. The supernatant was discarded, and the pellet was dissolved in 2mL 
of reagent B by vertexing. The suspension was then transferred to 15mL 
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propropylene centrifuge tube and 500ul of sodium perchlorate solution was 
added, the tube was inverted up and down at least 7 times and then 2mL of 
chloroform was added. The tube was inverted, then 300uL of nucleon resin 
was added, and centrifuged at 1,300xg for 3 minutes. Without disturbing the 
nucleon resin layer, the upper phase was transferred to a 15mL clean tube.  
Then, 2 volumes of 100% ethanol were added. The tub was then mixed until 
the precipitate appeared and centrifuged at 4,698xg for 5 minutes. Discarding 
the supernatant, the pellet was dissolved in 70% ethanol, inverted the tube 
several times and then centrifuged at 4,698xg for 5 minutes. After removing 
the supernatant, the DNA pellet was air dried for 2 minutes and re-dissolved 
in 500uL of TE buffer. The final product was incubated at -20°C until needed. 
3.5.15 Exome sequencing 
Exome sequencing and data analysis was performed by Newcastle genomic 
core facility service using the Nextseq 500 platform. The NextSeq 500 platform 
was run on the high output flow cell modes, which enabled 10 sequencing 
samples in 18 hours with 40 million pair end reads of length 75bp.  
Based on the type of DNA samples, different protocols were carried out. For 
DNA extracted from fresh blood samples, the DNA sample was processed 
through TruSeq Rapid Exome Kit. Whereas for formalin fixed samples, TruSeq 
Exome kit was used to process these samples. Before subjecting samples to 
exome sequencing, samples were measured using a Qubit fluorometric-based 
method to quantify the concentration of gDNA. The TrueSeq Rapid exome seq 
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kit required 50ng of total gDNA, whereas the TrueSeq exome seq kit 
demanded 100ng of gDNA.  
The Trueseq Rapid exome seq kit was performed following the manufacture 
manual. This involved fragmentation of gDNA and adapter addition via 
Nextera transposome. Followed by purification of tagmented DNA from 
transposome using sample purification Beads (SPB). Then, the tagmented 
DNA was amplified through adding Index adapters (i7 and i5) and amplified 
using 10 cycles PCR programme. The product was then purified using SPB to 
prevent interference of unwanted products with further processes. The DNA 
libraries with unique indexes were then hybridised to probes followed by 
addition of Streptavidin Magnetic Beads (SMB) to capture specific regions of 
DNA hybridised to probes. The non-hybridised DNA strands were washed off 
and the rest were eluted. The same processes of probe hybridisation and 
capturing were repeated to ensure high specificity of the constructed DNA 
library. The DNA library was then purified with SPB before amplifying using 10 
cycles of PCR amplification programme. After that, the enriched DNA library 
was clean-up to remove unwanted products. Finally, the quantity of enrich 
library was measured using Qubit dsDNA BR Assay kit and quality was 
validated through Agilent Technologies 2100 Bioanalyzer using a High 
Sensitivity DNA chip.  
The TrueSeq exome seq kit was processed according to the manufacture 
manual. After validation of gDNA quantity and quality using Qubit, the gDNA 
was fragmented into 150bp fragments. This shearing generated double 
stranded DNA with 5’ or 3’ overhangs. The DNA fragments were then cleaned 
Chapter 3: Archival Tissues Extraction & Sequencing  
131 
 
up to be prepared for the next step. Fragmentation of DNA resulted in 
fragments with overhangs, therefore, End Repair Mix (ERP3) was used to 
produce blunt end DNA. This is achieved through removing 3’ overhangs by 
3' to 5' exonuclease activity and filling in 5’ overhangs by the 5' to 3' 
polymerase activity. Then, the library size was nominated using SPB. In order 
to prevent 3’ overhangs from binding to each other or forming chimera, a single 
adenine (A) nucleotide and a complementary single thymine (T) nucleotide 
were added to the 3’ overhangs.  After that, DNA fragments are ligated to 
multiple indexing adapters. The DNA fragments with adapter molecules at both 
ends were selectively amplified using PCR to construct DNA library. The PCR 
was made with PCR primer Cocktail (PPC) annealing to adapter ends at a low 
number of PCR cycles to reduce the risk of sloping library representation. The 
enriched DNA library was then purified and validated by Qubit dsDNA BR 
Assay kit for quantity and Agilent Technologies 2100 Bioanalyzer for quality. 
This step combines DNA libraries containing unique indexes into a single pool, 
and then binds targeted regions of the DNA with capture probes. 
3.5.16 Statistical analysis 
All the statistical calculations were performed using SPSS (Version 22, IBM) 
software for Windows. All experiments were run in triplicates and data were 
presented as an average and standard error (SEM). One-way ANOVA test 
and unpaired t test were performed to assess the statistical significance of 
differences between the various DNA extraction methods. Only p-values less 
than 0.05 were considered significant.  




3.6.1 Optimising procedures for DNA extraction  
In order to extract DNA from tissues fixed in formalin, several fundamental 
steps were followed based on information in the published literature (Pandey 
et al. 2014; Farugia et al. 2010; Shi S et al., 2002; Idris and Goodwin, 2015; 
Liu x et al., 2013). Initially, intensive washes to remove residual formalin from 
tissues were carried out; then digestion with a high concentration of proteinase 
K (pK); followed by heat treatment to deactivate pK and Chelex-100 resin 
treatment; and finally, isolation of DNA using a salt-base method. Evaluation 
of the effect of heat treatment and use of Chelex-100 resin was particularly of 
interest because these treatments may improve the DNA quality extracted 
from formalin fixed tissues. Based on the published literature (Pandey et al., 
2014; Farugia et al., 2010; Green and Sambrook, 2012), an initial method that 
had several crucial steps, including extensive washing with GTE buffer 
(section 3.5.2), multiple digestions with pK, and deactivation of pK through 
heat at 100°C (ST-100), was established. A similar protocol but altering the 
temperature to 120°C (ST-120) (Section 3.5.3) for the deactivation step and 
also including Chelex resin and heating to 100°C or 120°C (CH-100) and (CH-
120) were compared to the standard protocol (ST-100) (Section 3.5.4/ 3.5.5) 
(Figure 3.7). For all protocols, a salt-based method, specifically sodium 
chloride precipitation and phenol-chloroform extraction, were implemented. All 
protocols had 10mg of a lung artery specimen from a healthy donor that was 
preserved in 10% neural buffered formalin at room temperature for 9 months 
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as preliminary material. To eliminate variation in tissue samples, the same 
specimen was used for each test group.  For each test protocol, initial analyses 
were performed to determine efficiency of the procedure including 
quantification of DNA yield and purity by NanoDrop/spectrophotometry; DNA 
fragment size distribution by gel electrophoresis; successful amplification by 
PCR; and reliability /reproducibility of sequence. Each protocol was repeated 
three times and the average of three-repeats for each protocol was presented.    
  
 
Figure 3.7: A flow chart showing the altered protocols with heating 
temperature and Chelex resin.  
See method chapter for full protocols. 
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3.6.1.1 DNA yield and fragment size assessments  
The quality and quantity of gDNA extracted by these different methods was 
compared by NanoDrop spectrophotometery and expressed in micrograms 
(µg) per 1mg of tissue. The DNA yield on average from the ST-100 method 
was significantly lower in comparison to both ST-120 and CH-100 protocols 
(Figure 3.8 A). A one-way ANOVA test (p value <0.006), indicated that higher 
temperature or use of Chelex-100 increased gDNA yield relative to the ST-100 
method. However, comparing the yield of gDNA between ST-120 and CH-100 
protocols showed no significant difference between the two protocols. 
Subsequently, the effect of Chelex-100 with higher temperature (CH-120) on 
gDNA yield was evaluated. However, the average gDNA yield was not 
statistically different from the ST-100 protocol (Figure 3.8 A).  
The quality of DNA was evaluated based on the A260/A280 ratio measured 
via the NanoDrop spectrophotometer. Similar purity was demonstrated 
between all methods with no significant difference as indicated by Tukey’s 
HSD test (p 0.3, Figure 3.8 B). Separation of gDNA by gel electrophoresis 
generated an overview of the fragment sizes produced by each method 
(Figure 3.8 C). The distribution of fragment sizes in the gel were analysed by 
ImageJ (Fiji, version 1.51g) and illustrated as a percentage with respect to the 
total gDNA yield for each method (Figure 3.8 D). Both ST-100 and CH-100 
methods produced fragment sizes ranging from 100bp to 3000bp, whereas 
ST-120 and CH-120 produced a range of 100bp to 1000bp. Regardless of 
Chelex-100 treatment, lower temperature (100˚C) generated larger fragment 
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size than higher temperature (120˚C). This indicates a negative relationship 
between heat treatment and fragment size, as increasing the temperature 
leads to reducing the DNA fragment size and vice versa.   
 
 
Figure 3.8: CH-120 protocol produced high quality DNA with large molecular 
weight.  
(A) Comparisons of the genomic DNA (gDNA) yield in (µg) per 1mg volume of 
formalin fixed tissues from different DNA extraction methods. The difference was 
statistically significant for ST-120 protocol and CH-100 protocol from ST-100 
protocol (p<0.006). (B) Comparison of the average gDNA purity for each method 
shows no significant difference between different protocols.  (C) The gel 
electrophoresis image shows total gDNA fragments, separated and visualised on 
a 0.8% agarose gel. lane1: 1kb molecular weight marker (1-kb DNA ladder), Lane 
2: 100bp molecular weight marker, Lane 3: ST-100 protocol, Lane 4: ST-120 
protocol, Lane 5: CH-100 protocol, Lane 6: CH-120 protocol. (D) Size of DNA 
fragment generated by different methods was analysed by ImageJ and illustrated 
in percentage (%) with respect to the total gDNA yield for each method. The 
experiments were run in triplicates and data were presented as an average and 
standard error (SEM) of three biological samples for each protocol. FF: formalin 
fixed.  
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3.6.1.2 Evaluation of PCR mediated DNA amplification 
The presence of contamination or high levels of DNA fragmentation interferes 
with the success of most subsequent molecular tests (Alaeddini, 2012). 
Therefore, assessment of the feasibility of amplification from the DNA isolated 
by each of the methods using the most common downstream application, 
PCR, was performed.  In order to identify the maximum length of DNA able to 
be amplified by PCR, primers specific to the human HAND1 gene, as this gene 
is associated with HLHS, were designed to generate amplicons of different 
sizes and were tested for efficacy using extracted DNA from fresh blood 
sample (Figure 3.9 A). Then, these primers were used to generate PCR 
products from the isolated DNA by the different protocols. All the protocols 
were able to generate PCR amplicon sizes of 200bp (Figure 3.9 C). However, 
the CH-100 and CH-120 gDNAs were also capable of generating amplicon 
sizes of up to 400bp. According to the intensity analysis performed on each 
amplicon band (Figure 3.9 B), the relative mass (ng) of an amplicon was 
associated with increased temperature. For example, both ST-120 and CH-
120 protocols, where heat treatment at 120˚C was carried out, demonstrated 
higher band intensity compared to the other methods where lower temperature 
was used. However, the CH-100 and CH-120 methods with Chelex-100 
treatment showed successful amplification of larger gDNA molecular length 
(Figure 3.9 C). This was probably because that Chelex-100 acts to release 
DNA from contaminating substances and at the same time protects DNA from 
heat damage (Walsh et. al., 1991; Turan et.at., 2015) thereby preserving it 
from shredding into small fragments. Also, amplified DNA demonstrated a 
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heat-dependent effect, as with the high temperature CH-120 protocol, the 
relative DNA mass obtained from 200bp and 400bp amplicons was higher than 
that with the low temperature CH-100 protocol (Figure 3.9 B). Based on these 
findings, heat treatment plays a major role in producing high quantity DNA and 
Chelex-100 is critical for isolation of larger molecular weight DNA with PCR-
amplifiable behavior. Therefore, CH-120 protocol is the optimal method for 
extracting large and amplifiable DNA for use in downstream applications.   
 
Figure 3.9: CH-120 protocol produced high quality DNA that is suitable for 
PCR amplification.  
(A) PCR amplification of fragments of different sizes within the HAND1 gene 
locus was used to assess the quality of gDNA; a control gel image showing the 
HAND1 gene fragment sizes of DNA extracted from fresh blood sample ranged 
between 200bp to 800bp. (B) A bar plot indicating the relative mass (ng) of each 
PCR product generated from the differently extraction methods. (C) PCR product 
of HAND1 gene obtained from ST-100, ST-120, CH-100, and CH-120 protocols 
with a 100bp molecular weight marker. The experiments were run in triplicates 
and data were presented as an average and standard error (SEM) of three 
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3.6.2 Introduced modifications to speed-up DNA extraction 
After demonstrating the effectivity of using high temperature with Chelex resin 
(CH-120) to generate efficient PCR template, it was important to consider 
reducing the duration and cost of the protocol. Several changes were 
introduced to the CH-120 protocol in order to reduce duration of processing 
and use of proteinase K. Therefore, modifications were applied to the wash 
step duration and temperature, and to the digestion step (Figure 3.10 A). The 
quality and quantity of gDNA was then compared to the CH-120 protocol. The 
first alteration was to reduce the washing duration from 72h to 12h while either 
keeping samples at 37˚C or increasing the temperature to 55˚C. The overall 
gDNA yield was not significantly changed in either alteration compared to the 
CH-120 protocol (Figure 3.10 B). After that, the effect of reduced proteinase 
K concentration on gDNA yield was compared. Although there was not a 
statistically significant difference between 1mg/mL proteinase K concentration 
and the standard 2mg/ml concentration used in the CH-120 protocol, this 
reduction in enzyme resulted in incomplete digestion of tissues, which made it 
necessary to extend the digestion period by 12h in order for tissues to be fully 
digested (Figure 3.10 B). Therefore, reducing proteinase K concentration did 
not affect gDNA yield but influenced the digest duration in a concentration-
dependent manner.  
Comparing the purity of gDNA obtained by these modified protocols revealed 
no significant difference when compared with the CH-120 protocol (Figure 
3.10 C). This indicated that these changes did not disturb the process of 
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purifying DNA, hence would not interfere with the success of subsequent 
molecular testing, including PCR. To further confirm no alteration occurred to 
the fragment size of gDNA, agarose gel electrophoresis was performed 
separating DNA fragments according to size (Figure 3.10 D). The DNA 
fragments were then analyzed by ImageJ to detect the varying size ranges. 
The percentage of DNA fragment size obtained by the modified protocols in 
respect to their total gDNA yield are presented (Figure 3.10 E). Distribution of 
DNA fragment size was similar to the CH-120 protocol. Therefore, shortening 
the wash step to 24h at 37˚C and using proteinase K at a concentration of 
2mg/mL revealed equal outcomes to the CH-120 protocol but time-effective 
alternatives, hence this improved method showed the best outcome. This is 
described hereafter as the improved CH-120 (iCH-120) protocol. 
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Figure 3.10: Reduction of proteinase K (PK) concentration and shortening 
of wash period.  
(A) a flow chart of alternation procedure (see method for full protocol). (B) 
Comparisons of the average gDNA yield (µg per 1mg volume of AFFT) obtained 
by different introduced changes to protocol. Changes in the methods shows no 
significant difference (p=0.46) in the gDNA yield. (C) Comparisons of the 
average gDNA purity for each introduced change show no significant difference 
between protocols. (D) A gel electrophoresis image showing DNA fragments 
separated on a 0.8% agarose gel. Lane 1: 100bp molecular weight marker, Lane 
2: CH-120 protocol, Lane 3: reduced PK concentration, Lane 4: shortened 
washing period to one day at 37˚C, Lane 5: shortened washing period to one day 
at 55˚C.  (E) Fragment size generated by variations in the protocol was analysed 
by ImageJ and presented as a percentage (%) in relation to the total gDNA yield 
for each procedure. The experiments were run in triplicates and data were 
presented as an average and standard error (SEM) of three biological samples 
for each protocol. 
 
3.6.3 Efficiency comparison of the generated protocol with 
UDG and a commercially available kit 
The Uracil-DNA/N glycosylases (UDG or UNG) is an evolutionarily-conserved 
enzyme that is known to repair DNA and reverse the amination caused by 
formalin through a base excision-repair pathway (Schormann et. al., 2014). 
The UNG enzyme was suggested to reduce the nucleotide changes that 
resulted from formalin cross-linkage (Kim et al., 2017). This enzyme is used in 
the commercially-available QIAgen DNA FFPE kit. Therefore, this section will 
compare the improve CH-120 (iCH-120) method described in 3.5.2 section, 
with and without UDG enzyme, to the commercial QIAgen DNA FFPE kit. The 
use of UDG enzyme was made after the heat treatment for one hour at 50°C 
(Figure 3.11 A).  
Similar to the previous assessment, the gDNA yield and purity for all protocols 
were measured by NanoDrop spectrophotometer and data presented in 
micrograms per 1mg of tissue. The average gDNA yield of the iCH-120+UDG 
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was significantly higher than that of the DNA FFPE kit that included UDG 
(p=0.03, Figure 3.11 B). However, based on NanoDrop measurement of the 
A260/A280 ratio, the purity of samples extracted by all methods was not 
significantly different, as indicated by a p value of 0.06 (Figure 3.11 C).  
In order to assess the fragment size produced by these methods, the extracted 
gDNA was separated by gel electrophoresis (Figure 3.11 D) and the fragment 
size ranges, analysed using ImageJ (Fiji, version 1.51g) in respect to the entire 
gDNA yield. Quantification of fragment sizes produced by the iCH-120 protocol 
showed 80% of produced DNA was between 100 to 500bp and 20% was DNA 
was in the ranged of 500 to 1000bp (Figure 3.11 E). Conversely, the iCH-
120+UDG showed 70% DNA fragment size between 100 to 500bp and 30% 
DNA fragment size between 500 to 1000bp (Figure 3.11 E). Similarly, the DNA 
FFPE kit (that included UDG) produced 75% of DNA size ranged between 100 
to 500bp and 25% between 500 to 1000bp (Figure 3.11 E).  
To further evaluate the suitability of isolated DNA for PCR amplification and to 
assess the maximum length of PCR-amplifiable DNA, the previously used sets 
of primers were employed to generate PCR products from the iCH-120 
protocol, iCH-120+UDG protocol and DNA FFPE kit. PCR gels demonstrate 
that all protocols were capable of amplifying PCR products of up to 400bp 
(Figure 3.11 F). Based on intensity analysis performed on each amplicon 
band, the relative mass (ng) of an amplicon was illustrated as a percentage 
and presented in (Figure 3.11 G). There were no significant differences 
between the band intensity of 200bp and 400bp generated by any of the 
Chapter 3: Archival Tissues Extraction & Sequencing  
143 
 
protocols. This indicates that all methods produced comparable PCR-
amplifiable DNA. 
Based on these findings, the iCH-120, either with UDG enzyme or without it, 
was effective for extracting high quality gDNA with high yield and fragment 
length. Although the DNA FFPE kit produced comparable results to the iCH-
120 protocol, the high cost (£231.00 per a kit, 2018) and small quantity (only 
50 DNA samples can be done using one kit) limit its use. Therefore, the iCH-
120 with/without UDG protocol provides an efficient, simple, time-effective and 
cheap procedure to isolate DNA from formalin fixed tissues.  
  

































Figure 3.11: Comparable results obtained from the iCH-120 with/without 
UDG enzyme and the DNA FFPE kit.  
(A) A flow chart showing the steps followed for each protocol. (B) Comparisons 
of the gDNA yield (µg per 1mg volume of FFT) between iCH-120, iCH-120+UDG 
and DNA FFPE kit. One-way ANOVA revealed a significant difference (p 0.03) 
between the iCH-120+UDG and the DNA FFPE kit methods. (C) Comparisons of 
the average gDNA purity obtained by the three protocols showed no significant 
difference (p 0.06). (D) The gel electrophoresis image showing DNA fragments 
separation on 0.8% agarose gel. Lane 1: 100bp molecular weight marker, Lane 
2: iCH-120, Lane 3: iCH-120+UDG protocol and Lane 4: DNA FFPE kit. (E) 
Fragment size generated by these protocols was analysed by ImageJ and 
presented in percentage (%) in relation to their total gDNA yield. (F) PCR product 
of different sizes within the HAND1 gene locus obtained from the iCH-120, iCH-
120+UDG protocols and DNA FFPE kit. All protocols amplified amplicon sizes 
ranged up to 400bp. (G) Quantification of the relative mass (ng) of each PCR 
band produced from these methods.  The 200bp band generated by iCH-120, 
iCH-120+UDG protocols and DNA FFPE kit demonstrated a band intensity of 
350ng, 309ng and 271ng, whereas the 400bp band intensity revealed 300ng, 
277ng and 320ng, respectively. The experiments were run in triplicates and data 
were presented as an average and standard error (SEM) of three biological 
samples for each protocol.   
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3.6.4 Quality and quantitative assessments of isolated gDNA 
by Sanger sequencing  
An important aspect of extraction of DNA from formalin-fixed tissues is the 
accuracy of sequence or reliability of the produced sequences from gDNA and 
whether the gDNA extracted is representative of the original sequence. 
Formalin-induced DNA damage frequently present in a small number of loci, 
hence, making match comparisons difficult and the distinction of real low 
frequency variants from sequencing artefacts challenging. Assessing the 
quality and validating the sequences generated by different extraction 
methods are fundamental for the interpretation of genomic results. Therefore, 
it is important to evaluate the various methods in order to understand the 
influence of different extraction methods on formalin-induced DNA damage. 
Since the possibility of distinguishing the real variants from artefacts is limited, 
in this study the term deviations or deviants rather than variants will be used 
to describe changes in the sequences. In order to determine this, gDNA was 
either sequenced from purified PCR products, or from PCR products that were 
subcloned into plasmids and then the plasmid DNA sequenced.  
DNA samples extracted by ST-100 (the original protocol tested, Figure 3.7), 
iCH-120, iCH-120+UDG protocols, and the commercial Qiagen DNA FFPE kit 
(Figure 3.11 A) were used to assess quality and reproducibility of sequences. 
Initially, evaluation of direct sequencing from purified PCR products was 
carried out using the previously designed forward and reverse primers to a 
200bp fragment of the HAND1 gene. The PCR was carried out as described 
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in the Methods section (Chapter 2) followed by gel extraction to purify the PCR 
products and finally sent for sequencing using Sanger sequencing.  Despite 
the various protocols used for DNA extraction, all methods produced similar 
outcomes (Figure 3.12). The first few bases adjacent to the forward primer 
binding site were missing from the resulting sequence, which were then 
recovered through an additional sequencing reaction using a reverse primer 
to enable these missing bases to be determined. Moreover, there was one 
deviant found in each sequence produced from all the methods, which was 
again recovered using the reverse sequence (Figure 3.12, red highlights). 
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Figure 3.12: Low quality templates obtained by direct sequencing of DNA from purified PCR.  
Sanger cycle sequencing for a 200bp fragment of HAND1 exon 2 was established in DNA acquired with ST-100, iCH-120, iCH-120+UDG 
protocols and QIAgen DNA FFPE kit. Sequencing of DNA from purified PCR using forward and reverse primers for a 200bp fragment of 
HAND1 exon2. Ref: reference sequence (HAND1 exon2), F: forward primer, R: reverse primer, Red box: primer binding site, Red highlight: 
mismatches of obtained sequence compared to the reference sequence. The sequencing of purified PCR product was performed on three 
different samples for each DNA extraction method. 
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Next, a PCR based cloning method was used to generate plasmids containing 
the maximum length of PCR amplified gDNA. Due to difficulties in the 
amplification of products greater than 200bp from gDNA extracted using the 
ST-100 protocol, a 200bp fragment was generated using the primers in 
(Chapter 2). These primers allowed a parallel comparison between a 200bp 
fragment generated by the ST-100 protocol and a 400bp fragment generated 
by other methods. Amplification of gDNA was performed using a high-fidelity 
DNA polymerase, followed by addition of a poly A tail to create a suitable 
molecule for TA cloning. Once the molecule had been cloned into pGEM-T 
easy and transformed into bacteria (JM109), resulting colonies were picked 
and cultured. For the purpose of increasing the accuracy of results, 20 colonies 
per sample, which was repeated three times, were investigated by plasmid 
DNA sequencing. The plasmid DNA was sequenced in both forward and 
reverse directions and resulting sequences from each plasmid DNA were 
compared to a reference sequence, in this case the HAND1 gene 
(ENSG00000113196). Initial analysis of data was based on pairwise 
comparisons of forward and reverse sequences from a single plasmid DNA to 
a reference sequence using ApE A plasmid editor software (v2.0.47) and 
Jalview (v2, Waterhouse et al., 2009). Then, quantification of the overall 
formalin-induced DNA damages was established for each method using 
GraphPad prism (v6), followed by calculation of the proportions of each type 
of nucleotide change from each extraction method. 
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Upon comparison of the 200bp sequence from HAND1 gene, the percentage 
divergence in the overall performance of ST-100, iCH-120, iCH-120+UDG 
protocols and DNA FFPE kit compared to the database sequence was 5%, 
6%, 9% and 17%, respectively. Comparison between the DNA extraction 
protocols indicated a significant difference between the ST-100 (p 0.02) and 
iCH-120 (p 0.03) protocols compared to the Qiagen DNA FFPE kit (Figure 
3.13 A). The percentage divergence of the ST-100 protocol suggests 
increased variation between sequences leading to difficulties in distinguishing 
true sequencing variants from artefacts. For further analysis of sequencing 
variants generated by each DNA extraction methods, the percentage of 
nucleotide divergence was normalised to a 100bp read length. The results of 
specific nucleotide changes are shown in (Figure 3.13 B) and demonstrated 
a high incidence (up to 10%) of G>A changes in DNA presented by all 
extraction methods. In addition, an incidence of (1.8%) of A>T changes was 
detected in samples extracted by iCH-120 protocol, whereas 3.75%, 1.14%, 
and 5.20% of C>T changes were detected in ST-100, iCH-120 and DNA FFPE 
kit, respectively. Strikingly, a high level of A and T deletions was confined to 
iCH-120 (1.8% and 3.9%, respectively) and iCH-120+UDG (5.3% and 5.5% 
respectively) protocols and T deletions (5.8%) to the Qiagen DNA FFPE kit. 
This could suggest that these methods failed to correct these variants and thus 
delete them. Consequently, these methods showed a high prevalence to 
nucleotide deletions rather than alterations.   
To determine if treating samples with UDG reduced sequence artefacts, a 
comparison of sequencing artefact divergence between the iCH-120 and iCH-
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120+UDG protocols was performed. As shown in (Figure 3.13 B), the high 
range of the variant calls A>T/T>C/C>T observed from the iCH-120 protocol 
samples was dramatically reduced in the iCH-120+UDG protocol samples. 
There was, however, a consistently higher rate (up to 5.5%) of specific A and 
T base deletions in the iCH-120+UDG protocol samples. This suggests that 
although treating samples with UDG may help to minimise some of the 
formalin-induced sequence artefacts by removing incorrect bases, it can also 
cause damage to sequences by random removal of nucleotides. To further 
investigate whether these changes occurred due to UDG treatment and not 
due to Chelex-100 treatment, comparisons between the iCH-120+UDG 
protocol and the Qiagen DNA FFPE kit was performed. The samples from the 
DNA FFPE kit showed a similar range of A>T changes (less than 1%) and T 
deletions (less than 6%) but did not show the reduction in C>T/T>C changes 
(iCH-120+UDG= 0.4%, DNA FFPE kit= 6.0%), or the increase in A deletion 
(iCH-120+UDG= 5.3%, DNA FFPE kit= 0%) observed with the iCH-120+UDG 
protocol samples (Figure 3.13 B). This suggests that a reduction in C>T/T>C 
changes and an increase in A deletion may occur as a result of treatment with 
both UDG and Chelex-100.     
Although formalin-induced nucleotide changes in gDNA from the various 
extraction methods seems, at first, to be random, sequence alignments of the 
changes from each method suggest that specific regions of DNA are affected. 
Figure 3.13 C shows alignments of a 400bp read length of 20 sequences 
produced from the iCH-120, iCH-120+UDG protocols and Qiagen DNA FFPE 
kit. Due to difficulties in amplification of a 400bp read length from the ST-100 
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protocol, the overlapping latter 200bp read length of sequences were aligned 
with other sequences and were all compared to the reference HAND1 
sequence. The consensus alignment of sequences from different methods 
demonstrated matched and specific formalin-induced nucleotide changes that 
varied in frequency depending on the DNA extraction procedure. Analysis of 
the formalin-induced DNA damage showed a specific pattern of nucleotide 
changes. As seen in Figure 3.13 C, the AT or T rich-regions in sequences 
produced by different methods were susceptible to be damaged by formalin. 
In addition, changes of T>C or C>T were present in all methods, but with lower 
frequency in the iCH-120+UDG protocol. However, a high rate of G>A 
changes was observed in DNA isolated by all methods. This phenomenon of 
highly detectable bias towards G>A changes in formalin paraffin embedded 
tissue or formalin tissues has previously been reported (Wong et al., 2014, 
Qach et al, 2004).  
Although UDG seemed to reduce the frequency of deamination events 
affecting PCR, this is not complete and, in some cases new deviations are 
found which may relate to different extraction methods and therefore be 
misleading. In addition, whilst comparing several sequence transcripts could 
overcome some of formalin-induced artefacts, in some cases the artefacts 
could be persistence and appeared in most of the transcripts making 
determination of real variants difficult (Figure 3.13 C, white lines). Therefore, 
it is still risky to rely on Sanger sequencing and cloning transcripts to identify 
unknown and rare variants, but they remain useful for confirmation of known 
variants.    























































Figure 3.13: Assessment of sequencing artefacts produced from plasmid DNA extracted by ST-100, iCH-120, iCH-120+UDG 
protocols and DNA FFPE kit. 
Assessment of sequencing artefacts produced from plasmid DNA extracted by ST-100, iCH-120, iCH-120+UDG protocols and DNA FFPE 
kit. (A) Comparisons of the overall divergence (%) of different extraction methods. All DNA extraction protocols excluding ST-100 protocol 
show a consistent level of divergence within their group, which indicates a constant frequency incidence of sequencing artefacts 
generated by these methods. Tukey's multiple comparisons test showed a p value of 0.02 for the ST-100 protocol and p 0.03 for iCH-
120 protocol compared to the DNA FFPE kit. (B) Stacked columns represent the prevalence (%) of each type of nucleotide divergence 
per 100bp read length. A high prevalence of guanine (G) changing to adenine (A) was observed in all protocols, followed by thymine (T) 
changing to cytosine (C) in ST-100, iCH-120 protocols and DNA FFPE kit or deletion of T in iCH-120, iCH-120+UDG and DNA FFPE kit. 
(C) Alignment of sequences generated by Sanger cycle sequencing for a 200bp or 400bp read length of HAND1 exon 2 was performed 
on DNA isolated with ST-100, iCH-120, iCH-120+UDG protocols and DNA FFPE kit. Plasmid DNA was extracted from 20 different colonies 
and sequenced in forward and reverse directions. Boxes show the nucleotide changes in sequences from each acquired method. 
Electropherograms detect the nucleotide peaks of sequencing artefacts




3.6.5 Qualitative and quantitative assessments of isolated 
gDNA by Next-Generation Sequencing (NGS) 
The analysis of exome sequencing data found in this section was carried out 
by Andrew Skelton from the Bioinformatics Support Unit in Newcastle 
University.  
Although it was feasible to extract high quality DNA with long amplifiable PCR 
products from formalin-fixed tissues that could be used for Sanger sequencing, 
the generated sequence information might contain formalin-induced artefacts 
that could not be discriminated from real disease-causing variants. These 
difficulties maybe overcome through the advances in sequencing technology, 
in the form of NGS. This is because NGS can perform paired-end reads, which 
means NGS allows sequencing of both fragment ends, then detects the 
common DNA rearrangements, and finally generates high-quality alignable 
sequence reads. In order to address the potential of NGS, the whole exome 
sequencing data of a DNA sample extracted from a fresh blood sample (FB-
DNA) was compared to that extracted from a piece of explanted right 
ventricular heart fixed in formalin for 2 years (FF-DNA) from the same patient. 
The extraction of DNA from the explant formalin-fixed heart tissue was 
performed using the iCH-120 protocol previously described (Figure 3.11 A), 
as this method provided less nucleotide alternations compared to other 
methods. 
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For equal evaluation of the FB-DNA and FF-DNA samples, quantification and 
assessment of gDNA integrity in both samples was performed using an 
automated electrophoresis system (Agilent 2200 TapeStation system). This 
system provided a distribution of gDNA fragment length and aided in 
determining whether pre-library preparation shearing was necessary. The FB-
DNA samples showed a mean fragment length of 280bp (Figure 3.14 A), 
whereas the FF-DNA sample had a mean of 141bp (Figure 3.14 B), which 
was anticipated from the previous results (Figure 3.11 F). As the FF-DNA 
sample showed small fragment length, no shearing was required. However, 
the FB-DNA sample required shearing to obtain a median fragment-length of 
150bp before library preparation; thus, a transposonase-based system was 
used (TrueSeq Rapid exome kit, Illumina). Both samples were then processed 
using NextSeq 500 platform (Illumina) at high output mode to produce 40 
million pair reads of 75bp length. Construction of exome data was made using 
the GATK best practice pipeline and both library preparations were made from 
identical bed files (Figure 3.14 C). 
 




Figure 3.14: Next-generation sequencing analysis on FF-DNA and FB-DNA 
samples.  
(A) quantification of gDNA integrity using automated electrophoresis system for 
FB-DNA and (B) FF-DNA. FB-DNA sample showed a fragment length product up 
to 3500bp, whereas FF-DNA sample only had a fragment length up to 141bp. (C) 
a flow chart indicating the process of sequencing date using an Illumina 
NextSeq500 and the analysis was performed using GATK (3.8) best practice. 
Pre-processing included the BWA-MEM alignment, duplicates removal, re-
alignment of indel, and then base quality score recalibration (BQSR). The 
genotyping call was performed using the HaplotypeCaller (HC), which was run 
using two distinctive mode: Single sample calling and gVCF mode to examine 
the effect of different modes on improving calls from formalin-fixed tissues. The 
single sample calling was used the recommended hard filtering for filtering 
variants, whereas the joint calling with 216 exomes with different phenotypes 
used variant quality score recalibration (VQSR) to filter variants. Annotation of 
variants was made using Ensembl’ variant effect predictor (VEP, v90) with two 
plugins: LOFTEE and dbnsfp. The VCF file was then converted to a tab-delimited 
table file using the GATK’s VariantsToTable tool before it was exported to R 
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3.6.5.1 Genomic analysis of FB-DNA and FF-DNA: Coverage, depth, 
and GC content  
The BAMQC, a quality control application, was run on the alignment .BAM files 
and reported a mean coverage of high-quality aligned reads of 78-fold with 
FB-DNA but only 15-fold with FF-DNA (Figure 3.15 A). This coverage was 
equally distributed throughout all chromosomes (Figure 3.15 B). Analysis of 
the GC content indicated lower reads gained from the FF-DNA sample 
compared to the FB-DNA sample (Figure 3.15 C). This might be because the 
GC-rich regions are prone to low coverage depth, partly due to their instability 
during amplification. Alternatively, this could be due to formalin-induced 
changes of G and C bases to A and T bases. This was then further analysed 
through inspecting the various single nucleotide polymorphisms (SNPs) found 
in the aligned .bam files compared to the original sequence in the initial .bam 
files generated by BWA-MEM. There were differences in the SNP frequency 
observed between the two samples, however this could be limited to the 
inconsistent coverage between samples and failure to recognise indels 
(Figure 3.15 D). An important aspect of NGS is the paired-end reads, which 
allows both ends of the DNA fragments to be sequenced. Hence it provides 
two reads for the same DNA fragment region, which enables identification of 
genomic rearrangements and repetitive elements within sequences. 
Therefore, comparison between read1 and read2 for FF-DNA sample was 
performed to detect whether the observed changes in SNP frequency was due 
to formalin and not to technical limitation of NGS. As anticipated, there was 
enrichment of G>A and C>T in read2 along with minor alterations between the 
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two reads (Figure 3.15 E) indicating induced-formalin damages. Strikingly, 
read2 data showed less distortion in SNPs suggesting misrecognition of the 
genomic positions of read1 leading to inability to correctly match read2 
transcripts on the genomic scaffold. 
  





Figure 3.15: Validation of genomic data for FF-DNA sample through 
coverage, depth and GC content.  
The mean coverage of FB-DNA sample was higher than FF-DNA sample by 78 
folds (A), although the coverage was equally distributed throughout all 
chromosomes for both samples (B). (C) GC content for FF-DNA sample was 
lower than that for FB-DNA sample. (D) Comparison of the single nucleotide 
polymorphisms (SNPs) found in the aligned .bam files compared to the original 
sequence in the initial .bam file between FF-DNA and FB-DNA samples. (E) 
Comparison of the paired-end reads, read 1 and read2, in FF-DNA sample 
showed less distortion in SNPs between the two reads but enrichment of G>A 
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3.6.5.2 Variant calling pipelines for this study   
After the quality metric analysis of FB-DNA and FF-DNA samples, it was 
important to consider whether the variant caller tool used in this study 
providing accurate information regarding filtering and SNP calling errors. 
Several potential variant calling pipelines were identified, but the GATK 
pipeline was favoured among other suggested pipelines (Hwang et. al., 2015). 
Therefore, the GATK pipeline was used for variant calling in combination with 
a BWA-MEM read aligner in this study. This is summarised in Figure 3.14 C. 
Initially, the reads were mapped to the reference genome Hg19 
(http://grch37.ensembl.org/index.html), then duplicates were marked, 
sequence was re-aligned to known indels, and base score quality recalibration 
(BSQR) was conducted to generate the clean alignment .bam file. The .bam 
file was then processed either solely using HaplotypeCaller (HC), a variant 
caller tool, or in combination with a large exome group to permit joint calling. 
Joint calling is the analysis of variants simultaneously throughout all samples. 
This then generated variant call files (.vcf), which were subjected to hard 
filtering after simple HC, or to variant quality score recalibration (VQSR) after 
joint calling.    
The single HC and hard filtering generated 5,239 variants from FB-DNA, 
compared to 13,079 variants generated by FF-DNA samples. Conversely, this 
data showed low specificity and sensitivity (13% and 32.5%, respectively) as 
more of variants (11,377 variants) were identified in FF-DNA sample but not 
in the FB-DNA sample (Figure 3.16 B). The joint calling and VQSR filtering, 
however, represented higher specificity and sensitivity (94.2% and 73.3%, 
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respectively) when variants between FB-DNA and FF-DNA samples were 
compared to the previous filtering. It showed 104,387 variants from the FF-
DNA sample that was matched with the FB-DNA sample (Figure 3.16 A). 
Therefore, analysing the data using the joint calling with VQSR significantly 
improved the sensitivity and specificity of variant calling. This could be 
explained by the joint calling advantage of sharing information throughout all 
samples, which increases its sensitivity toward rescued genotype calls that 
located in low coverage regions, by searching for a consistent variant at that 
region found within other samples.  
Lastly, analysis of base changes after the two variant calling methods was 
carried out. Both methods produced similar base change counts and the 
preference of formalin to produce G>A and C>T and other minor base changes 
observed in the initial analysis (Figure 3.15 D) were not presented by both 
filtering systems (Figure 3.16 D). Also, comparing the number of detected 
SNPs in FF-DNA to that in FB-DNA revealed similar call counts for both variant 
calling methods (Figure 3.16 C). This suggests that both single variant calling 
with hard filtering and joint calling with VQSR were able to reduce deviant calls 
produced from formalin-induced damage, but at the risk of losing real rare 
variants.  
  














Figure 3.16: Assessment of FF-DNA sequencing reads using two modes of 
GATK best practice pipeline: joint calling with VQSR mode and single 
calling with hard filtering mode.  
Comparison between the joint calling with VASR filtering (A) and the single 
calling with hard filtering (B) for FF-DNA and FB-DNA (Blood-source DNA) 
revealed higher read sensitivity and specificity when the joint calling with VQSR 
was applied. (C) Base change analysis between FF-DNA and FB-DNA using the 
joint calling with VQSR reads indicated similar base change counts between the 
two samples. (D) Comparison between the base changes in the joint VQSR and 
single with hard filtering for FF-DNA sample showed minor changes between the 
two modes indicating that both modes were able to reduce deviant calls produced 
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3.6.5.3 Phred Quality scoring 
As a final assessment of the quality of sequencing reads in the FF-DNA 
compared to the FB-DNA, the Phred quality score (Q score) was used. It 
provides a logarithmic value to describe the probability of a base calling error 
during automated DNA sequencing (Kulkarni and Pfeife, 2015). When using 
this to filter results, this means that a higher cut-off Q score reduces the 
likelihood of reads containing a base-calling error and results in higher call 
accuracy. For example, A Phred Q score of 30 (Q30) refers to a base with an 
error probability of 1 in 1000, or conversely 99.9% accuracy, whereas the Q 
score of 10 (Q10) equates an error rate of 1 in 10 or 90% accuracy (Cliften, 
2015).  
In this study, intention was made to examine the effect of three different levels 
of base filtering using three different Phred Q scores; Q score of 10 (Q10; error 
rate of 1 in 10), 20 (Q20; error rate of 1 in 100) and 30 (Q30; error rate of 1 in 
1000).  
  






Figure 3.17: Venn diagrams showing relationship of reads obtained from 
formalin fixed DNA and blood using filtering of variants at different Phred 
scores.  
At all Phred scores there was no difference in the number of variants detected 
in blood, but not in the formalin samples, and no difference between the variants 
that were discovered in the blood and the formalin sample. However, with 
increasing Phred score there was a reduction in the number of variants unique 
to the formalin DNA sample. Thus, the sensitivity of variant calling in formalin 
samples was unchanged, but the specificity increased from 58.0% to 67.4%. 
 
The quantitative analysis with Phred Q score of 10 (Q10) generated 37,022 
variants that were in common between FF-DNA and FB-DNA with 55.8% 
sensitivity and 58% specificity (Figure 3.17). Although the Phred Q score of 
20 (Q20) revealed similar sensitivity (55.8%) to Q10, it showed higher 
specificity (63%) as 21,732 variants were identified in FF-DNA but not in FB-
DNA. The Phred Q score of 30 (Q30), compared to both Q10 and Q20, 
illustrated comparable sensitivity (55.9%), but elevated specificity (67.4%) 
indicating less variability between FF-DNA and FB-DNA with only 17,909 
variants found in FB-DNA (Figure 3.17). Therefore, the Q30 showed 
comparable sensitivity to both Q10 and Q20, but higher specificity 
demonstrating the best Phred Q score to analyse formalin fixed samples.     
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Overall, it is possible to extract DNA from tissues that had been fixed in 
formalin for up to 2 years using the iCH-120 method. Although Sanger 
sequencing and cloning showed less reliability sequencing data with tissues 
fixed in formalin for less than one year, NGS presented here a better option to 
generate a reliable sequencing data particularly when a specific filtering 
system is applied. Therefore, using the iCH-120 protocol to extract DNA from 
prolonged fixation period in formalin and to sequence DNA through NGS can 
produce high specificity with limited sensitivity data. 
 
   




This study investigated the possibility of extracting a good quality and quantity 
DNA from formalin-fixed tissues. In addition, the potential of sequencing the 
formalin fixed genomic DNA using the gold standard Sanger sequencing and 
Next Generation sequencing was investigated. In order to achieve this, an in-
house and cheap method was developed to obtain large amounts of DNA with 
high purity, large fragment size and PCR products up to 400bp through using 
proteinase K digestion and heat treatment along with Chelex-100. The final 
method (iCH-120) described in this study provides a better and cost-effective 
system compared to the commercial QIAgen DNA extraction kit. This method, 
also, showed efficiency in extracting DNA from tissues that had been 
preserved in formalin for up to two years. Although treatment with UDG 
resulted in the removal of deamination incidences, alternative corruptions can 
arise. Even with the gold standard Sanger sequencing and cloning methods, 
there were still variants that appeared in most of the transcripts making 
determination of real rare variants from artefacts very difficult. In addition, it 
was demonstrated that NGS from formalin-fixed materials was successful and 
when the joint variant calling and VQSR pipeline along with the Phred Q score 
of 30 (Q30) were applied, high call specificity was obtained compared to the 
single calling with hard filtering, Q10 and Q20 systems. Conversely, sensitivity 
of calls ranged between 55% to 73% and therefore there would still be a 
chance of concluding false positive or false negative variants for inherited 
genetic defects using NGS on formalin-fixed tissues, but at the same time NGS 
provides more reliable data compared to the Sanger sequencing. 
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The rationale behind this study was to investigate whether it was possible to 
carry out genomic studies on long-term formalin-fixed archival human tissues, 
as this could be useful for the archival hypoplastic left heart syndrome hearts 
that were phenotyped in the previous chapter (Crucean, Alqahtani et al., 
2017). Previously, there was a genomic study carried out on 31 formalin-fixed 
malformed hearts with either hypoplastic left or right ventricles (Reamon-
Buettner et al., 2008). This study showed that 24/31 hearts had a deletion of 
G at position 376 in HAND1 gene, causing a frameshift in the amino acid 
sequencing beginning at Alanine 126 in the basic Helix-Loop-Helix domain of 
HAND1. This frameshift mutation was predicted to lead to a truncated protein 
that was unable to regulate combinatorial interactions (Reamon-Buettner et 
al., 2008). Engineering a conditional Hand1A126fs mouse allele resulted in 
abnormalities of cardiac outflow tract and intraventricular septum, but definitely 
not HLHS. Moreover, this mutation led to lethality at E14.5 (Firulli et al., 2017). 
It was therefore concluded that this mutation was not causative for HLHS, but 
more importantly, this mutation was originally identified from HLHS formalin-
fixed tissues using Cycle Sequencing, which had similar principles to Sanger 
sequencing. However, in the current study, it was shown that formalin-fixed 
tissues had a high preference for G>A artefacts when normal PCR and Sanger 
sequencing were used (Figure 3.13). Since the A126fs mutation resulted from 
G changing to A and in the current study, the high preference of G>A artefacts 
were illustrated; this therefore suggests, together with the absence of HLHS in 
the mutant mouse and the failure to replicate this finding in other HLHS 
patients, that this mutation could result from formalin-induced damage rather.  
Moreover, as illustrated previously, when NGS was used with joint calling, with 
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VQSR pipelines along with the Phred quality score of 30, most of the formalin 
artefacts including the G>A artefacts were excluded. Therefore, NGS 
produces more reliable data for DNA extracted from formalin fixed tissues 
compared to Sanger sequencing  
Next-generation sequencing (NGS) technology is a powerful tool that can 
quantify expression levels, map diseases and, most importantly for this study, 
identify de novo and rare variants (Liu et al., 2013). To call variants using NGS, 
several aligners and variant callers have been established and combined into 
various pipelines. In a typical pipeline, an aligner or algorithm is required to 
map the NGS reads to a reference genome, and a variant caller to recognise 
variant locations and then allocate a genotype to the subjects. There are 
several aligners that have been extensively studied including Bowtie, BWA, 
SOAP and mrFAST (Ruffalo et al., 2011). In this study, the widely-used aligner 
BWA was utilised. This is because BWA provides mappings/reads with a 
quality score, which can be used to remove unsupported mappings or 
mappings with a high number of mismatches (Ruffalo et al., 2011; Liu et al., 
2013). Moreover, the variant caller used in the study was the GATK best 
practice (Poplin et al., 2017). The GATK has a new single-sample calling 
pipeline, which allows combining per-sample gVCF and performs joint analysis 
of a cohort at an advance stage. The advantage of involving gVCF is to record 
all the variant sites regardless of variant presence or not and this subsequently 
provides a file of every represented site, which is necessary for performing a 
joint call analysis at the subsequent stage. Therefore, the chosen pipeline 
permits performing two distinct modes in order to compare the variant calls 
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between the FB-DNA and FF-DNA samples. The analysis of coverage, depth, 
and GC content revealed some differences between the FB-DNA and FF-
DNA, which were most likely to be caused by the formalin-induced damage 
(Figure 3.15). However, after filtering the data by single HC with hard filtering 
or joint calling with VQSR, both methods generated less formalin-induced 
calls, although at the expense of losing real rare variants. Although both 
filtering modes increased the chances of producing correct variants, the joint 
calling with VQSR presented high specificity (94%) and sensitivity (73.3%) 
compared to the single HC with hard filtering mode. Moreover, assessment of 
the Phred quality score (Q score) for the FF-DNA and FB-DNA samples 
showed that a Q score of 30 yielded the highest specificity and sensitivity of 
the sequencing reads. Therefore, in order to obtain the maximum reliability 
sequencing reads from formalin materials, it is important to consider running 
the GATK best practice pipeline with the joint calling and VQSR filtering mode 
and to assess the sequencing quality with Q30.    
Comparison between the reliability of sequencing data obtained from formalin-
fixed tissue by the NGS or Sanger sequencing with cloning methods revealed 
that NGS could generate reliable results with a limited sensitivity. However, as 
the sensitivity of data ranged between 55% to 73%, which leaves only between 
a 27% to 45% chance of inaccurate identification of variants, it seemed to be 
acceptable as long as further investigation follows. This includes using the gold 
standard Sanger sequencing and the cloning method to confirm the identified 
variants. The advantages and disadvantage of using both NGS and Sanger 
sequencing are listed in the table below (Table 3.3).   
Chapter 3: Archival Tissues Extraction & Sequencing  
172 
 
Table 3.3: list of the pros and cons of using NGS and Sanger sequencing to analyse 
DNA from formalin-fixed tissues.  
 pros cons 
Sanger 
sequencing cheap 
Produce persistence variants 
through different clone 
transcripts. 
NGS Reliable data Limited sensitivity and 
expensive 
 
Overall, it is possible to extract high quality and quantity DNA from long-term 
formalin-fixed materials using a cheap and scalable in-house method. It was 
previously reported that reliable NGS data could only be obtained from tissues 
that had been fixed in formalin for one day (Einaga et al., 2017). However, this 
study proved that it was possible to extract DNA and generate a reliable NGS 
data using the iCH-120 method. Although it was suggested that Sanger 
sequencing data generated from formalin-fixed DNA could not be used to 
discover new rare variants, it remained useful to use the Sanger sequencing 








Formalin is an effective conservative medium for biological structures, but it 
damages DNA by crosslinking bases, fixing proteins, generating breaks and 
modifying bases. However, it is still possible to extract DNA from long-term up 
to two-year formalin fixed tissue and carry out PCR. In this chapter, a cheap 
scalable method for extracting DNA from formalin-fixed tissues was described. 
This method allowed efficient PCR to generate at least 400bp product length 
and this was comparable to the leading commercial kit. Nevertheless, the 
extracted DNA from formalin-fixed tissue was unreliable for Sanger 
sequencing, as it was not possible to separate formalin artefact from, for 
example, heterozygosity. It might be possible to improve discrimination 
through next generation sequencing and paired reads. Altogether, the current 
study proposes that the GATK best practice pipeline, with joint calling and 
VQSR, and assessing with Phred quality score of 30 is a good pipeline to 
obtain high specificity with moderate sensitivity sequencing reads from 
formalin-fixed materials. Whereas, Sanger sequencing data generated from 
formalin-fixed DNA cannot be used to discover new rare variants, but it 
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In the previous chapter, various methods to extract DNA from formalin fixed 
tissues (FFT) were described. Whilst isolation of DNA from FFT can be limited 
by DNA degradation, crosslinking with proteins and sequence unreliability, it 
is still possible to extract high quality DNA using the described optimal method. 
However, the determination of the accuracy and reliability of DNA sequences 
extracted from FFT is still variable. Therefore, using FFT to identify mutations 
can be achieved but it raises risks of producing false positive results. 
Henceforth, until a further advance in technology, FFT best remain a valuable 
source for mutation validation studies, rather than for primary identification of 
mutations. In fact, there have been several studies that suggested different 
genes to cause hypoplastic left heart syndrome (HLHS). Therefore, the 
following chapter will focus on analysing all the key genes reported for HLHS 
and provide a complete profile for their main roles and expression during heart 
development.  
  




4.2  Main suggested genes involved in HLHS 
The genetic aetiology of HLHS has been supported with a growing body of 
evidence throughout the years. Initially, in 1971, Shokeir described a 
transmission pattern of autosomal recessive inheritance for HLHS after 
analysing 13 patients from 5 independent families (Shokeir, 1971). A couple 
of years later, in 1974, Shokeir provided further evidence to support his 
hypothesis of the autosomal recessive inheritance through describing 6 
families with 15 patients diagnosed with HLHS (Shokeir, 1974). However, in 
1974, Brownell and Shokeir proposed the polygenetic inheritance hypothesis 
based on the recurrence of HLHS in the second generation of 42 families 
(Brownell and Shokeir, 1976). Slightly more recently, Gerboni et al. (1993) 
reported an autosomal dominant inheritance of HLHS rather than polygenetic 
inheritance. His hypothesis was based on a study of 5 members in three 
generation of a single family affected with various congenital heart defects, 
where first degree relatives of HLHS patients had a high risk of reoccurrence 
(Gerboni et al., 1993). Altogether, there are three suggested transmission 
patterns of HLHS: autosomal recessive, autosomal dominant and polygenic 
inheritance. Since there are three ventricular subgroups of HLHS described in 
this study, this may implicate different aetiologies for different HLHS 
subgroups.         
Over the years, several genes have been suggested to either directly cause 
or associate with HLHS. These genes include GJA1  (Dasgupta et al., 2001), 
NKX2.5 (Elliott et al., 2003; McElhinney et al., 2003), 




NOTCH1/NOTCH3/NOTCH4 (Garg et al., 2005; Yang et al., 2017; Durbin et 
al., 2017), HAND1 (Reamon-Buettner et al., 2008), FOXC2 (Iascone et al., 
2012; Yu et al., 2010; Finegold et al., 2001), ETS1 (Ye et al., 2010), RBFOX2 
(Verma et al., 2016) and PCDHA13/SAP130 (Liu et al., 2017). Consequently, 
evaluation of these gene expressions during heart development will be 
discussed.  
  




4.3 Limitation and restriction of involved genes 
There are 15 genes that have been implicated in HLHS. This section will focus 
on discussing the main roles of the suggested genes for HLHS and describe 
the core mutations found in these genes.   
 GJA1 
In normal heart development, GJA1, encoding connexin-43, is abundant and 
found in myocytes of ventricles and atria (Michela et al., 2015). The gap 
junction protein, connexin 43 (Cx43), is located at the intercalated disk; which 
are found at the longitudinal ends of cardiomyocytes, allowing intercellular 
communication between cardiomyocytes and metabolic interchange between 
contiguous cells (Dermietzel et al., 2000). Also, Cx43 is essential for ensuring 
accurate regulation of vascular tone, cardiac rhythm, and endothelial function 
(Iwasaki et al., 2011). With all of these central roles in cardiac tissues, GJA1 
is one of the key genes in cardiomyocyte development. Homologous deletion 
of Gja1 in mice causes death at birth due to stenotic pulmonary artery and 
hypertrophy of the ventricular outflow tract (Dermietzel et al., 2000).  
Variations in GJA1 were the first to be proposed to cause HLHS, as four 
substitution variations (2 missense and 2 polymorphisms) were identified in 8 
children out of 14 cases diagnosed with HLHS (Dasgupta et al., 2001). 
However, Huang et al. (2011) carried out a screening study of 300 patients 
with various congenital heart defects (CHD) including four cases with HLHS. 
This screening study revealed that none of the previous suggested GJA1 




variants were found, although two novel variants were identified. These two 
variants were then recreated as Gja1 knock-in mice, to assess the relevance 
of these point mutations in CHD. However, the knock-in mice showed normal 
lifespan with no CHD. Therefore, both screening and knock-in model studies 
showed that mutations in Gja1 gene were less significant for CHD in general 
and HLHS in particular. Overall, GJA1 plays important roles in the 
cardiovascular system through regulating endothelial function and intercellular 
communication in ventricles (Huang et al., 2011). Although the suggested 
mutations in GJA1 showed no cardiac abnormalities, GJA1 remains an 
important gene that may be indirectly contributing to the ventricular 
cardiomyopathy observed in HLHS.  
 NKX2.5 
NK2 homeobox5 (NKX2.5) is one of the critical cardiac transcription factors 
during cardiogenesis (Stanley et al., 2002; Akazawa and Komuro, 2005). 
Expression of NKX2.5 is abundant in the early cardiac progenitor cells of the 
first and second heart fields, which support a role in differentiation of 
myocardial lineages (Dupays et al., 2019). In addition, the fact that NKX2.5 is 
expressed in specialised myocardial conduction cells indicates a core role for 
NKX2.5 in conduction system development (Akazawa and Komuro, 2005). 
During embryogenesis, NKX2.5 is involved in cardiac morphogenesis through 
regulating rightward looping, consequent specification and septation of the 
chambers, and in functional maturation and maintenance of ventricular 
cardiomyocytes (Stanley et al., 2002). During adulthood, NKX2.5 is involved 




in maintaining the homeostasis of cardiomyocytes (Akazawa and Komuro, 
2005). More recently, NKX2.5 was found to play a direct role in the formation 
of atrioventricular junction through modulating BMP signalling by suppression 
of Furin, which is a secretory proprotein convertase (Dupays et al., 2019). 
Knockout mouse model of Nkx2.5 demonstrated disrupted growth and 
chamber specification as well as severe impaired regulatory transcriptional 
network during embryonic cardiogenesis, and eventually caused early 
embryonic lethality (Furtado et al., 2016). Therefore, NKX2.5 is a fundamental 
gene to ensure a normal cardiac formation. 
Variations in NKX2.5 were initially suggested to cause HLHS by Elliott et al. 
(2003), as a missense mutation was found in one child out of 18 patients with 
HLHS (included both sporadic and familial cases; Elliott et al, 2003). 
McElhinney et al. (2003), likewise, reported a missense NKX2.5 mutation that 
was found in one patient out of 80 cases diagnosed with left-sided cardiac 
lesions included HLHS (McElhinney et al., 2003). Although the significance of 
this mutation was not clear, it was suggested to cause impairment of NKX2.5 
protein dimerization leading to lower its ability to monomeric or dimeric DNA 
binding sites (McElhinney et al., 2003). However, the study of Esposito et al. 
(2011) on cardiac tissues of 24 HLHS patients identified no NKX2.5 mutations 
speculating that somatic NKX2.5 mutations were not the cause of HLHS 
(Esposito et al., 2011). Altogether, although these studies showed conflicting 
views on the importance of NKX2.5 for HLHS, the significance of NKX2.5 
during cardiac development makes it a possible contributor to HLHS. 




 NOTCH family  
The NOTCH signalling pathway was firstly described by Morgan more than 90 
years ago (Morgan and Bridges, 1916; Zhou and Liu, 2014), and ever since it 
has been well-documented to be a phylogenetically conserved signalling 
pathway (Borggrefe and Oswald, 2009). The NOTCH family consists of four 
genes (NOTCH1, NOTCH2, NOTCH3, and NOTCH4) encoding type 1 
transmembrane proteins, that share similar structural properties with one 
another (Zhou and Liu, 2014).  This section will discuss NOTCH1, NOTCH3 
and NOTCH4 only, as the suggested mutations in HLHS were reported only 
in these genes. 
 NOTCH 1 
The product of NOTCH1 is linked to several crucial activities related to cell 
differentiation, proliferation, cell fate specification and survival (Zhou and Liu, 
2014). NOTCH1 is widely expressed in different organs including stomach, 
lungs and heart. In heart, it acts as a receptor, binding specific membrane-
bound ligands including Delta1, Jagged1 and Jagged2, to regulate cell-
specification processes. Therefore, the Notch1 receptor plays a major role 
during cardiac development through interactions with these ligands (Miazga 
and McLaughlin, 2009). In early cardiogenesis, NOTCH1 modulates the timing 
of heart field specification, and is responsible for heart tube looping and left-
right axis formation (Zhou and Liu, 2014). NOTCH1 is also involved in valve 
primordia formation and trabeculation of the left ventricle (Grego-Bessa et al., 
2007). Notch intracellular domain NICD1-activated mice showed several 




cardiac abnormalities including atrioventricular myocardium defect, disrupted 
cardiomyocyte differentiation, and intraventricular septum shifting to the right. 
These mice then eventually died during embryogenesis (Watanabe et al., 
2006). Therefore, Notch1 signalling is fundamental for proper cardiac 
development.  
Several studies have suggested that variants in the NOTCH1 gene are 
associated with HLHS. Garg et al. in 2005 reported the first NOTCH1 variant, 
a frameshift mutation (H1505del), that proposed to cause bicuspid aortic valve 
(BAV) identified in a HLHS patient with a family history of different congenital 
heart diseases (Garg et al., 2005). Another three variants affecting the coding 
region of NOTCH1 were identified in patients with HLHS along with other left 
ventricular outflow tract (LVOT) malformations including BAV (McBride et al., 
2008). These variants were NOTCH1G661S, NOTCH1A683T, and NOTCH1A1343V. 
Assessment of ligand-induced Notch1 activity by comparing the Notch1-
dependent signalling induced by JAGGED1 between wild-type NOTCH1 and 
mutant NOTCH1 showed that the first and second variants significantly 
changed the level of JAGGED1-induced activation (McBride et al., 2008). 
However, the NOTCH1A1343V variants, which was present in controls and 
patients at similar rates, showed no significant difference in JAGGED1-
induced activation level. This observed reduction in the ligand-induced 
signalling by NOTCH1G661S and NOTCH1A683T variants was speculated to 
cause the aortic valve defects observed in the patients through 
haploinsufficiency for the NOTCH1 receptor, which suggesting that Notch 




signalling levels must be tightly regulated and sight changes to its activity level 
could cause abnormalities in the heart.    
In another study, 53 HLHS patient; characterized according to Tchervenkov et 
al. 2006 classification of HLHS; were analysed (Iascone et al., 2012). It was 
reported that there were two NOTCH1 de novo variants; one splicing 
(p.Asp1790Asp) and one frameshift (p.Gly1476Asp) identified in 30/53 HLHS 
patients (Iascone et al., 2012). Although the biological significance of these 
variants was unclear, it was suggested that the NOTCH1 signalling pathway 
might be implicated in HLHS, at least in the valve malformations observed in 
the syndrome. More recently, a novel NOTCH1 germline frameshift/stop-gain 
mutation was identified in a HLHS patient with family history of both HLHS and 
hypoplastic right heart syndrome (HRHS). This study proposed that there is a 
strong association between NOTCH1 mutations and HLHS based on the 
identification of this variant in multiple family members (Durbin et al., 2017).  
According to animal studies, mutations in NOTCH1 have been linked to 
impaired endothelial mesenchymal transformation (EMT) during early stages 
of valvulogenesis (Timmerman et al., 2004). Knocking out a large portion of 
NOTCH1 gene in mice showed reduce ability to form endocardial cushions 
through EMT leading to hypoplastic endocardial cushions (Andersen et al., 
2014; Timmerman et al., 2004). This illustrated that NOTCH1 plays an 
important role during cardiovascular development, and mutations in this gene 
could promote cardiac defects including HLHS. 




NOTCH1 signalling pathway is one of the most important pathways for heart 
development. Although there have been several NOTCH1 mutations 
associated with congenital heart defects including HLHS, BAV and HRHS, 
none of these mutations were actually proved to be pathogenic or most 
importantly to cause HLHS.  
 NOTCH3 
NOTCH3 receptors are located at the surface of vascular smooth muscle cells 
(VSMC) or pericytes that found around blood vessels and it has been reported 
that they play an important role in VSMC maturation and differentiation (Joutel 
et al., 2010). NOTCH3 receptors also have been implicated in the 
development of pulmonary artery SMC, as it involves in different cell activities 
including survival and function of vascular smooth muscle cells (Li et al., 2009). 
Expression of NOTCH3 was detected in late embryonic brain tissue, and in 
most of the organs during adulthood, particularly the vagina. Interestingly, 
unlike Notch1 knockout mouse models, homozygous Notch3 mutant mice 
showed normal embryonic growth; and were fertile and viable in adulthood; 
suggesting that Notch3 is not essential for mouse embryonic development 
(Krebs et al., 2003). 
Mutations in NOTCH3 have been associated with pulmonary arterial 
hypertension and cerebral autosomal dominant arteriopathy with subcortical 
infarcts and leukoencephalopathy (CADASIL). However, recently, a mutation 
in the NOTCH3 coding region (exon 11: c.A1766C:p.Q589P) was reported in 
(3/5) induced pluripotent stem cells (iPSC) from HLHS patients (Yang et al., 




2017). Inducing this mutation to the iPSC derived from patient fibroblasts, 
which were differentiated to cardiomyocytes, enhanced the ability of these cell 
to differentiate into SMC, leading to disorganised sarcomeres and 
sarcoplasmic reticulum, and reduced beating rate. Consequently, it was 
suggested that mutations in NOTCH3 could cause dysfunction of the left 
ventricle, leading to HLHS. Thus, NOTCH3 might be a good candidate for 
HLHS.  
 NOTCH4 
NOTCH4 is the most specific receptor as it is almost solely expressed in the 
vasculature, whereas other NOTCH family genes are found in most tissue 
types (James et al., 2014: Uyttendaele et al., 1996).  NOTCH4 plays a minor 
role in angiogenesis in embryos. Since NOTCH4 is the least studied receptor, 
it is the least understood in term of its potential functions and signalling (James 
et al., 2014). Similar to homozygous Notch3 mutant mouse model, Notch4-
knockout mice showed no obvious mutant phenotype, indeed they were fertile 
and viable (Krebs et al., 2000).  
Recently, there were three NOTCH4 novel mutations (exon1:c.33_44del: 
p.11_15del, exon1:c.17_28del:p.6_10del and exon18:c.G2834A:p.C945Y) 
that were identified in (4/5) induced pluripotent stem cells (iPSC) from HLHS 
patients (Yang et al., 2017). These mutations were reported to reduce 
differentiation into mature cardiomyocytes and mesodermal cells and were 
speculated to subsequently diminish left ventricular growth and eventually lead 




to dysfunctional left ventricle (Yang et al., 2017). Therefore, NOTCH4 could 
have a potential association with HLHS.  
 HAND1 
HAND1 is basic helix-loop-helix (bHLH) transcription factor of the Twist family 
(Vincentz et al., 2011). HAND1 has an important role during cardiac 
morphogenesis. During cardiac looping in mice, HAND1 is predominantly 
expressed in the outer curvature of the left ventricle and the myocardial cuff of 
the outflow tract suggesting its role in the expansion of chamber myocardium 
(McFadden et al., 2005). Also, HAND1 was documented to modulate the 
morphogenesis of endocardial cushion through a myocardium-derived signal 
(McFadden et al., 2005; Barnes et al., 2010). Targeted mutation of Hand1 in 
mice causes lethality of embryos at E8 to E8.5 with severe placental and 
extraembryonic membrane defects. This therefore reflects the important role 
for Hand1 in differentiation of trophoblast and hence in embryogenesis 
(McFadden et al., 2005). 
Mutations in HAND1 have been implicated in congenital heart defects, 
including HLHS and tetralogy of Fallot (Reamon-Buettner et al., 2009). A 
frameshift mutation (A126fs) in the bHLH domain of HAND1 was reported in 
24 of 31 formalin-fixed hypoplastic left ventricles (Reamon-Buettner et al., 
2008). This mutation resulted in a truncated and premature protein that is 
dysfunctional (Reamon-Buettner et al., 2008). However, modelling of the 
A126fs mutation in mice was embryonic lethal at E14.5, as mutant mice 
showed abnormalities in cardiac outflow tract, ventricular septal defect, and 




thin myocardium; but at the same time they showed normal sized left 
ventricular chamber. This therefore suggested that this mutation did not cause 
HLHS, but instead it caused a dominant negative function of the vital Hand1 
role during cardiogenesis (Firulli et al, 2017). It is important to note that this 
mutation could be a consequence of formalin-induced changes to DNA, as it 
was originally identified in formalin-fixed paraffin embedded tissues of patients 
with hypoplastic left or right ventricles (Reamon-Buettner et al., 2008; chapter 
4). Overall, HAND1 plays a major role during embryogenesis in general and 
carcinogenesis in particular, hence it remains a candidate for HLHS despite 
having no definitive evidence.  
 FOXC2/FOXL1  
The FOX gene family comprises of 50 members identified in human genomes 
and at least 43 members found in the mouse genome (Jackson et al., 2010). 
Several functions have been associated with the FOX gene family including 
modulation of cell senescence or proliferation, development of different 
organs, and metabolic homeostasis (Jackson et al., 2010). This section will 
only focus on the members of FOX family that have implicated in HLHS; 
FOXC2 and FOXL1.   
A great deal of attention has been paid to FOXC2, as it is closely related to 
FOXC1 transcription factor and both have important roles in heart formation 
(Kume et al., 2001). During embryonic development, FOXC1 and FOXC2 
share similar expression patterns in overlapping domains in various tissues, 
suggesting complementary functions. In the heart, FOXC2 is localised to 




endothelial cells and neural crest cell-derived endocardial cushions (Seo and 
Kume, 2006). Likewise, FOXL1 expressed in epithelial cells, mesoderm 
underlying the endoderm, in the mesenchyme of the palate, and in the lung 
(Wotton et al., 2008). It has been shown that the null mutation of Foxc2 in mice 
leads to perinatal lethality, a skeletal malformation, lymphatic system defects, 
as well as severe cardiovascular defects including ventricular septal defects 
and aortic arch patterning defects (Iida et al., 1997; Uddin et al., 2015). 
However, the deletion of Foxl1 in mice caused a delay in gastric gland and 
intestinal villi formation during foetal development and in adulthood, with the 
mice exhibiting gastric mucosa and intestinal villi hypoplasia (Takano-
Maruyama et al., 2006). This therefore indicates that FOXC2 has roles during 
heart development, whereas the role of FOXL1 in the heart remains unclear.  
It was reported that deletion of FOXC2 and FOXL1, along with FOXF1, which 
were located close to each other on the same chromosome, in patients caused 
HLHS along with other distinct malformations including lung developmental 
disorder, urinary tract malformations, and gastrointestinal atresia (Stankiewicz 
et al., 2009). In addition, a de novo deletion of chromosome 16q24.1-q24.2 
that contained the FOXC2 gene was suggested to cause HLHS along with 
several other malformations, including polyhydramnios, pleural effusion and 
bilateral hydronephrosis, in a new born male baby (Yu et al., 2010). However, 
a study conducted by Iascone et al. (2012) based on screening 53 well-
characterized HLHS patients showed no contributory effect of FOXC2 and 
FOXL1 on underdevelopment of the left ventricle in the HLHS patients 
(Iascone et al., 2012). Whilst FOXL1 and FOXC2 were both suggested to 




associate with HLHS, it is still unclear how these genes were implicated during 
heart development. However, since FOXC2 null mice showed defects in the 
heart but not FOXL1 knock out mice, this suggests that FOXC2 may be a 
better candidate for association with HLHS than FOXL1.  
 SMAD3  
The protein encoded by SMAD3 belongs to the SMAD family, which are 
intracellular proteins that transmit extracellular signals from the cell surface to 
the nucleus for activation of downstream transcription (OMIM: 603109). The 
signal transducer, SMAD3, acts through the transforming growth factor-beta 
(TGF-β) signalling pathway and plays an essential role in both cardiac and 
renal fibrosis (Liu et al., 2016). SMAD3 is expressed in ovary, thyroid and 
heart. In heart, it was found to regulate formation of cardiac fibroblasts (Euler-
Taimor and Heger, 2006). Knocking out Smad3 in mice resulted in aortic 
aneurysms, colonic dilation, and renal fibrosis (Zanninelli et al., 2006). 
Variants in SMAD3 have been associated with several disorders including 
aneurysms-osteoarthritis syndrome, Loeys-Dietz Syndrome 3, and leukaemia 
(Van de Laar et al., 2011; Walfraim et al., 2004). Recently, a single study 
proposed an association of SMAD3 with HLHS. A novel variant in SMAD3 
(c.3G>A, p. Met1Ile) was reported in a 14-year-old boy who was born with 
HLHS and developed progressive aortic aneurysm after completing staged 
palliation (Fitzgerald et al., 2014). However, this SMAD3 variant was also 
found in two family members of the proband, although both had normal 
echocardiography and magnetic resonance angiography (MRA) with no 




evidence of osteoarthritis (Fitzgerald et al., 2014). Therefore, it seems less 
likely for SMAD3 to be associated with HLHS.      
 TBX5  
The T-box transcription factor, TBX5, is a member of a large T-box family of 
transcription factors that plays a role in forelimb formation and identity as well 
as in cardiac development (OMIM: 601620). TBX5 is expressed in retina, 
forelimb buds and heart. In early heart development, TBX5 is found in the 
precardiac mesoderm, then becomes limited to the posterior region of the 
looping heart tube. After the specification of the cardiac chambers, TBX5 is 
expressed in the atria, the left ventricle and the ventricular septum. Targeted 
mutation of Tbx5 in mice (Tbx5del/del) demonstrated cardiac and forelimb 
abnormalities that caused severe hypoplastic posterior domains during 
carcinogenesis. Interestingly, although these Tbx5-deficiency mice die during 
embryogenesis, they demonstrated that Tbx5 is not important for heart 
formation; but rather in programming cardiac development particularly heart 
chamber patterning (Bruneau et al., 2001; Bimber et al., 2006). 
Dominant mutations in TBX5 have been associated with Holt–Oram 
syndrome, a developmental abnormality, which often includes cardiac defects 
including isolated atrial and ventricular septal defects, conduction system 
defects and HLHS (Steimle and Moskowitz, 2017). The association of HLHS 
with TBX5 mutations resulted from reviewing the spectrum of cardiac defects 
reported in 240 patients with Holt-Oram syndrome and additional cases 
reported in literature (Bruneau et al., 1999). There was not enough evidence 




to show that the reported case was HLHS, and not speculation of HLH. 
Therefore, TBX5 seems less significant for HLHS since there is little evidence 
to link TBX5 to HLHS.  
 ETS1  
ETS1 belongs to the ETS family of transcription factors, which are known for 
their essential roles in different cellular functions, vascular development and 
angiogenesis, and cardiovascular development (Ye et al., 2010). Expression 
of ETS1 is predominantly found in the lymphoid organs and brain. A murine 
expression study showed that Ets1 expression increased after embryonic 
implantation and during organogenesis. However, in foetal stages, Ets1 
expression becomes restricted to the lymphoid tissues, branching organs, and 
brain (Kola et al., 1993). Expression of Ets1 was also detected in embryonic 
heart, particularly in the neural crest cells and endocardium of developing 
mouse heart (Ye et al., 2010). The first implication of Ets1 in heart 
development came from non-mammalian species such as chicks, frogs and 
fruit flies (Lie-Venema et al., 2003). Years later, the role of Ets1 in mammalian 
heart development was demonstrated through deletion of Ets1 in mice (Ye et 
al., 2010). This study showed that loss of Ets1 functions caused impaired 
ventricular development (non-apex forming left ventricle), membranous 
ventricular septal defects, and mostly led to embryonic lethality. 
Chromosomal microarray mapping of three patients with Jacobsen syndrome 
and heart defects, such as ventricular septal defects; double outlet right 
ventricle; and HLHS, ETS1 gene was identified as a potential causative gene 




for the heart defect observed in these patients. Based on the Ets1 knockout 
mouse model, which showed underdevelopment/non-apex forming left 
ventricle, and expression of Ets1 during heart development; it was suggested 
that ETS1 was associated with HLHS (Ye et al., 2009). This, therefore, 
suggested that ETS1 plays a critical role during heart development and 
manipulating its function could lead to congenital heart defects such as HLHS. 
Hence, ETS1 might be a good candidate for HLHS. 
 PCDHA9/SAP130 
PCDHA9 is a member of a 15 superfamily protocadherin alpha gene cluster 
that has similar genomic organization to B-cell and T-cell receptor gene groups 
(OMIM: 606315). The PCDHA9 gene is an integral plasma membrane protein 
with a critical role in the formation and function of cell-cell communications (Wu 
and Maniatis, 1999). Over the years, the PCDHA9 gene has been associated 
with different defects including autism, a dysfunctional nervous system and 
brain disorders (Anitha et al., 2013; Kohmura et al., 1998). Accordingly, 
expression of PCDHA9 was reported in several brain tissue types during 
adulthood, including the forebrain and cerebellum (Kohmura et al., 1998), 
which supported the association between PCDHA9 mutations with several 
brain disorders. Only recently, the expression of Pcdha9 was studied in mouse 
heart. Whilst Pcdha9 expression was reported to be weakly expressed in the 
developing heart ventricle and atrium at E9.5 (Liu et al, 2017), no specific role 
has been determined for this gene in the cardiovascular system.  




The histone deacetylase subunit, SAP130, is a member of the SIN3A co-
repressor complex, which functions as a transcriptional repressor or regulates 
interactions between the complex and another regulatory complex (Fleischer 
et al., 2003). There is limited information about the roles of SAP130, although 
it was reported to promote oncogenesis and tumorigenesis (Wardwell-Ozgo et 
al., 2014). Analysis of the expression pattern of Sap130 in mice using Sap130-
lacZ knockout (KO) showed ubiquitous expression of Sap130 throughout the 
whole developing embryo (Liu et al, 2017). Moreover, homozygous and 
heterozygous mouse knockout of Sap130 demonstrated peri-implantation 
lethality and hence suggesting its significant role in embryogenesis (Liu et al, 
2017). Although SAP130 was reported to be expressed in the developing 
heart, its specific roles during cardiogenesis remains unknown.  
Recently, both PCDHA9/SAP130 genes were implicated in the congenital 
heart defect, HLHS (Liu et al, 2017). Based on a large-scale analysis of 
ethylnitrosourea mutagenesis in mice, which aimed to recover mutations 
resulting in congenital cardiac defects, Cecelia Lo’s group recovered eight 
mouse strains with a HLHS-related phenotype (Figure 4.1 A) (Liu et al., 2017; 
Benson et al., 2016). From screening these mice, it was suggested that HLHS 
was caused by digenetic interactions between Pcdha9 and Sap130 although 
this combination of genes was only seen in one mouse of the original 
recovered strains. It was also suggested that mutations in Pcdha9 but not in 
Sap130 resulted in a normal left ventricle size but a dysplastic aorta, whereas 
mutations in Sap130 caused hypoplasia in the left ventricle. Therefore, 
combination of both genes together was required to cause all HLHS features 




(Liu et al., 2017). However, the obtained phenotype from the proposed HLHS 
digenic model revealed a well-recognised, but rare form of double-outlet right 
ventricle (DORV) with both great arteries (aorta and pulmonary) arising from 
the right ventricle and intact ventricular septum (Figure 4.1 B) (Chaudhry et 
al., 2019). In addition, linking this finding to human HLHS patients revealed 
that one out of 68 HLHS patients had the rare mutations in SAP130 and in 
PCDHA13, which was proposed to be homologous to Pcdha9 identified in 
HLHS mice (Liu et al., 2017). Altogether, although a digenic model for HLHS 
was proposed, the interaction between these two genes was not necessarily 
causing HLHS; as a range of other cardiac malformations were also found 
(Cecilia et al., 2019). This included double-outlet right ventricle (DORV), aortic 
arch anomalies, outflow tract malalignment defect, and hypoplastic RV with 
tricuspid hypoplasia (Liu et al., 2017). Therefore, considering the multiple 
abnormalities that can arise from the interaction between these genes and the 
lack of homologous protocadherin mutations between humans and mice, 
suggested less significant roles for these genes in causing HLHS. However, 
for the purpose of this study, it is still important to identify SAP130 and Pcdha9 










Figure 4.1: The proposed HLHS digenic model.  
(A) The recovered mutant mouse line for a HLHS-related phenotype at P0 and 
E14.5. The mutant showed both aorta and pulmonary arteries connected to the 
right ventricle (red dashed lines: aorta, yellow arrows: connection point). Also, 
thickening in the left ventricular wall, which could be resulted from blocking blood 
flow though the transposition of aorta to the right ventricle. (B) CRISPR–Cas9 
mutant of Sap130m/m; Pcdha9m/m mouse model. The generated mouse model for 
the proposed genes also showed no HLHS features, instead it showed double-
outlet right ventricle (DORV) phenotypes, as the aorta demonstrated right 























RNA binding protein FOX2 or RBFOX2 is a binding protein with high affinity 
for (U)GCAUG-rich sequences. One of the critical functions of RBFOX2 is to 
control alternative splicing events, which are important for pluripotent stem cell 
differentiation and epithelial to mesenchymal transition during heart 
development (Venables et al., 2013). RBFOX2 is widely expressed in brain, 
muscles, neurons and various progenitor cells (Partridge and Carter, 2017). 
Experimental non-mammalian model of rbfox-deficient in zebrafish exhibited 
severe abnormalities in heart, including decreased heart rate and myofibrillar 
disarray, and skeletal muscles that led to embryonic motility loss (Conboy, 
2016). Also, conditional deletion of Rbfox2 in mice caused an alternative 
splicing event that led to brain developmental disorders. Moreover, 
downregulation of Rbfox2 in mice led to pressure overload that induced heart 
failure (Wei et al., 2016).  
In a large cohort of congenital heart defect patients, RBFOX2 was recognised 
as a key risk allele for HLHS, as three de novo loss of function mutations 
(splice site, nonsense and frameshift mutations) in RBFOX2 and one de novo 
copy number loss RBFOX2 mutation, were identified in four CHD proband with 
HLHS (Homsy et al., 2015). However, there were various speculations 
regarding the effect of each mutation. For example, the splice site mutation 
was predicated to include around 1.6kb of intron 10, which could lead to 
nonsense-mediated decay (NMD) of the RBFOX2 mRNA. Similarly, the 
frameshift mutation was also predicted to induce a stop codon that would 




eventually result in NMD of RBFOX2 mRNA (Homsy et al., 2015). The effect 
of the de novo nonsense mutation (281 C>T), which was reported previously 
by Homsy et al (2015), was investigated. It was found that expression and 
localisation of Rbfox2 in cardiomyocytes of HLHS patient right ventricles (RV) 
was predominantly cytoplasmic with low level expressions in nucleus, 
compared to cardiomyocytes of RV controls that showed equal expression 
Rbfox2 in both the nucleus and cytoplasm (Verma et al., 2016). In addition, 
the effect of this mutation on protein levels was measured in cells infected with 
Rbfox2 nonsense mutation, using Western blotting with a Rbfox2 antibody. 
This showed that the Rbfox2 protein in the Rbfox2 mutant cells had ~3KDa 
reduced molecular weight compared to Rbfox2 wild type cells. Moreover, 
examination of transcriptome changes in HLHS RV patients revealed that the 
majority of transcripts in patients identified as Rbfox2 targets implicating its 
important function in RNA/protein metabolism. Therefore, it was suggested 
that the RBFOX2 nonsense mutation resulted in incomplete formation of the 
RBFOX2 C-terminal, leading to protein truncation and impair subcellular 
distribution, which affected its function in RNA metabolism contributing to early 
changes in transcriptome observed in HLHS patients (Verma et al., 2016). 
Overall, both studies highlighted the significance of RBFOX2 mutations in 
HLHS, as these mutations resulted in major effects on RBFOX2 functional 
protein. Therefore, RBFOX2 seems to be a good candidate gene to investigate 
its relevant to HLHS. 
 




4.4 Expression of HLHS-implicated genes in the relevant 
regions of the developing heart 
The majority of the suggested genes seems to have a strong associated with 
HLHS. Therefore, the expression patterns for genes with strong significant for 
HLHS will be investigated in respect to the specific structures that are affected 
in HLHS. 
All HLHS cases involve abnormalities in the development of the left ventricle 
and its communicating valves. These abnormalities might happen during the 
primary development of these regions and lead to the predominant 
malformations observed in the left side of the heart in HLHS patients. 
Alternatively, HLHS could occur in the window after the heart has formed, 
which at embryonic day E15.5 or Carnegie Stage CS23 (week 8), but before 
15 weeks, when HLHS is earliest diagnosed antenatally (Hunter et al., 2003; 
Andrews et. al., 2004). This is important because it brings the argument of 
intact ventricular septum in HLHS patients, which means abnormalities in 
HLHS may occur after the completion of septation (Grossfeild et al., 2019). In 
order to address these possibilities, it is important to specifically identify the 
crucial stages involved in the development of the main affected regions 
including the left ventricle, aortic valve and mitral valve. 
Since there is a window from the beginning of heart formation (week4) through 
ventricular and valve formation and development, and after septation to the 
time of HLHS diagnosis (week 15), HLHS can occur at any stage during this 




period (Figure 4.2). Therefore, the stages between week 4 to week 15 will be 
investigated. 
 
Figure 4.2: Main developmental stages in human and mouse for HLHS.  
CS: human Carnegie stages, E: mouse embryonic days, PCW: postconceptional 
weeks. 
 
The initial formation of the primitive heart tube begins at week 4 (CS9-CS11 in 
human and E6.5-E8.5 in mouse), where cardiac progenitor cells undergo an 
epithelial to mesenchymal transition (EMT) in order to migrate and establish a 
cardiac crescent (Hunter et al., 2003).  Through several signals and induction 
of cardiac transcription factors, the cardiac crescent folds and fuses at the 
midline forming a primitive cardiac tube, which swiftly begins to bump blood. 
The cardiac tube is composed of an outer myocardial layer surrounded by an 
inner endocardial cell layer and in between an extracellular matrix filled cardiac 
jelly (Vincent and Buckingham, 2010). As embryo development progresses, 
the heart tube suspends in the developing pericardial cavity where it 




undergoes a rightward looping process causing the developing chambers to 
be placed into their adult positions (Kelly et al., 2014). After the poorly 
understood looping process and expansion of myocardium, the heart tube 
develops four-recognisable chambers at week 5 (CS12-CS14 and E9.0-
E10.5). At the same time, the endocardial cells of the cardiac tube undergo 
EMT process to invade into the cardiac jelly, particularly at the proximal outflow 
tract and the atrioventricular canal, and initial the formation of endocardial 
cushions. The mitral valve is formed by the atrioventricular cushion and the 
aortic valve forms at the distal part of endocardial cushions located in the 
outflow tract (Henderson et al., 2018). After several developing processes and 
by week 7 (CS17-CS18 and E12.5-E13.5), the aortic three-leaflet and mitral 
two-leaflet valves are formed and permits unidirectional blood flow. However, 
by these stages, these valves have not matured yet, as they resemble solid 
bulky structures. Thus, over the later stages, the cushions grow and remodel 
to start forming mature valves with thin leaflets from CS19-CS23 and E14.0-
E16.5 to Birth (Geng et al., 2017). By these stages E15.5, the ventricular 
septum has completely formed, and the left ventricular chamber becomes 
thickly packed with trabecular meshwork, in which the left ventricle can be 
distinguished from the right ventricle (Captur et al., 2016; Moorman et al., 
2003). Therefore, all the highlighted developmental stages are essential for 
normal heart development and understanding the key genes for cardiogenesis 
may reflect their implications in HLHS. 
Overall, the current study focused on using mouse tissues to study expression 
of HLHS implicated genes in the crucial stages of developing the main effected 




regions in HLHS, including the mitral and aortic valves and left ventricle. 
Hence, mouse embryos at E10.5 were used to illustrate the expression pattern 
of the selected genes in the early stage of cushions (future valves) and 
ventricular developments. Also, in order to illustrate the roles of these genes 
during the remodelling of cushions to valve leaflets, E13.5 stage was selected. 
Finally, to understand these gene roles in further remodelling of valves into 
thin leaflets and after the completion of ventricular septum, E15.5 was 
selected. Thus, the expression of HLHS-implicated genes will be investigated 
in the mouse embryonic stages: E10.5, E13.5 and E15.5.  
 
  




4.5 Aims of this chapter 
Several genes have been described to be associated with HLHS. However, 
none of the mutations in these genes were confirmed as being pathogenic and 
a clear mechanism underpinning the development of HLHS delineated (Liu et 
al., 2017, Firulli et al., 2017). Therefore, this chapter intends to discuss the 
most significant genes for HLHS with respect to their potential functions and 
expressions during heart development. Although some of these gene 
expression patterns have been described previously, they have not been 
investigated in respect to the specific structures that are affected in HLHS 
neither been linked to HLHS subgroups.  
To achieve this, this chapter will:   
• Identify the expression pattern of HLHS-implicated genes in the mouse 
heart at various developmental stages including E10.5, E13.5 and 
E15.5 using in situ hybridisation  
• Critically analyse the HLHS-implicated genes in HLHS based on these 
expression patterns and the published literature.  
 
  




4.6 Materials and methods 
 Mouse lines  
All mouse embryos used in this project were from the outbred CD1 mouse line 
to provide genetic diversity. Embryos were collected at embryonic days (E) 
10.5, E13.5 and E15.5.  
 Paraffin wax embedding of mouse tissues  
All collected embryos were fixed at 4°C in 4% paraformaldehyde made in 
DEPC water. Based on the embryo age, wax embedding time was altered 
(Table 4.1). All solutions used in the fixation and embedding processes were 
made in DEPC water.  
Table 4.1: Steps for embryo paraffin wax embedding processes  
  E10.5 E13.5 E15.5 
4% PFA at 4°C 1 night 2 nights 2 nights 
50% EtOH Shaking at RT 30 mins 2 hours 3 hours 
70% EtOH (x2) Shaking at RT 30 mins 2 hours 3 hours 
30 mins 2 hours 3 hours 
Embryos could be stored at room temperature 
95% EtOH Shaking at RT 30 mins 2 hours 3 hours 
100% EtOH (x2) Shaking at RT 30 mins 2 hours 3 hours 
1 hour O/N O/N 
Histoclear (x2) Shaking at RT 15 mins 20 mins 30 mins 
15 mins 20 mins 30 mins 
Histoclear/Wax Heat 60-65°C 20 mins 30 mins 1 hour 
Wax (x3 or 4) Heat 60-65°C 
  
30 mins 1 hour 1 hour 
30 mins 1 hour 1 hour 
30 mins 1 hour 1 hour 
  1 hour 




 Sectioning paraffin wax tissues  
Paraffin wax tissues were sectioned at 10µm thickness using Leica RM2235 
manual rotary microtome (Biosystems Swaziland). Before use, microtome 
surface was wiped with a RNaseZap solution (Invitrogen, AM9780). Tissue 
sections were lined up on microscope glass slides (Marienfeld Superior, 
1000612) and adhered to the slides through heating the slides with water to 
37°C. The slides were then left overnight in 37°C incubator. Next day, slides 
were kept in fridge at 4°C.   
  RNA in situ hybridisation   
The RNA in situ hybridisation experiments were conducted in an RNase-free 
environment at room temperature unless otherwise stated.  
 Glassware and solution treatments 
A glass funnel, 500ml measuring cylinder, 7 glass troughs and a metal slide 
holder were needed. All glassware were washed in a dish washing machine 
and wiped with the RNaseZap solution before use. The following table 
summarises the preparation method for in situ hybridisation stock solutions 
(Table 4.2).  
Table 4.2: Preparation method for treatment solutions. 
Solution Preparation method Storage conditions 
DEPC-H2O 
2mL Diethyl pyrocarbonate 
dissolved in 2L dH2O 
incubate 
overnight in a 
fumehood then 
autoclave 





200mL 10x PBS-H2O mixed 
with 2mL Diethyl 
pyrocarbonate, topped up to 2L 
dH2O 
incubate 
overnight in a 
fumehood then 
autoclave 
20x Saline Sodium 
Citrate (SSC) 
175.3g NaCl and 88.2g 
Trisodium Citrate dissolved in 
800mL dH2O, adjust to pH6 
then make up to 1L dH2O 
Autoclaved prior to 
use, and stored at 
room temperature  
2x SSC 4ml 20x SSC diluted in 36ml DEPC-H2O 
Stored at room 
temperature 
5x MAB 
29g Maleic acid, 21.9g NaCl, 
19.5g NaOH pellets dissolved 
in 400mL dH2O; the pH was 
adjusted to 8 then the solution 
was topped up to 500mL dH2O 
Autoclaved and 
stored at room 
temperature 
200ml 1x MABT 40mL 5x MAB, 0.2mL tween-20 
mixed with 160mL dH2O 
Stored at room 
temperature 
400ml 1x MABT 80mL 5xMAB, 0.4mL tween-20, and 320mL dH2O 
Stored at room 
temperature 
90% ethanol 315mL ethanol mixed with 35mL DEPC-H2O 
Stored at room 
temperature 
70% ethanol 245ml ethanol mixed with 105ml DEPC-H2O 
Stored at room 
temperature 
50% ethanol 175ml ethanol mixed with 175ml DEPC-H2O 




25ml 50% formamide, 12.5ml 5x 
SSC (pH6), 100µl 200 µg/mL T-
RNA, 50µl 100 µg/mL Heparin, 
and 0.5ml 0.1% tween-20, 
mixed with 11.85ml DEPC-H2O 
Stored at 200C 
Post-hybridization 
buffer I 
200mL formamide, 100mL 20X 
SSC (pH6), 20mL 20%SDS, 
made up to 400mL with dH2O 
Incubate at 60°C, 
only used once. 
Post-hybridization 
buffer II 
200mL formamide, 40mL 20X 
SSC (pH6), 4mL 20%SDS, 
made up to 400mL with dH2O 
Incubate at 60°C, 
only used once. 
2% Blocking buffer 2g blocking agent dissolved in 
100mL 1xMABT 
Autoclaved and 
stored at 4°C 
AP-buffer 
10mL 5M NaCl (292.5g/L), 
25mL 1M MgCl2 (203g/L), 
50mL 1M Tris HCL pH9.5 
(121.1g/L), 500µL Tween-20, 
made up to 500mL with DEPC-
H2O 
Must be made on 
Day 3 of the in situ; 
stored at  
-20°C 
 




In situ hybridization method is a three-day experiment. Table 4.3 summarises 
the main steps that were performed in each day. 
Table 4.3: a summary of the main steps of in situ hybridization. 
Day 1 Day 2 Day 3 
• Hydration 
• Fixation  
• Digestion  
• Post-fixation  
• Acetylation 
reaction  
• Pre-hybridization  




• Blocking  
• Antibody 
detection   
• Washing  
• Developing  
• Mounting  
 
 Hydration of wax sections  
The slides were placed on a metal slide holder and were immersed in the 
following solutions for the indicated time periods (Table 4.4).  
Table 4.4: Slides hydration.  
Solution Time (minute) 
Histoclear 10 
Histoclear 10 
100% etOH 5 
100% etOH 5 
90% etOH 5 
70% etOH 5 
50% etOH 5 
1st wash with PBS-DEPC 5 
2nd wash with PBS-DEPC 5 
 Fixation 
An RNase-cleaned slide box was humidified with DEPC-PBS socked tissues. 
1ml of 4% PFA-DEPC was added to each slide and incubated for 20 minutes 
at room temperature away from the light in the humid chamber. The slides 




were washed twice with PBS-DEPC each for 5 minutes then placed back in 
the humid chamber.  
 Digestion 
In order to allow an efficient probe penetration; partial tissue digestion with 
proteinase K was conducted. The timing was critical for this step as less 
digestion time would result in a weak signal and prolonged digestion periods 
would damage the morphology of tissues. Proteinase K was prepared by 
diluting 10µl of 10mg/ml proteinase K in 10mL PBS-DEPC making a final 
concentration of 10µg/ml. 1ml proteinase K was added to the slides and 
incubated for 10 minutes at 370C then washed twice with PBS-DEPC each for 
5 minutes. The slides were placed back in the dark humid chamber.  
 Post-fixation 
This step is crucial for fixing proteinase K-digested tissue. 1ml 4% PFA-DEPC 
was added for each slide and incubated for 5 minutes at room temperature 
away from light in the humid chamber. The slides were washed twice with 
PBS-DEPC each for 5 minutes.  
 Acetylation reaction 
Acetylation reaction was conducted to reduce background noise by acetylating 
any positive charge in tissues. This step was performed in a fumehood. Acetic 
anhydride buffer was kept at room temperature for 10 minutes with continuous 
stirring. In a glass trough with a magnetic stirrer, 392 mL PBS-DEPC, 5.31 mL 




of 7.53M TEA, 1.4 mL HCl, and lastly 1mL acetic anhydride were added. Fresh 
PBS-DEPC was used to wash the slides twice for 5 minutes then a final wash 
with DEPC-dH2O for 5 minutes.  
 Pre-hybridisation   
To maintain humidity, the tissue rolls were replaced with newly 2x SSC-soaked 
ones. 500µL of hybridisation buffer was added to each slide and incubated for 
2h at 680C. The time period could be extended up to 12h.  
 Hybridisation  
Hybridisation buffer was warmed up to 680C for 10 minutes. The probes were 
defrosted on ice and 1:300 dilution was prepared in the hybridisation buffer 
(50ng probe/200µl buffer/slide). To denature secondary structures in probes, 
the hybridisation mix was incubated at 700C for 5 minutes then immediately 
placed on ice. 200µl hybridisation mix was added to each slide and covered 
with a coverslip. The slides were incubated overnight (12h to 16h) at 680C.  
 Post-hybridisation washes  
This step was crucial for controlling stringency. The post-hybridisation buffers 
were incubated in water bath at 680C for 30 minutes. The slides were covered 
with post-hybridisation buffer I in the oven at 680C for 30 minutes. The buffer 
was discarded, and the slides were again covered with post-hybridisation 
buffer I at 680C for further 30 minutes. The slides were then incubated in post-
hybridisation buffer II for 30 minutes at 680C. The buffer was discarded, and 




the slides were once again incubated in the post-hybridisation buffer II at 680C 
for 30 minutes. The slides were washed with 1x MABT buffer three times each 
for 5 minutes at room temperature.  
 Blocking step 
The slides were kept humidified by using blue tissue rolls soaked in 1x MABT 
in the humid chamber. 500µl of freshly made 2% blocking buffer was added to 
each slide and incubated for 2h at room temperature.  
 Antibody detection  
A piece of paraffin film was used to cover the slides and ensure even spread 
of antibody. 1:1000 dilution of the antibody was prepared by diluting anti-DIG 
AP in 2% blocking solution and supplement it with 10% goat serum. 150µL of 
the antibody mix was added to each slide and incubated overnight at 40C.  
 Washing  
The washing step was conducted to remove excessive background and was 
performed at room temperature on a shaker. Table 4.5 summarises the 










Table 4.5: Summary of the washing step and time required.  
Solution Volume (mL) Time (minute) 
1xMABT  60 10 
1xMABT  60 10 
1xMABT  60 60 
1xMABT  60 60 
1xMABT  60 60 
AP-Buffer- 1st wash 60 10 
AP-Buffer- 2nd wash 60 10 
AP-Buffer- 3rd wash 60 10 
 
 
 Developing sections  
100µL NBT/BCIP solution was diluted in 5mL AP buffer for a final 
concentration of 20µL/mL. 0.4mL was added to each slide. The slides were 
incubated in humid chamber away from light with tissue soaked in AP buffer 
to sustain humidity. The slides were allowed to develop until blue stain was 
visible. When the blue stain was sufficient enough, the slides were washed in 
60mL 1x PBS twice for 5 minutes. The slides were placed back in the humid 
chamber with tissues soaked in PBS. 500µL 4% PFA was added to each slide 
for fixation and the slides were incubated for 15 minutes at room temperature. 
The slides were washed with 1x PBS twice, each for 5 minutes at room 
temperature and were dehydrated with non-DEPC ethanol as indicated in 








Table 4.6: Dehydration procedure.  
Solution Volume (mL) Time (minute) 
100% Methanol 200 5 
1x PBS 200 5 
1% Eosin  200 7 
1x PBS 200 5 
50% ethanol 200 5 
70% ethanol 200 5 
90% ethanol 200 5 
100% ethanol- 1st 200 5 
100% ethanol- 2nd 200 5 
Histoclear- 1st 200 10 
Histoclear- 2nd 200 10 
 
 Mounting  
Histomount was used to mount slides and coverslips were placed over it. The 
slides were allowed to dry and stored at room temperature. Brightfield imaging 
was used to capture images.  
 Preparation of RNA probes  
RNA probes were made either from plasmid (Notch1) or PCR (all other genes). 
 Probe synthesis from plasmid  
The plasmid of interest was identified in the plasmid library. Synthesizing 
probes from plasmid involved three main steps: transformation, digestion and 
clean-up of digested fragments. 





Two LB agar plates were prepared for ligation reactions. The agar plates were 
supplemented with 100µg/ml ampicillin, 100µl 100mM IPTG, 50µl 20mg/ml X-
Gal by spreading those on the surface of the plates and allow absorption for 
30 minutes at 370C. Tubes containing ligation mix were briefly centrifuged and 
5μl of ligation mix was added to a 1.5ml eppendorf tube on ice. JM109 High 
Efficiency Competent Cells were briefly thawed on ice for 5 minutes and the 
cells were gently mixed by flicking the tube. 50μl of competent cells were 
transferred to the eppendorf containing the ligation mix and mixed gently then 
placed on ice for 20 minutes. In a 420C water bath, the cells were heat-shocked 
for 45-50 seconds then immediately placed on ice for 2 minutes. 950μl of warm 
SOC medium was added to the cells and incubated shaking (approximately 
150rpm) at 370C for 1.5 hours. The cells were centrifuged at 1000xg for 10 
minutes and the pellet was resuspended in 125μl SOC medium. The cells were 
plated on the agar plates and incubated overnight (16h-24h) at 370C.  
Using a sterile tip, the colonies were transferred to LB broth supplemented 
with 1% 100mg/ml ampicillin (a single colony per 5ml LB broth for miniprep or 
50ml LB broth per colony for midiprep) and incubated overnight at 370C, 
shaking at 225rpm.  
The 5ml bacterial culture was centrifuged at 3000xg for 10 minutes at room 
temperature, the supernatant was discarded, and the pellet was resuspended 
in 250μl buffer P1. The suspension was transferred to a fresh eppendorf and 
250μl buffer P2 was added and mixed thoroughly by inverting the tube up and 




down until the suspension turned blue in colour. This step should not exceed 
a 5-minute time limit. 350μl buffer N3 was added to the tube to end the reaction 
and the suspension became colorless. This step should not exceed 5 minutes. 
The cells were centrifuged for 10 minutes at 17,900xg (13,000rpm). 800μl of 
the supernatant was pipetted into QIAprep 2.0 spin column and centrifuged for 
30-60 seconds. The flow through was discarded and the QIAprep 2.0 spin 
column was washed with 0.5ml buffer PB and centrifuged again for 30-60 
seconds. The flow through was discarded and the column was washed again 
with 0.75ml buffer PB and centrifuged for 30-60 seconds. A final 1-minute 
centrifugation was performed to remove all residual buffer PB. The QIAprep 
2.0 spin column was placed in a fresh 1.5ml eppendorf and 50μl buffer EB 
(10mM trisCL, pH 8.5) or H2O was added to the spin column and allowed to 
stand for 1 minute at room temperature. The column was centrifuged for 1 
minute then stored at -200C. 
4.6.5.1.2 Digestion of plasmid  
DNA in plasmid was quantified using NanoDrop spectrophotometer. The 
restriction digestion mix was calculated as indicated in table 4.7. the reaction 
mix was incubated overnight at 370C. A mixture of 10μl digestion mix plus 3μl 
loading dye was detected on 1% agarose gel.  
Table 4.7: Reagents for restriction digestion.  
Reagent Volume (μl) 
DNA (5ng-10ng) X μl 
Buffer (e.g cutsmart) 8μl 
Enzyme 2μl 
dH2O Up to 80μl 




4.6.5.1.3 Clean-up of digested fragments 
Equal volumes of phenol, chloroform and isopropanol were added to the 
digestion mix and vortexed. The tube was centrifuged at 12,000rpm for 3 
minutes, the upper layer was transferred to a fresh tube and an equal volume 
of chloroform was added then vortexed. The tube was centrifuged for at 
12,000rpm for 5 minutes and the upper was transferred to a fresh tube. 200μl 
ice-cold 100% ethanol plus 8μl 3M sodium acetate was added to the tube. The 
tube was gently mixed and stored at -800C for 1h prior to centrifugation at 
13,000rpm for 5 minutes at 40C. The supernatant was discarded and 500μl 
ice-cold 70% ethanol was added. The tube was centrifuged at 40C for 5 
minutes at 13,000rpm. The ethanol was discarded and the pellet was allowed 
to air-dry for 1 minute. The pellet was resuspended in 15μl DEPC-H2O and 
stored at -200C. Nanodrop quantifications were conducted prior to proceeding 
to the synthesis of DIG-labelled probe (see section 2.2).   
 Probe synthesis from PCR  
Primers were designed using ensemble or primer 3. After designing the 
primers, T7 primer was added to the reverse primer for antisense probe (AS) 
and the forward primer for the sense (S) probe. See example below:  











All the designed probe primers were listed in the table below (Table 4.8). 
Table 4.8: List of probe primers used as antisense and sense in this study. 
genes Product 
size 
Forward primer Reverse primer 
Gja1 1149bp ATGGGTGACTGGAGCGCCT TTAAATCTCCAGGTCATCAG 
Nkx2.5 753bp CAGAACCGTCGCTACAAGTG GCGCACTCACTTTAATGGGA 
Notch3 646bp GCTATACTGGACCTCGCTGT CCATCACGGCAAACTCCAAA 
Notch4 641bp AGTGTCTCCCAGGCTTTGAA GAAAGTGCCAGGCTTGTTCA 
Hand1 526bp CAGCTACGCACATCATCACC CTCCCTTTTCCGCTTGCTTT 
Foxc2 1315bp GAGCAAAACTACTACCGGGC ACGAGTTGTCCAGTCCTAGC 
Pcdha9 414bp GCTACTCTGCCTCGCTAAGA TCGTGCTGTTCCCTTTCTCT 
Sap130 925bp CGGCCCACTTTATCTATCCA CATCTGCCAACACCACTGA 
Rbfox2 1141bp CCAGGAGCCAACAACAACTC TCACGTCACTTCAGTAGGGG 
After that, PCR was conducted using the newly designed primers and the PCR 
reaction in (Table 4.9). The PCR cycles and annealing temperature were 
carried out as described in (Table 4.10). 
Table 4.9: PCR volumes for the newly designed primers.  
Component Volume (μl) 
Forward primer 1μl 
Reverse primer 1μl 
dNTPs 0.4μl 
5x reaction buffer 4μl 
Taq DNA polymerase 0.2μl 
Template cDNA 2μl 
Nuclease-free H2O 11.4μl 
Table 4.10: Temperature and time for PCR cycles.  











Finally, 2% gel electrophoresis was performed using 2g of agarose (Genaxxon 
bioscience, M3044.0250) to 100mL of 1x TAE, ran for 25mins at 125V and the 
PCR products were cleaned from gel agarose (see section 4.5.5.1.3). DIG-
labelled probes were synthesised as demonstrated in the next section.  
  Synthesis of Digoxiogenin-labelled (DIG) probes 
The table below summarizes the reagents and volumes used in DIG-labelled 
probe synthesis (Table 4.11). All buffers were defrosted on ice and briefly 
vortexed before use.  
Table 4.11: Reagents and volumes used in DIG-labelled probe synthesis.  
Reagent Volume (μl) Manufacturer 
DNA 10 - 
10X DigNTPs (DIG-labelling 
mix) 
2 Roche; Cat#17109820 
Buffer X5 4 Promega; Cat#P1188 
RNase inhibitor 1 ThermosScientific; 
Cat#EO0381 
100mM DTT 1 Promega; Cat#P1178 
Enzyme T7 2 Promega; Cat#P207E 
 
The probe mix was incubated in a water bath at 370C for 3h. 2μl DNA product 
mixed with 3μl nuclease-free water plus 1μl loading buffer were used for 
detection on a 2% agarose gel, ran at 150 volts for 10 minutes. 3μl 100bp 
ladder was used as a size marker. The probe could be stored at -200C at this 
stage. 31μl DEPC-H2O, 5μl ammonium acetate, and 165μl ice-cold 100% 
ethanol were added to the probe and incubated for a minimum of 1h at -800C. 
The probe was then centrifuged at 40C for 30 minutes at 13,000rpm. The 




supernatant was discarded, and the pellet was washed twice with 500μl 70% 
ethanol-DEPC, each time the pellet was centrifuged at 40C for 15 minutes at 
13,000rpm and supernatant was discarded.  The pellet was allowed to air-dry 
for 2 minutes prior to resuspension in 50μl nuclease-free H2O-DEPC 
depending on the size of the pellet. For detection, a 1.5% agarose gel was run 
at 125 volts for 10 minutes. 3μl DNA product mixed with 6μl loading buffer 
were loaded on the gel. The DNA was denatured at 650C for 5 minutes then 
incubated on ice for a few seconds prior to loading on the gel. The remaining 
probes were stored at -800C.  
  




4.7 Results  
 Assessment of the suggested genes for HLHS during 
development of the crucial regions in heart 
The fact that HLHS can be prenatally diagnosed by the 15th week of gestation, 
shows that it must, by definition, have occurred during stages of embryonic 
and fetal development prior to this, and perhaps early in gestation. Therefore, 
mapping the expression of the predicted HLHS genes at early cardiac 
developmental stages, particularly in the main parts of the heart affected in 
HLHS, may provide insight into their likely participation in HLHS. The following 
section, hence, will look at the expression pattern of the implicated genes for 
HLHS including Gja1, Nkx2.5, Notch family, Hand1, Foxc2, Ets1, Pcdha9, 
Sap130, and Rbfox2, at different developmental stages (E10.5, E13.5 and 
E15.5) and focussing on the regions of the heart affected by HLHS. This 
includes the atrioventricular (AV) junction, mitral valve, outflow tract (OFT), 
aortic valve, and left ventricle. Since abnormalities in the aorta werw found to 
be secondary to defects in the aortic valve, the aorta was excluded. Presence 
of these gene expressions in well-established and previously reported regions, 
where is applicable, was used as control.  
  





Expression of Gja1 was mapped to the main regions of the heart affected in 
HLHS, including left ventricle, mitral valve and aortic valve. These regions 
were investigated at three different time-points: E10.5, E13.5 and E15.5 (see 
section 4.3).  
4.7.1.1.1 Left ventricle  
At E10.5, Gja1 was expressed in the left and right ventricles, specifically in the 
myocardium. However, it expressed higher in the left than right ventricular 
myocardium (Figure 4.3 A). At E13.5, Gja1 expressed in both the left and right 
ventricles, particularly in the ventricular endocardium. Also, Gja1 expressed at 
higher level than that observed in E10.5 (Figure 4.3 B). Likewise, at E15.5, 
Gja1 showed a similar expression pattern to that at the previous stage (Figure 
4.3 C). Remarkably, expression of Gja1 was higher in the left ventricle than 
the right ventricle throughout heart development. No expression was observed 
in the Gja1 sense probe (Figure 4.3 D). 





Figure 4.3: Restricted expression of Gja1 to the ventricular cambers 
through different developmental stages. 
(A) Gja1 was expressed in the left and right ventricles at E10.5, with higher 
expression in the left than the right ventricles. Also, expression of Gja1 was 
observed in both ventricular endocardium at (B) E13.5 and (C) E15.5. (D) Gja1 
sense probe showed no expression in the heart at E10.5. Scale bar = 200µm. 
  




4.7.1.1.2 Mitral valve  
Expression of Gja1 was not detected in the endocardial cushion of the 
atrioventricular canal at E10.5 (Figure 4.4 A). Similarly, it was not detected in 
the mitral valve leaflets at E13.5 and E15.5 (Figure 4.4 B, C). No expression 
was observed in the Gja1 sense probe (Figure 4.4 D). 
 
 
Figure 4.4: No expression of Gja1 in the mitral valve. 
(A) Gja1 was not expressed in the endocardial cushions of the atrioventricular 
canal at E10.5. No expression was observed in the mitral valve leaflets at (B) 
E13.5 and (C) E15.5. (D) Gja1 sense probe showed no expression in the heart 
at E13.5. Scale bar: A-C= 100µm, D= 200µm. 
 
 




4.7.1.1.3 Aortic valve  
Expression of Gja1 was not detected in the endocardial cushion of the outflow 
tract at E10.5 (Figure 4.5 A). Similarly, it was not detected in the aortic valve 
leaflets at E13.5 and E15.5 (Figure 4.5 B, C). No expression was observed in 
the Gja1 sense probe (Figure 4.5 D). 
 
 
Figure 4.5: No expression of Gja1 in the aortic valve. 
(A) Gja1 was not expressed in the endocardial cushions of the outflow tract at 
E10.5. No expression was observed in the aortic valve leaflets at (B) E13.5 and 
(C) E15.5. (D) Gja1 sense probe showed no expression in the heart at E15.5. 
Scale bar: A-C= 100µm, D= 200µm. 
 
 




4.7.1.1.4 Summary  
Overall, Gja1 expression showed restricted expression to the left and right 
ventricles, although at all stages the expression was higher in the left than the 
right ventricles. Expression of Gja1 in this study was consistent to that 
previously reported (Christoffels et al., 2004). The fact that Gja1 was 
expressed higher in the left ventricle than the right ventricle indicated a specific 
role for Gja1 in the early development of the left ventricular chamber. This 
therefore suggested that Gja1 contributed to the initial process of the left 
ventricle formation and hence could associate with hypoplasia of the left 
ventricle that observed in HLHS cases. 
  




 Nkx2.5  
Expression of Nkx2.5 was mapped to the main regions of the heart affected in 
HLHS, including left ventricle, mitral valve and aortic valve. These regions 
were investigated at three different time-points: E10.5, E13.5 and E15.5. 
4.7.1.2.1 Left ventricle  
Expression of Nkx2.5 was localised in both left and right ventricles at E10.5 
(Figure 4.6 A). However, this expression was decreased in the ventricular 
chambers at E13.5 (Figure 4.6 B). By E15.5, the expression of Nkx2.5 was 
undetectable in both cardiac chambers (Figure 4.6 C). No expression was 
observed in the Nkx2.5 sense probe (Figure 4.6 D). Altogether, Nkx2.5 was 
widely expressed in the left and right ventricles at the early stages of heart 
development, specifically at E10.5, but this expression reduced as the 
ventricles fully formed (E15.5). 






Figure 4.6: Broad expression of Nkx2.5 in the early heart developmental 
stage. 
(A) Nkx2.5 expressed in both left and right ventricles at E10.5. However, it was 
not expressed in both ventricles at (B) E13.5 and (C) E15.5. (D) Nkx2.5 sense 
probe showed no expression in the heart at E10.5. Scale bar = 200µm. 
  




4.7.1.2.2 Mitral valve  
The expression of Nkx2.5 at E10.5 was broadly observed in the endocardial 
cushions of the atrioventricular canal (Figure 4.7 A). However, Nkx2.5 
expression was not detected in the mitral valve at E13.5 and E15.5 (Figure 4.7 
B, C). No expression was observed in the Nkx2.5 sense probe (Figure 4.7 D).  
 
 
Figure 4.7: Broad expression of Nkx2.5 in the early heart developmental 
stage. 
(A) Nkx2.5 expressed in the endocardial cushions of the atrioventricular canal. 
However, Nkx2.5 was not expressed in the mitral valve at (B) E13.5 and (C) 
E15.5. (D) Nkx2.5 sense probe showed no expression in the heart at E13.5. 
Scale bar: A-C= 100µm, D= 200µm. 
 




4.7.1.2.3 Aortic valve  
At E10.5, Nkx2.5 was found in most of the heart regions including the outflow 
tract, particularly the myocardial cells and mesenchymal cells lining the outflow 
tract (arrows) (Figure 4.8 A). However, Nkx2.5 expression was not detected in 
the aortic valve at E13.5 and E15.5 (Figure 4.8 B, C). No expression was 
observed in the Nkx2.5 sense probe (Figure 4.8 D). 
 
 
Figure 4.8: Broad expression of Nkx2.5 in the early heart developmental 
stage. 
(A) Nkx2.5 expressed in the endocardial cushions of the outflow tract. However, 
Nkx2.5 was not expressed in the aortic valve at (B) E13.5 and (C) E15.5. (D) 
Nkx2.5 sense probe showed no expression in the heart at E15.5. Scale bar: A-
C= 100µm, D= 200µm. 
 




4.7.1.2.4 Summary  
Overall, Nkx2.5 showed high expression in the endocardial cushions that form 
the future mitral and aortic valves as well as the left and right ventricular 
chambers in the early heart formation (E10.5). Nevertheless, this expression 
disappeared from these regions as the heart developed (E13.5 and E15.5). 
This therefore indicates a significant role for Nkx2.5 during the initial formation 
stage of these regions.  
Similar expression patterns of Nkx2.5 in mouse heart was previously reported 
(Tanaka et al., 1999; Scherptong et al., 2012), and beside its expression in 
heart it was also reported to express in head fold at E10.5 (Pu et al., 2013) 
(Figure 4.9 A) and in mantle layer of spinal cord, but not marginal layer at 
E13.5 and E15.5 (Visel et al., 2004) (Figure 4.9 B,C), this therefore was used 
as control in this section. 
 
 
Figure 4.9: Nkx2.5 expression at different stges. 
Nkx2.5 expression in embryonic mouse head fold at E10.5, and in the mantle 
layer (arrow), but not in the marginal layer (arrow head) at both E13.5 and E15.5. 
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The fact that Nkx2.5 expressed in the cardiac regions that affected in HLHS 
suggested that variations in Nkx2.5 could lead to the abnormalities observed 
in HLHS. However, at the same time, because the expression was not limited 
to the left-side structures, this also implicated that variations in this gene could 
affecting the left as well as the right-side structures at the same level, which 
could lead to abnormalities without HLHS features.  
  




 Notch1  
The Notch family member, Notch1, was mapped to find the expression pattern 
in the selected cardiac regions including atrioventricular canal, outflow tract, 
mitral valve, aortic valve, and the left ventricle at E10.5, E13.5 and E15.5.  
4.7.1.3.1 Left ventricle  
At E10.5, Notch1 was found in both the left and right ventricles, particularly in 
the endocardium of the left ventricle and epicardium and myocardium of the 
right ventricle (Figure 4.10 A). At E13.5, Notch1 expression was highly 
detected in the right more than the left ventricular endocardium (Figure 4.10 
B). At E15.5, however, Notch1 was reduced in both left and right ventricles 
(Figure 4.10 C). No expression was observed in the Notch1 sense probe 
(Figure 4.10 D). 
 






Figure 4.10: Notch1 expression in ventricles throughout the developmental 
stages. 
(A) Notch1 was expressed in the endocardium of the left ventricle and 
myocardium of the right ventricle at E10.5. Also, expression of Notch1 was 
observed in both the left and right ventricles at both (B) E13.5 and (C) E15.5, 
but higher in E13.5 than E15.5. (D) Notch1 sense probe showed no expression 
in the heart at E10.5. Scale bar = 200µm. 
  




4.7.1.3.2 Mitral valve  
Notch1 expression was localised to the endocardial cushions found in the 
atrioventricular canal (AVC), but not in the wall of AVC at E10.5 (Figure 4.11 
A). At E13.5, Notch1 was observed in the endothelial cells (arrows) and 
interstitial cells (asterisks) found in both posterior and anterior leaflets of the 
mitral valve (Figure 4.11 B). However, at E15.5, the expression of Notch1 was 
reduced from the endothelial and interstitial cells located in the mitral valve 
compared to that observed at E13.5 (Figure 4.11 C). No expression was 
observed in the Notch1 sense probe (Figure 4.11 D). 
  






Figure 4.11: Notch1 expression in the mitral valve throughout the 
developmental stages. 
(A) Notch1 was expressed in the endocardial cushion found in the 
atrioventricular canal at E10.5, but its expression was not identified in the wall 
of AVC. (B) At E13.5, Notch1 expressed in the endothelial cells (arrows) and 
interstitial cells (asterisk) of mitral valve leaflets. (C) Similarly, at E15.5, 
expression of Notch1 was detected in the leaflets of the mitral valve, but at low 
level than that seen in E13.5. Scale bar: A-C= 100µm, D= 200µm. 
  




4.7.1.3.3 Aortic valve 
At E10.5, Notch1 transcripts were found to be expressed in the endothelial 
cells lining the outflow tract as well as in the pericardium (Figure 4.12 A). At 
E13.5, Notch1 was expressed in the leaflets of the aortic valve, specifically in 
the subendothelial cells and weakly in the endothelial cells lining the leaflets 
(Figure 4.12 B). Likewise, at E15.5, Notch1 showed similar expression to that 
observed at E13.5 in the aortic valve leaflets (Figure 4.12 C). No expression 
was observed in the Notch1 sense probe (Figure 4.12 D). 
  






Figure 4.12: Notch1 expression in the aortic valve throughout the 
developmental stages. 
(A) At E10.5, restricted expression of Notch1 to the endocardium and endothelial 
cells (arrow) lining the outflow tract (OFT) tube, and pericardium (P, arrow), was 
observed. (B) At E13.5, Notch1 expression was in the subendothelial cells 
(arrows), but not in the endothelial cells (arrow heads). (C) At E15.5, Notch1 
expression was observed in the aortic valve, but at reduced level compared to 
that observed in E13.5. (D) Notch1 sense probe showed no expression in the 
heart at E15.5. Scale bar: A-C= 100µm, D= 200µm. 
  




4.7.1.3.4 Summary  
Overall, Notch1 expressed in the early stage (E10.5) at the endocardial 
cushions of the atrioventricular canal and the outflow tract, and the left 
ventricular endocardium. In later stages (E13.5 and E15.5), Notch1 was 
expressed in the mitral and aortic valves, as well as the left ventricle. Similar 
expression patterns of Notch1 were reported by Del Monte et al (2007). 
Altogether, Notch1 was expressed throughout the different developmental 
stages although the expression was higher at E10.5 and E13.5 than E15.5. 
The fact that Notch1 was mapped to the left ventricle and both the mitral and 
aortic valves indicates its significant roles in formations of these regions. 
Therefore, Notch1 could contribute to abnormalities observed in all the 
affected regions in HLH. 
  




 Notch3  
The Notch family member, Notch3, was mapped to find the expression pattern 
in the selected cardiac regions including atrioventricular canal, outflow tract, 
mitral valve, aortic valve, and the left ventricle at E10.5, E13.5 and E15.5.  
4.7.1.4.1 Left ventricle  
Notch3 was found to be mainly expressed in the epicardium of the left ventricle 
at E15.5 with very minor expression in the right ventricle (Figure 4.13 C). 
However, no expression was detected in the left ventricle at E10.5, neither at 
E13.5 (Figure 4.13 A,B). No expression was observed in the Notch3 sense 
probe (Figure 4.13 D). 
  






Figure 4.13:  Restricted expression of Notch3 to the left ventricle at E15.5. 
Notch3 was found to express in the left ventricle at E15.5 with low level 
expression in the right ventricle (C). No expression was found in the left ventricle 
at (A) E10.5 and (B) E13.5. (D) Notch3 sense probe showed no expression in 
the heart at E10.5. Scale bar = 200µm. 
  




4.7.1.4.2 Mitral valve  
Notch3 was not expressed in the endocardial cushions of the atrioventricular 
canal at E10.5 (Figure 4.14 A). Similarly, no expression was detected in the 
mitral valve leaflets at E13.5 (Figure 4.14 B), neither at E15.5 (Figure 4.14 C). 
No expression was observed in the Notch3 sense probe (Figure 4.14 D). 
 
 
Figure 4.14: No expression of Notch3 in the mitral valve. 
(A) No expression was found in the endocardial cushion of the atrioventricular 
canal (AVC) at E10.5. Also, no expression was detected in the mitral valve at 
(B) E13.5 nor (C) at E15.5. (D) Notch3 sense probe showed no expression in the 
heart at E13.5. Scale bar: A-C= 100µm, D= 200µm. 
 




4.7.1.4.3 Aortic valve  
Notch3 was not expressed in the endocardial cushions of the outflow tract at 
E10.5 (Figure 4.15 A). Similarly, no expression was detected in the aortic valve 
leaflets at E13.5 (Figure 4.15 B), neither at E15.5 (Figure 4.15 C). No 
expression was observed in the Notch3 sense probe (Figure 4.15 D). 
 
 
Figure 4.15: No expression of Notch3 in the aortic valve. 
(A) No expression was found in the endocardial cushion of the outflow tract 
(OFT) at E10.5. Also, no expression was detected in the aortic valve at (B) E13.5 
nor (C) at E15.5. (D) Notch3 sense probe showed no expression in the heart at 
E15.5. Scale bar: A-C= 100µm, D= 200µm. 
 




4.7.1.4.4 Summary  
Altogether, Notch3 did not express at the early developmental stages (E10.5 
and E13.5), whereas at E15.5 it expressed exclusively to the left ventricle. 
Although Notch3 expression was not previously reported in mouse heart at 
E10.5, it was reported in head fold at E10.5 (Mason et al., 2005) (Figure 4.16 
A) and in pulmonary artery and valve at E13.5 and E15.5 (Visel et al., 2004) 
(Figure 4.16 B,C) in which these regions were used here as controls.  
 
 
Figure 4.16: expression of Notch3 in the head fold at E10.5 and pulmonary 
artery and valve at E13.5 and E15.5. 
Scale bar: A=µm 50µm B,C= 100µm. 
 
Overall, the specific expression of Notch3 in the left ventricle at E15.5 
suggested that variations in Notch3 could cause abnormalities in the left 
ventricle, hence contributed to the left ventricular hypoplasia observed in 
HLHS.   
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 Notch4  
The Notch family member, Notch4, was mapped to find the expression pattern 
in the selected cardiac regions including atrioventricular canal, outflow tract, 
mitral valve, aortic valve, and the left ventricle at E10.5, E13.5 and E15.5.  
4.7.1.5.1 Left ventricle  
At E10.5, Notch4 was found in the left and right ventricular chambers, 
particularly localised to the ventricular endocardium (Figure 4.17 A). However, 
at E13.5 and E15.5, Notch4 expression was not detected in the left and right 
ventricles (Figure 4.17 B, C). No expression was observed in the Notch4 sense 
probe (Figure 4.17 D). 
 






Figure 4.17: Restricted expression of Notch4 to the ventricles at E10.5. 
(A) At E10.5, Notch4 expression was detected in the left and right ventricles. 
However, no expression was detected in the ventricles at (B) E13.5 and (C) 
E15.5. (D) Notch4 sense probe showed no expression in the heart at E10.5. 
Scale bar = 200µm. 
  




4.7.1.5.2 Mitral valve  
At E10.5, no expression of Notch4 was detected in the endocardial cushions 
of the atrioventricular canal (Figure 4.18 A). Similarly, at E13.5 and E15.5, the 
expression of Notch4 was not detected in the mitral valve leaflets (Figure 4.18 




Figure 4.18: No expression of Notch4 in the mitral valve. 
(A) No expression was found in the endocardial cushion of the atrioventricular 
canal (AVC) at E10.5. Also, no expression was detected in the mitral valve at 
(B) E13.5 nor (C) at E15.5. (D) Notch4 sense probe showed no expression in the 
heart at E13.5. Scale bar: A-C= 100µm, D= 200µm. 
 




4.7.1.5.3 Aortic valve 
At E10.5, no expression of Notch4 was detected in the endocardial cushions 
of the outflow tract (Figure 4.19 A). Similarly, at E13.5 and E15.5, the 
expression of Notch4 was not detected in the aortic valve leaflets (Figure 4.19 




Figure 4.19: No expression of Notch4 in the aortic valve. 
(A) No expression was found in the endocardial cushion of the outflow tract 
(OFT) at E10.5. Also, no expression was detected in the aortic valve at (B) E13.5 
nor (C) at E15.5. (D) Notch4 sense probe showed no expression in the heart at 
E15.5. Scale bar: A-C= 100µm, D= 200µm. 
 




4.7.1.5.4 Summary  
Altogether, Notch4 was highly expressed in the left and right ventricle at E10.5 
while no expression was detected in other cardiac regions in later 
developmental stages. Previous study had shown a general expression of 
Notch4 in mouse embryo at E11.5 and E15.5, where Notch4 was expressed 
in the spinal cord and brain while no expression in the heart was detected 
(Magdaleno et al., 2006). Other studies showed that Notch4 was expressed in 
the aorta and pulmonary arteries at E13.3 (Villa et al., 2001) and in the brain 
at E10.5 (Shirayoshi et al., 1997). Therefore, Notch4 expression in brain at 
E10.5 (Figure 4.20 A), aorta and pulmonary arteries at E13.5 (Figure 4.20 B), 
and spinal cord at E15.5 (Figure 4.20 C) was used as controls.  
 
Figure 4.20: Expression of Notch4 in the brain at E10.5, aorta and pulmonary 
arteries at E13.5 and spinal cord at E15.5. 
Scale bar: A= 50µm, B=150µm, C= 70µm. 
Overall, Notch4 demonstrated a specific expression in the left and right 
ventricles, which suggested that Notch4 played a role during early 
development of the ventricles and thus could contribute to the hypoplasia 
observed in the left ventricle of HLHS.  
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 Hand1  
Expression of Hand1 was mapped to the main regions of the heart affected in 
HLHS, including left ventricle, mitral valve and aortic valve. These regions 
were investigated at three different time-points: E10.5, E13.5 and E15.5. 
4.7.1.6.1 Left ventricle  
At E10.5, Hand1 demonstrated expression in the developing left ventricle 
(Figure 4.21 A) and the outer curvature of the developing right ventricle at low 
level (Figure 4.21 A arrow). At E13.5, Hand1 was expressed in endocardium 
and myocardium of the left and right ventricles but at a low level in the right 
ventricle compared to the left ventricular expression (Figure 4.21 B). Moreover, 
at E15.5, Hand1 was exclusively expressed in the endocardium of the left 
ventricle, whereas no expression was detected in the myocardium of the left 
ventricle, or in the right ventricle (Figure 4.21 C). No expression was observed 
in the Hand1 sense probe (Figure 4.21 D). 






Figure 4.21: Hand1 expressed in the left ventricle at different developmental 
stages. 
(A) At E10.5, Hand1 expressed in the endocardium of the left ventricle with low 
expression level in the right ventricle (arrow). Similarly, (B) at E13.5 and (C) 
E15.5, expression of Hand1 observed in the left ventricle and right ventricle. (D) 
Hand1 sense probe showed no expression in the heart at E10.5. Scale bar = 
200µm. 
  




4.7.1.6.2 Mitral valve 
At E10.5, no expression of Hand1 was detected in the endocardial cushions 
of the atrioventricular canal at this stage (Figure 4.22 A). At E13.5, Hand1 was 
expressed in the mitral valve, particularly in the endothelial cells covering the 
leaflets as well as in the interstitial cells found at the distal tip of developing 
primordia (Figure 4.22 B). At E15.5, Hand1 showed similar expression pattern 
to that seen in E13.5 as it was found in the endothelial cells and the interstitial 
cells of anterior and posterior leaflets of the mitral valve (Figure 4.22 C). No 
expression was observed in the Hand1 sense probe (Figure 4.22 D).  
  






Figure 4.22: Hand1 expressed in the mitral valve at E13.5 and E15.5. 
(A) At E10.5, Hand1 was not expressed in the endocardial cushions of the 
atrioventricular canal (AVC). However, (B) at E13.5, Hand1 was expressed in 
the endothelial cells (arrows) covering the leaflets of the mitral valve and the 
interstitial cells (asterisks) in the distal tip of developing primordia. (C) Similarly, 
at E15.5, both endothelial (arrows) and interstitial cells (asterisks) of the mitral 
valve leaflets expressed Hand1. (D) Hand1 sense probe showed no expression 
in the heart at E13.5. Scale bar: A-C= 100µm, D= 200µm. 
  




4.7.1.6.3 Aortic valve 
At E10.5, Hand1 was expressed in the in the early development of the outflow 
tract, particularly throughout the aortic sac at the distal end of the outflow tract 
(Figure 4.23 A). At E13.5, Hand1 was expressed in the wall of the aortic valve. 
Although Hand1 was not found in the endothelial cells lining the aortic valve 
leaflets (Figure 4.23 B arrows), it was found in the sub-endothelial cells located 
in the aortic valve leaflets. At E15.5, there was no expression of Hand1 in the 
sub-endothelial cells found in the aortic valve leaflets, whereas high 
expression was seen in the endothelial cells covering these leaflets (Figure 
4.23 C). No expression was observed in the Hand1 sense probe (Figure 4.23 
D). 
  






Figure 4.23: Hand1 expressed in the aortic valve throughout the different 
developmental stages. 
(A) Expression of Hand1 at E10.5 was detected in the in the mesenchymal cells 
(arrows) covering the outflow tract (OFT). (B) At E13.5, expression of Hand1 was 
detected in the sub-endothelial cells of the aortic valve leaflets (asterisks), but 
not in the endothelial cells covering the leaflets (arrows). (C) At E15.5, Hand1 
expression was restricted to the endothelial cells covering aortic valve leaflets. 
(D) Hand1 sense probe showed no expression in the heart at E15.5. Scale bar: 
A-C= 100µm, D= 200µm. 
  




4.7.1.6.4 Summary  
Altogether, Hand1 demonstrated high expression in the left ventricle and its 
associated valves throughout the different cardiac developmental stages. The 
expression patterns of Hand1 in this section was consistent with the previously 
reported expression (Huanget al, 2004; McFadden et al., 2005), as Hand1 
expression was observed in the early development of the outflow tract and left 
ventricle. The fact that Hand1 expressed highly in the left-side structures with 
minor expression in the right side indicated its essential role during early 
cardiogenesis. Since HLHS mainly affects the left side structures, Hand1 can 
contribute to the defects observed in the affected regions in HLHS, and hence 
it seems a significant gene for HLHS. Although the previously reported 
variation in this gene showed no HLHS features, but instead caused 
embryonic lethality, Hand1 has been implicated in survival of the embryo and 
thus Hand1 is important for cardiogenesis as well as embryogenesis. 
  




 Foxc2  
Expression of Foxc2 was mapped to the main regions of the heart affected in 
HLHS, including left ventricle, mitral valve and aortic valve. These regions 
were investigated at three different time-points: E10.5, E13.5 and E15.5. 
4.7.1.7.1 Left ventricle  
At the early development stage E10.5, Foxc2 was not expressed in the left 
and right ventricles (Figure 4.24 A). Likewise, at E13.5 and E15.5, there was 
no expression of Foxc2 in the left and right ventricles (Figure 4.24 B C). No 
expression was observed in the Foxc2 sense probe (Figure 4.24 D). 
  






Figure 4.24: No expression of Foxc2 in the left ventricle throughout the 
different developmental stages. 
(A) At E10.5, Foxc2 expression was not detected in the left and right ventricles. 
Also, no expression was detected in the ventricles at (B) E13.5 and (C) E15.5. 
(D) Foxc2 sense probe showed no expression in the heart at E10.5. Scale bar = 
200µm. 
  




4.7.1.7.2 Mitral valve  
At E10.5, no expression of Foxc2 was observed in the atrioventricular 
endocardial cushions (Figure 4.25 A). Also, Foxc2 was not expressed in the 
mitral valve at E13.5 and E15.5 (Figure 4.25 B C). No expression was 
observed in the Foxc2 sense probe (Figure 4.25 D). 
 
 
Figure 4.25: No expression of Foxc2 in the mitral valve throughout the 
different developmental stages. 
(A) At E10.5, Foxc2 expression was not observed in the endocardial cushions 
(EC) of the atrioventricular canal (AVC). Similarly, no expression of Foxc2 was 
detected in the mitral valve at (B) E13.5 and (C) E15.5. (D) Foxc2 sense probe 
showed no expression in the heart at E13.5. Scale bar: A-C= 100µm, D= 200µm. 




4.7.1.7.3 Aortic valve  
The early expression of Foxc2 was detected at E10.5 in the mesenchymal 
cells covering the cardiac tube (Figure 4.26 A). After that, Foxc2 became 
restricted to the aortic valve, as it was found in the endothelial cells covering 
the leaflets of the aortic valve at E13.5 (Figure 4.26 B) and sub-endothelial 
cells of the aortic valve leaflets as well as the wall of the aortic valve at E15.5 
(Figure 4.26 C). No expression was observed in the Foxc2 sense probe 
(Figure 4.26 D). 
  







Figure 4.26: Restricted expression of Foxc2 to the aortic valve during heart 
development. 
(A) At E10.5, Expression of Foxc2 was observed in the mesenchymal cells 
(arrows) covering the outflow tract (OFT). (B) At E13.5, Foxc2 was expressed in 
the endothelial cells (arrows) covering the aortic valve leaflets. (C) At E15.5, 
Foxc2 was detected in the endothelial cells (arrows) found in the aortic valve 
leaflets and wall. (D) Foxc2 sense probe showed no expression in the heart at 
E15.5. Scale bar: A-C= 100µm, D= 200µm. 
  




4.7.1.7.4 Summary  
Overall, Foxc2 expressed in the mesenchymal cells in the outflow tract at 
E10.5, before it became restricted to the aortic valve at E13.5 and E15.5. The 
expression of Foxc2 in this section was consistence with the previously 
reported expression of Foxc2 (Gitler et al., 2003; Uddin et al., 2016). Also, it 
was previously reported that expression of Foxc2 in endothelial cells covering 
the pulmonary and aorta arteries at E13.5 and E16.5, and hence it was used 
as controls (Figure 4.27 A,B) (Gitler et al., 2003). Altogether, Foxc2 is found 
mainly in the mesenchymal cells and then expressed exclusively in the aortic 
valve, which implicates its essential roles in early formation of the aortic valve. 
Particularly, during remodelling of valve leaflets, as aortic valve undergoes an 
endothelial–mesenchymal transformation (EMT) process during maturation of 
the valve leaflets and mesenchymal cells play important role during this 
process. Therefore, Foxc2 could contribute to the defects observed in the 
aortic valve of HLHS.   
 
 
Figure 4.27: Expression of Foxc2 at different stges. 
Expression of Foxc2 in endothelial cells covering the pulmonary and aorta 
arteries at E13.5 and E15.5. Scale bar = 150µm. 
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 Ets1  
Expression of Ets1 was mapped to the main regions of the heart affected in 
HLHS, including left ventricle, mitral valve and aortic valve. These regions 
were investigated at three different time-points: E10.5, E13.5 and E15.5. 
4.7.1.8.1 Left ventricle  
At E10.5, no expression of Ets1 was detected in the left and right ventricles 
(Figure 4.28 A). However, at E13.5, Ets1 expressed in the left and right 
ventricles (Figure 4.28 B). It was reported that Ets1 expressed in the epicardial 
and the myocardial cell membranes of the ventricles, which reflected the 
expression observed here (Figure 4.28) (Cao et al., 2010).  At E15.5, the 
expression of Ets1 was completely absent from both ventricles (Figure 4.28 
C). No expression was observed in the Ets1 sense probe (Figure 4.28 D). 
  






Figure 4.28: Expression of Ets1 in the left ventricle at E13.5. 
(A) No expression of Ets1 in the left ventricle at E10.5. (B) A membrane-like 
expression of Ets1 was found in the left and right ventricles at E13.5 (arrows = 
high power image of the left ventricle. (C) At E15.5, no expression of Ets1 was 
observed in the left and right ventricles. (D) Ets1 sense probe showed no 


















4.7.1.8.2 Mitral valve 
At E10.5, Ets1 was expressed in the endocardial cushions of the 
atrioventricular canal (Figure 4.29 A). At E13.5, strong expression of Ets1 was 
observed in the endothelial cells and the interstitial cells of the posterior leaflet 
of the mitral valve, whereas it was found only in the endothelial cells of the 
mitral valve anterior leaflet (Figure 4.29 B). At E15.5, the expression of Ets1 
was completely absent from the mitral valve (Figure 4.29 C). No expression 
was observed in the Ets1 sense probe (Figure 4.29 D). 
 
Figure 4.29: Expression of Ets1 in the mitral valve at E10.5 and E13.5. 
(A) At E10.5, Ets1 expressed in the endocardial cushions (EC) of the 
atrioventricular canal (AVC) and in the wall of AVC. (B) Expression of Ets1 was 
detected in in the endothelial cells lining the anterior and posterior leaflets of 
the mitral valve as well as in the interstitial cells in the distal tip of developing 
primordia at E13.5. (C) At E15.5, Ets1 was not expressed in the mitral valve. (D) 
Ets1 sense probe showed no expression in the heart at E13.5. Scale bar: A-C= 
100µm, D= 200µm. 




4.7.1.8.3 Aortic valve  
At E10.5, Ets1 was expressed in the outflow tract (Figure 4.30 A). Also, as 
previously reported (Cao et al, 2010), high level expression of Ets1 was 
observed in the mesenchymal cells located in the aortic sac at E10.5 (Figure 
4.30 A). At E13.5, Ets1 was strongly expressed in the endothelial cells 
covering the aortic leaflets, but not in the subendothelial cells of the leaflets 
(Figure 4.30 B). At E15.5, the expression of Ets1 however was completely 
absent from the aortic valve (Figure 4.30 C). No expression was observed in 
the Ets1 sense probe (Figure 4.30 D). 
  






Figure 4.30: Expression of Ets1 in the aortic valve at E10.5 and E13.5. 
(A) Ets1 was expressed in the mesenchymal cells covering the outflow tract tube 
and the endocardial cushion (EC) of the outflow tract (arrows). (B) At E13.5, 
Ets1 expressed in the endothelial cells (arrows) covering the leaflets of the aortic 
valve, but not in the sub-endothelial cells. (C) At E15.5, no expression of Ets1 
was detected. (D) Ets1 sense probe showed no expression in the heart at E15.5. 
Scale bar: A-C= 100µm, D= 200µm. 
  




4.7.1.8.4 Summary  
Altogether, Ets1 showed strong expression in the early stages (E10.5 and 
E13.5) of the mitral and aortic valve formation as well as in the developing right 
and left ventricles at E13.5. However, this expression completely reduced as 
heart developed E15.5. Similar expression of Ets1 was previously reported in 
mouse and chick embryos (Lie-Venema et al., 2003; Cao et al., 2010). Overall, 
Ets1 shows essential roles during early heart development, which illustrated 
through its expression patterns at E10.5 and E13.5. These two stages are 
important for initial formation of valves and left ventricle, therefore Ets1 could 
contribute to the abnormalities observed in the aortic and mitral valves as well 
as the left ventricle hypoplasia of HLHS.   
  





Expression of Pcdha9 was mapped to the main regions of the heart affected 
in HLHS, including left ventricle, mitral valve and aortic valve. These regions 
were investigated at three different time-points: E10.5, E13.5 and E15.5. 
4.7.1.9.1 Left ventricle  
Pcdha9 expression was absent from the left and right ventricles at E10.5 
(Figure 4.31 A). Similarly, the expression of Pcdha9 was absent from both left 
and right ventricles at E13.5 and E15.5 (Figure 4.31 B C). No expression was 
observed in the Pcdha9 sense probe (Figure 4.31 D). 
  






Figure 4.31: No expression of Pcdha9 in the left ventricle at different 
developmental stages. 
No expression of Pcdha9 was detected in the left and right ventricles at (A) 
E10.5, (B) E13.5, and (C) E15.5. (D) Pcdha9 sense probe showed no expression 
in the heart at E10.5. Scale bar = 200µm. 
  




4.7.1.9.2 Mitral valve 
At E10.5, Pcdha9 expression was strongly detected in the endocardial 
cushions of the atrioventricular canal (Figure 4.32 A). However, at later stages 
(E13.5 and E15.5) the expression of Pcdha9 was absent from the mitral valve 
(Figure 4.32 B C). No expression was observed in the Pcdha9 sense probe 
(Figure 4.32 D). 
 
 
Figure 4.32: Restricted expression of Pcdha9 in the endocardial cushions 
at E10.5. 
(A) Pcdha9 expressed in the endocardial cushions (EC) of the atrioventricular 
canal (AVC). No expression of Pcdha9 was detected in the mitral valve (B) at 
E13.5, nor (C) at E15.5. (D) Pcdha9 sense probe showed no expression in the 
heart at E13.5. Scale bar: A-C= 100µm, D= 200µm. 
 




4.7.1.9.3 Aortic valve 
Strong expression of Pcdha9 was identified at E10.5 in the outflow tract and 
the mesenchymal cells found in the aortic sac (Figure 4.33 A). However, this 
expression was absent from the developed aortic valve at E13.5 and E15.5 
(Figure 4.33 B C). No expression was observed in the Pcdha9 sense probe 
(Figure 4.33 D). 
 
 
Figure 4.33: Restricted expression of Pcdha9 in the endocardial cushions 
at E10.5. 
(A) Pcdha9 expressed in the endocardial cushion (EC) of the outflow tract 
(arrows) and Pcdha9 was expressed in the mesenchymal cells covering the 
outflow tract (OFT) tube. Pcdha9 was not expressed in the aortic valve at (B) 
E13.5 and (C) E15.5. (D) Pcdha9 sense probe showed no expression in the heart 
at E15.5. Scale bar: A-C= 100µm, D= 200µm. 
 




4.7.1.9.4 Summary  
Altogether, Pcdha9 is strongly expressed in the early cardiac developmental 
stage E10.5 and absent from the later stages of heart development E13.5 and 
E15.5. Expression of Pcdha9 was previously reported using a quantitative 
PCR analysis, where Pcdha9 expressed the highest in heart at E9.5. However, 
Pcdha9 showed low expressions at E10.5, E13.5 and E15.5 (Liu et al., 2017). 
Expression study of Pcdha9 using in situ hybridization in E9.5 mouse embryo 
showed localisation of its transcripts in brain and spinal cord; thus these 
regions were used as controls for this study (Figure 4.34 A,B,C) (Liu et al., 
2017). Overall, expression of Pcdha9 in the endocardial cushions during early 
development of the aortic and mitral valves suggests that Pcdha9 can 
contribute to the valve abnormalities associated with HLHS.   
  
Figure 4.34: Expression of Pcdha9 at different stges. 
Expression of Pcdha9 in the brain at E10.5, and spinal cord at E13.5 and E15.5. 
Scale bar: A= 50µm, B,C= 70µm.  
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Expression of Sap130 was mapped to the main regions of the heart affected 
in HLHS, including left ventricle, mitral valve and aortic valve. These regions 
were investigated at three different time-points: E10.5, E13.5 and E15.5. 
4.7.1.10.1 Left ventricle  
At E10.5, Sap130 was not expressed in the left and right ventricles (Figure 
4.35 A). However, Sap130 expression was highly found in both the 
endocardium and myocardium of the left and right ventricles at E13.5 (Figure 
4.35 B). Likewise, at E15.5, Sap130 was highly expressed in the endocardium 
with low expression in the myocardium of left and right ventricles (Figure 4.35 
C). No expression was observed in the Sap130 sense probe (Figure 4.35 D). 






Figure 4.35: Expression of Sap130 in the left ventricle during development 
of heart. 
(A) No expression of Sap130 detected in the left and right ventricles at E10.5. 
However, Sap130 expression was detected in the left and right ventricular 
myocardium and endocardium at (B) E13.5, whereas only in the endocardium at 
(C) E15.5. (D) Sap130 sense probe showed no expression in the heart at E10.5. 
Scale bar = 200µm. 
  




4.7.1.10.2 Mitral valve  
At E10.5, Sap130 was expressed in the endocardial cushions of the 
atrioventricular canal (Figure 4.36 A). At E13.5, Sap130 expression was 
observed in the interstitial cells filling the mitral valve leaflets, but not in the 
endothelial cells covering the leaflets (Figure 4.36 B). However, at E15.5, the 
expression of Sap130 was seen in both interstitial and endothelial cells of the 
mitral valve leaflets (Figure 4.36 C). No expression was observed in the 
Sap130 sense probe (Figure 4.36 D). 
  






Figure 4.36: Expression of Sap130 in the mitral valve during development 
of heart. 
(A) Sap130 expressed in the endocardial cushions (EC) of the atrioventricular 
canal (AVC). (B) At E13.5, expression of Sap130 was detected in the interstitial 
cells (asterisk), but not in the endothelial cells (arrow heads) of the mitral valve 
leaflets. (C) However, at E15.5, Sap130 was expressed in the interstitial cells 
(asterisk) and the endothelial cells (arrows) of the mitral valve leaflets. (D) 
Sap130 sense probe showed no expression in the heart at E13.5. Scale bar: A-
C= 100µm, D= 200µm. 
  




4.7.1.10.3 Aortic valve  
At E10.5, Sap130 expression was seen in the outflow tract and the 
mesenchymal cells found in the aortic sac (Figure 4.37 A). Expression of 
Sap130 in the aortic valve at E13.5 was localised to both endothelial and 
subendothelial cells of covering the leaflets (Figure 4.37 B), whereas at E15.5 
it was only localised to the endothelial cells covering the leaflets (Figure 4.37 
C). No expression was observed in the Sap130 sense probe (Figure 4.37 D). 
 
Figure 4.37: Expression of Sap130 in the aortic valve during development 
of heart. 
(A) At E10.5, Sap130 was expressed in mesenchymal cells (arrows) and the 
endocardial cushion (EC) of the outflow tract. (B) At E13.5, Sap130 was 
expressed in endothelial cells (arrow) and subendothelial cells of the aortic valve 
leaflets. (C) At E15.5, on the other hand, expression of Sap130 was detected in 
the endothelial cells (arrows) covering the leaflets of the aortic valve. (D) Sap130 
sense probe showed no expression in the heart at E15.5. Scale bar: A-C= 
100µm, D= 200µm. 




4.7.1.10.4 Summary  
Altogether, expression of Sap130 was detected throughout the different 
developmental stages. Sap130 expression was previously reported using a 
quantitative PCR analysis, where Sap130 expressed the highest in heart at 
E9.5, whereas other stages including E10.5, E13.5 and E15.5 showed lower 
expression level than that at E9.5 (Liu et al., 2017). Also, expression study of 
Sap130 using in Sap130-lacZ knockout (KO)-first allele in E9.5 and E13.5 
mouse embryo showed that ubiquitous LacZ expression throughout the whole 
embryo (Liu et al., 2017). The fact that Sap130 expresses in the cardiac 
cushions and mesenchymal cells at E10.5 and then become localised to the 
endothelial cells in the valves at later stages, suggesting it important role 
during initial formation and remodelling of valve leaflets. Also, because it 
expresses in the left and right ventricular endocardium, this suggests a role in 
the developing the ventricles. Therefore, Sap130 could contribute to 
abnormalities observed in the ventricle and valves of HLHS. 
  





Expression of Rbfox2 was mapped to the main regions of the heart affected in 
HLHS, including left ventricle, mitral valve and aortic valve. These regions 
were investigated at three different time-points: E10.5, E13.5 and E15.5. 
4.7.1.11.1 Left ventricle  
At E10.5, Rbfox2 was not expressed in the right and left ventricles (Figure 4.38 
A). However, at E13.5, Rbfox2 highly expressed in the left and right ventricles 
(Figure 4.38 B). The expression of Rbfox2 became more in the left than the 
right ventricular endocardium at E15.5 (Figure 4.38 C). No expression was 
observed in the Rbfox2 sense probe (Figure 4.38 D). 
 






Figure 4.38: Expression of Rbfox2 in the left ventricle at E13.5 and E15.5. 
(A) Rbfox2 expression was not detected in the left and right ventricles at E10.5. 
However, Rbfox2 was highly expressed in the left and right ventricles at (B) 
E13.5 and (C) E15.5; higher expression in the left ventricle compared to the right 
ventricle was detected, particularly in the endocardium. (D) Rbfox2 sense probe 
showed no expression in the heart at E10.5. Scale bar = 200µm. 
  




4.7.1.11.2 Mitral valve  
Expression of Rbfox2 was expressed in the endocardial cushions of the 
atrioventricular canal at E10.5 (Figure 4.39 A). At E13.5, Rbfox2 was 
expressed in the interstitial cells, but not in the endothelial cells of mitral valve 
leaflets (Figure 4.39 B). Similarly, at E15.5, the expression of Rbfox2 was 
detected in the interstitial cells in the tips of mitral valve leaflets (Figure 4.39 
C). No expression was observed in the Rbfox2 sense probe (Figure 4.39 D). 
 
Figure 4.39: Expression of Rbfox2 in the mitral valve during different 
developmental stages. 
(A) Rbfox2 expressed in the endocardial cushions (EC) of the atrioventricular 
canal (AVC) at E10.5. (B) Expression of Rbfox2 was detected in the interstitial 
cells (asterisk), but not in the endothelial cells (arrow heads) covering the mitral 
valve leaflets at E13.5. (C) Similarly, at E15.5, Rbfox2 was expressed in the 
interstitial cells (asterisk) found in the tips (arrows) of the mitral valve leaflets. 
(D) Rbfox2 sense probe showed no expression in the heart at E13.5. Scale bar: 
A-C= 100µm, D= 200µm. 




4.7.1.11.3 Aortic valve 
At E10.5, Rbfox2 expressed in the endocardial cushions of the outflow tract 
(Figure 4.40 A). At E13.5, it expressed in the sub-endothelial cells of the aortic 
valve leaflets and aortic valve wall (Figure 4.40 B), whereas at E15.5 Rbfox2 
expression became restricted to the sub-endothelial cells found in the aortic 
valve leaflets (Figure 4.40 C). No expression was observed in the Rbfox2 
sense probe (Figure 4.40 D). 
  






Figure 4.40: Expression of Rbfox2 in the aortic valve during different 
developmental stages. 
(A) At E10.5, Rbfox2 was expressed in the endocardial cushion (EC) of the 
outflow tract. (B) At E13.5, Rbfox2 was expressed in the sub-endothelial cells of 
the aortic valve leaflets as well as the wall of the aortic valve (arrows).  (C) At 
E15.5, while expression of Rbfox2 was detected in the sub-endothelial cells 
found in the leaflets of the aortic valve (arrows), no expression was seen in the 
aortic valve wall (arrow heads) (D) Rbfox2 sense probe showed no expression 
in the heart at E15.5. Scale bar: A-C= 100µm, D= 200µm. 
  




4.7.1.11.4 Summary  
Altogether, Rbfox2 showed a strong expression in the endocardial cushion of 
the future mitral and aortic valves at E10.5, whereas no expression was seen 
in the ventricles at the same stage. At E13.5, high expression of Rbfox2 in the 
ventricles was observed, which then restricted to the left ventricle at E15.5. 
Expression of Rbfox2 was reported to be broadly expressed throughout the 
embryo including brain and cartilage at E14.5 (Visel et al., 2004). Thus, 
expression of Rbfox2 at these regions was used as control (Figure 4.41 A-C). 
Overall, the fact that Rbfox2 expressed in the endocardial cushions and in the 
left ventricle, the affected regions in HLHS, implicates its roles during the initial 
formation of these regions. This, therefore, suggests that Rbfox2 can 
contribute to the abnormalities observed in HLHS.  
 
 
Figure 4.41: Expression of Rbfox2 at different stges. 
Expression of Rbfox2 in the Brian at E10.5 and cartilage at E13.5 and E15.5 
(arrows). A= 50µm, B,C= 70µm. 
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 Critical analysis of HLHS-implicated genes 
In summary, there are several genes that were suggested to implicate in HLHS 
including Gja1, Nkx2.5, Notch family, Hand1, Foxc2, Ets1, Pcdha9, Sap130 
and Rbfox2. The expression pattern for these genes was mapped during the 
crucial time points of development of the important cardiac regions in HLHS. 
A summary of these genes and where they expressed at different 
developmental stages as well as how they relevant to HLHS is illustrated in 











Table 4.12: HLHS implicated genes. 
 
E10.5 E13.5 E15.5 Comments 
OFT AVC LV RV AoV MV LV RS AoV MV LV RS 
Gja1 
✗ ✗ ✓ ✓ ✗ ✗ ✓ RV ✗ ✗ ✓ RV Gja1 expressed at the initial stages of 
ventricular formations, which could indicate its 
fundamental roles in hypoplasia of the left 
ventricle found in HLHS. However, since this 
gene was mapped to both left and right 
ventricles, it suggests that variations in this 
gene would affect both ventricles equally. 
Therefore, this gene seems less significant to 
HLHS. 
Nkx2.5 
✓ ✓ ✓ ✓ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ Nkx2.5 expressed during early developmental 
stage of valves and both ventricles. This 
suggested that Nkx2.5 could affect early 
cardiac development with no specification to 
the left-side structure of the heart. Thus, 
Nkx2.5 seems less significant to HLHS. 
Notch1 
✓ ✓ ✓ ✓ ✓ ✓ ✓ RV 
PulV 
TV 
✓ ✓ ✓ RV 
PulV 
Notch1 expressed during all developmental 
stages with no specification to one side. 
Although this suggested the importance of 
Notch1 for heart development, it also 
suggested that Notch1 could lead to defects in 




both sides of the heart. Hence, Notch1 seems 
less significant to HLHS. 
Notch3 
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✓ RV 
PulV 
Notch3 expressed in the left ventricle at E15.5 
with minor expression in the right ventricle, 
which suggested that Notch3 played roles in 
the later developmental stage of the left 
ventricle. This therefore highlights its significant 
for defects associated with the left ventricle in 
HLHS, particularly in the miniturised group or 
the thick-walled ventricle group of HLHS. 
Hence, Notch3 seems significant for HLHS. 
Notch4 
✗ ✗ ✓ ✓ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ Expression of Notch4 was found in the left and 
right ventricles at E10.5, with no expression at 
later stages. This indicated its roles in the early 
developing of the ventricles. Since Notch4 
expressed in the left and right ventricles, it 
could contribute to defects in both ventricles 
equally. This therefore makes Notch4 less 
significant for HLHS.  
Hand1 
✓ ✗ ✓ ✓ ✓ ✓ ✓ RV 
TV 
✓ ✓ ✓ RV 
TV 
Hand1 expressed in most of the interesting 
regions in HLHS except the atrioventricular 
cushions, which suggested its important roles 
in developing the left sided structures of the 
heart. However, the fact that modeling the 
suggested Hand1 mutation in mice produced 
severe heart abnormalities but normal left 




ventricle size; and knocking out Hand1 
completely caused embryonic lethality; 
illustrated the important of maintaining its 
regulation during heart development. 
Nevertheless, the expression patterns of 
Hand1 makes it an interesting gene that needs 
to be investigated further in order to 
understand the mechanisms behind its 
functions. Therefore, Hand1 seems to be 
significant for HLHS.  
Foxc2 
✓ ✗ ✗ ✗ ✓ ✗ ✗ ✗ ✓ ✗ ✗ ✗ Foxc2 expressed in the outflow tract at E10.5 
and then restricted to the aortic valve, which 
suggested its essential roles in the formation 
and developing of the aortic valve. Thus, Foxc2 
could contribute to the malformation affecting 
the aortic valve in HLHS, particularly HLHS 
subgroup with severe aortic valve 
malformation, such as the thick-walled ventricle 
group. Therefore, Foxc2 seems significant for 
HLHS. 
Ets1 
✓ ✓ ✗ ✗ ✓ ✓ ✓ RV 
TV 
✗ ✗ ✗ ✗ Expression of Ets1 was mapped at E10.5 to 
the endocardial cushions and E13.5 to the 
aortic and mitral valves and left ventricle, but 
no expression was seen at E15.5. This 
suggested that Ets1 could involve in the 
original development of the valves as well as 




the ventricular morphogenesis. However, the 
fact that Ets1 expressed in these regions and 
in the right-side regions indicated that this gene 
could also cause abnormalities in both sides 
equally. Therefore, Ets1 seems less significant 
to HLHS. 
Pcdha9 
✓ ✓ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ Expression of Pcdha9 was mapped to the 
endocardial cushions at E10.5, but not to the 
left ventricle, nor in any other cardiac regions at 
later developmental stages. This suggested 
that Pcdha9 played roles in the early formation 
of valves through endocardial cushions. Thus, 
Pcdha9 could contribute to the abnormalities 
associated with the mitral and aortic valves in 
HLHS. Since Pcdha9 affects both endocardial 
cushions of the outflow tract (future aortic 
valve) and atrioventricular canal (future mitral 
valve) at the same level, this suggests that 
Pcdha9 contributes to the abnormalities 
associated with HLHS subgroup that has 
similar defect level of mitral and aortic valve; 
such as the miniaturized ventricle group. 
Therefore, Pcdha9 seems significant to HLHS.  
Sap130 
✓ ✓ ✗ ✗ ✓ ✓ ✓ RV ✓ ✓ ✓ RV Expression of Sap130 was mapped to most of 
the regions in the heart throughout the different 
stages, excluding the left/right ventricles at 








E10.5. The fact that Sap130 expressed in the 
left and right sides of heart and also throughout 
the embryonic body (Liu et al, 2017), 
suggested that this gene had multiple roles 
throughout the heart and the rest of the body, 
and thus losing its functions could not only lead 
to heart defects, but also to embryonic lethality. 
Therefore, this gene seems less significant for 
HLHS. 
Rbfox2 
✓ ✓ ✗ ✗ ✓ ✓ ✓ RV 
PulV 
TV 
✓ ✓ ✓ PulV Expression of Rbfox2 was mapped in all the 
heart regions of HLHS throughout the different 
stages, excluding left/right ventricle at E10.5. 
The ubiquitous expression of Rbfox2 
suggested essential roles for this gene during 
heart development. However, since this gene 
was also expressed outside the heart, 
suggested a significant role for Rbfox2 not only 
in the heart but in normal development of 
embryo. Therefore, Rbfox2 seems less 
significant for HLHS.  
OFT: outflow tract, AVC: atrioventricular canal, LV: left ventricle, RV: right ventricle, AoV: aortic valve, MV: mitral valve, RS: right 
structure of the heart, PulV: pulmonary valve, TV: tricuspid valve.
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4.8 Discussion  
Although several genes have been proposed to implicate in hypoplastic left 
heart syndrome (HLHS), none of these genes were confirmed as being 
pathogenic with a clear mechanism underpinning the development of HLHS 
delineated (Liu et al., 2017, Firulli et al., 2017). In this study, however, the most 
significant genes for HLHS were highlighted and their potential functions and 
expressions during heart development, particularly in the specific structures 
that are affected in HLHS were described. The analysed genes in this study 
included Gja1, Nkx2.5, Notch1,3,4, Hand1, Foxc2, Ets1, Pcdha9, Sap130, and 
Rbfox2. Investigation of their expression patterns during development of the 
affected regions in HLHS illustrated their potential involvement in 
formation/functionality of these regions. Although some of these genes 
presented broad expression throughout the developmental stages, some 
genes, such as Notch3, Hand1, Foxc2, and Pcdha9, showed specific 
expression to the cardiac regions of HLHS. Hence, this demonstrated their 
essential roles in developing these regions and at the same time suggesting 
the subgroup of HLHS that could potentially cause.    
As yet, no genetically engineered animal models have been generated for 
HLHS. Although several animal models have been proposed for HLHS, none 
of them showed left ventricular hypoplasia in the setting of an intact ventricular 
septum with maintaining the ventriculoarterial and atrioventricular connections 
(Grossfeld et al., 2019). The difficulty in generating appropriate animal model 
was explained for specific epigenetic factors, such as NKx2.5, by a 
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combination of genetic, environmental and epigenetic factors, which proposed 
to be necessary to cause HLHS (Schulkey et al., 2015). However, conditional 
deletion of Nkx2.5 in murine ventricle generated a cardiomyopathic phenotype 
accompanied with BMP10 upregulation. This over-expression of BMP10 in 
murine left/right ventricles produced a thinned compact layer with increased 
ventricular trabeculations, and hence loss of chamber cavity. Although this 
model had proposed that the hypoplastic left ventricular cavity was caused by 
overgrowth of the trabecular layer, rather than the compact layer 
(Pashmforoush et al., 2004). This model also affected the right ventricular 
cavity, which suggested less specificity for left ventricular hypoplasia. 
Therefore, Nkx2.5 is less significance for HLHS. 
Previous studies have implicated Notch1 as one cause of hypoplastic left 
ventricle in HLHS (Garg et al., 2005; McBride et al., 2008). It was reported that 
loss-of-function mutations in Notch1 in Drosophila led to increase cardiac 
myocytes and a total loss of pericardial cells. Hence, it generated an abnormal 
bifid heart with a diminished chamber volume (Hartenstein et al., 1992). The 
investigation in this chapter showed that Notch1 expressed in endocardial 
cushions, endocardium and myocardium during murine cardiac development. 
This suggested that defects in one or all of these cell lines could lead to 
produce the phenotypic findings of HLHS. Nevertheless, knocking out the 
Notch intracellular domain (NICD1), which is important for subcellular 
localisation, in mice did not show the anticipated phenotypes of HLHS 
(Watanabe et al., 2006). Instead, several cardiac abnormalities including 
atrioventricular myocardium defect, disrupted cardiomyocyte differentiation, 
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and intraventricular septum shifting to the right were generated (Watanabe et 
al., 2006). Hence, Notch1 has a very high penetrance and can produce various 
cardiac defects.  
Similar to Notch1, loss-of-function mutations in Ets1 in Drosophila 
demonstrated an increased number of cardiomyocytes with a loss of 
pericardial cells in the posterior aspect of the heart tube, which thought to 
resemble the left ventricle in mammalian heart (Alvarez et al, 2003). In addition 
to that, the expression patterns for Ets1, in this chapter and consistent with 
(Ye et al., 2010) study, was mapped to the endocardial cushions, neural crest 
cells and endocardium. This therefore suggested that abnormalities in these 
cells, or at least one of them, could produce HLHS phenotypic features. 
Nevertheless, Ets1 neural crest cells knockout embryos and Ets1 cardiac 
mesodermal knockdown embryos did not generate the anticipated features of 
HLHS. Instead these embryos exhibited either various cardiac defects 
including double outlet right ventricle and isolated dilation of the ascending 
aorta, or growth arrest in the left ventricle leading to small and thin-wall looking 
ventricle and eventually die at E11 (Kelle et al., 2015; Snider et al., 2014). 
Therefore, Ets1 seems less significance for HLHS.  
There were other suggested genes for HLHS including Gja1, Notch3 and 
Notch4 that showed specific expressions in the ventricles. Expression of Gja1 
was found mainly in the myocardial cells of left and right ventricles and thus 
knocking down Gja1 in mice caused a reduction in myocardial gap junctions 
and altered the structure and function of both ventricles, yet did not cause 
HLHS phenotypic features (Flenniken et al., 2005). Similarly, although Notch4 
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was mapped to the early heart development (E10.5) of the left and right 
ventricles and in vascular endothelial cells (Costa et al., 2013), knocking out 
its expression did not cause HLHS. In fact, it did not even lead to any 
detectable abnormalities, but rather mice developed normally. Conversely, 
homozygous loss of Notch1 and Notch4 in mice caused vascular abnormalities 
and embryonic lethality, which compared to the homozygous Notch1 null mice 
that developed the same abnormalities but less severity than that observed in 
the combination (Krebs et al., 2000; Costa et al., 2013). This suggested that 
Notch4 plays a role in vascular development, which remains unknown, but it 
definitely exacerbated the consequence of Notch1 deficiency. However, the 
consequences of knocking out Notch3 was found to decrease the progenitor 
cells and resulted in small arterioles with abnormal vessels on the cardiac 
ventricular wall (Tao et al. 2017). Although these changes were reported in 
adult mice (7-9 month-old), this implicated a significant role for Notch3 in 
vascular maturation during embryogenesis. There is less knowledge about the 
specific roles of Notch3 during heart development, but its expression in the 
late developmental stage of the left ventricle suggested an interesting role for 
Notch3 during the left ventricle formation. Therefore, Notch3 may contribute to 
the left ventricular abnormalities associated with HLHS.  
Other genes, such as Foxc2, which were found to express in the aortic valve 
and associated with HLHS and other congenital heart defects (CHD). The fact 
that Foxc2 was mapped to mesenchymal cells of the outflow tract highlighted 
the possibility of producing HLHS phenotypic features through abnormalities 
in these cells. Association of FOXC2 with HLHS patients has been suggested. 
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A study using high-resolution oligonucleotide array identified variants in 
FOXC2 in 2 out of 7 patients with HLHS (Stankiewicz et al., 2009). Likewise, 
variants in FOXC2 were identified in 23 out of 53 patients with HLHS (Iascone 
et al., 2012), although the biological significance of these Foxc2 variants 
remains unknown. These findings in addition to Foxc2 expression pattern, 
suggest that Foxc2 may contribute to at least abnormalities in the aortic valve 
observed in HLHS. Further investigation of Foxc2 roles, particularly in the 
mesenchymal cells, remains important, as it is quite possible that Foxc2 may 
have other yet to be determined impacts on HLHS.  
Some of the implicated genes in HLHS showed very similar expression pattern 
including Rbfox2 and Sap130, as they expressed in the regions of interest for 
HLHS at different developmental stages and also in various regions of the 
body, particularly in brain. In addition to Rbfox2 embryonic expression in the 
heart, it expressed postnatally during heart remodelling; which suggested an 
important role for Rbfox2 in embryonic and postnatal heart development 
(Partridge and Carter, 2017; Ye et al, 2017). Double knockdown of 
Rbfox1l/Rbfox2 in zebrafish embryos labelled with GFP myocardial cells 
showed ventricular defects in these embryos. Nevertheless, injection of these 
embryos with rbfox2 alone rescued the heart ventricle, which indicated its 
significant roles in the left ventricular growth (Gallagher et al., 2011). Similarly, 
Sap130 was reported to express in the embryonic heart and new-born heart. 
Knockdown of sap130a in Zebrafish revealed a reduce in ventricular 
cardiomyocytes at 72 h postfertilization, when the first heart field cells found in 
the heart (Cordero-Espinoza et al., 2013). Hence, Sap130 was suggested to 
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involve in cardiomyocyte cell proliferation and cell cycle arrest. However, the 
cellular and molecular mechanisms driving the hypoplastic left ventricle 
through Rbfox2 and Sap130 remain unknown. Therefore, further investigation 
is needed to understand their roles in hypoplasia of the left ventricle.  
The fact that Hand1 was mapped to the left side structures of the heart, 
particularly to epicardium, endocardium and outflow tract neural crest cells 
indicated essential roles for Hand1 during cardiogenesis (Barnes et al., 2010). 
The suggested causation of HLHS was a mutation in HAND1A126fs (Reamon-
Buettner et al, 2008), which was directly tested in mice. Although neither 
Mef2CAHF-Cre (targeting endothelial SHF) and Nkx2.5Cre (targeting SHF) 
resulted in HLHS when crossed to the HAND1SFA126fs allele, these Cre drivers 
caused elongated outflow tract and eventually led to early embryonic lethality 
(Firulli et al., 2017). Therefore, it was suggested that the HAND1A126fs mutation 
was not biologically relevant to HLHS, yet mutations within Hand1 enhancer 
domain that changes its spatiotemporal expression and led to less deleterious 
effects would be more likely to associate with HLHS. The association of 
Pcdha9 with HLHS has been suggested, although its roles in cardiogenesis 
remains largely unknown. Nonetheless, expression patterns of Pcdha9 
implicated roles for this gene in formation of valves as it was found in the 
endocardial cushions of the outflow tract (future aortic valve) and 
atrioventricular canal (future mitral valve). Therefore, further investigation on 
the significant of Pcdha9 during heart development is required to understand 
its association with HLHS. 
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Together, these data suggest that some HLHS implicated genes showed very 
specific expression patterns, particularly at the regions of HLHS, whereas 
other genes showed broad expression throughout the embryo. Although the 
genes with broad expressions showed significant roles during cardiogenesis 
and possible association with HLHS, the likelihood of these genes to be the 
main causative of HLHS seems low. It is speculated that Notch3, Hand1, 
Foxc2, and Pcdha9 would be more likely to correlate, based on their 
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4.9 Summary  
In summary, there have been several genes implicated for HLHS in which 
some of them showed low significance for being a HLHS causative. This 
indeed can be explained by the low prevalence of HLHS, which makes many 
genetic studies pooling HLHS cases with other phenotypically related heart 
malformations and this hence raises questions about relevance of these genes 
to HLHS. Also, from the current study, it is well-recognised that HLHS has 
various subgroups that can be caused by different genes and these subgroups 
need to be analysed separately to avoid implication of insignificant genes to 
HLHS. In this chapter, evaluation of all the suggested genes for HLHS was 
performed. Description of HLHS-implicated genes roles and detecting their 
expression patterns were carried out using the main developmental stages for 
HLHS. Some genes showed very broad and less significant association with 
HLHS including Gja1 and Sap130, whereas other genes showed specific 
expression to the affect regions of HLHS. Further, these genes were linked to 
the potential subgroup of HLHS that could be resulted from mutations within 
that gene.  
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Hypoplastic left heart syndrome (HLHS) is a severe form of congenital heart 
defect that affects multiple regions of the hearts to a varying degree. In this 
study, a series of 78 hearts from the Birmingham Children’s Hospital (using 
the standard valve-based classification method), classified as having HLHS, 
was re-analysed and a novel classification method was proposed, based on 
the ventricular phenotypes. Hence, three distinctive ventricular morphologies 
were identified: slit-like ventricle, thick-walled ventricle and miniaturised 
ventricle. Although the standard valve-based classification reflects the clinical 
approach to treatment, it does not demonstrate the genetic aspect of HLHS. 
However, the proposed ventricular classification provides possible 
explanations for HLHS developmental origins and hence reveals a route for 
genetic studies via the perspective of progenitor contributions to particular 
affected structures in HLHS. In addition, the fact that the thick-walled 
ventricular group has resulted in categorising the AA/MS and severe AS/MS 
clinical groups that showed identical anatomical features as one group, while 
presenting great differences between the other clinical groups. This 
demonstrates the advantage of the ventricular-based classification, as it 
presents the HLHS hearts with similar ventricular morphology together to 
highlight parallel genetic causes for both the AA/MS and severe AS/MS 
subgroups. Moreover, although HLHS is routinely diagnosed through 
echocardiogram; which provides high frequency sound waves to generate 
moving images of heart structure and blood flow; classification of HLHS 
subgroups using the valve-based classification can be misleading. For 
example, severe aortic stenosis could be misclassified because imperceptible 
blood flow through the aortic valve would categorise as aortic atresia. Whereas 
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this could be due to the left ventricle being unable to pump blood to the aortic 
valve and with the aortic valve being severely affected the blood would not 
appear to flow through it. Therefore, utilizing the ventricular-based 
classification should provide accurate indication of HLHS subgroups. 
Altogether, the ventricular-based classification demonstrates a good basis for 
exhibiting the different HLHS subgroups.  
The current study not only suggested a novel classification of HLHS, it also 
showed the importance of archival heart collections in understanding the 
morphological appearances of HLHS in the different subgroups. On the basis 
of the close similarity of hearts in the three identified subgroups, it is suggested 
that it could be used as a basis for genetic studies of HLHS. However, because 
formalin was used to preserve the archival hearts, using these hearts for 
molecular studies would be a challenge. This is because formalin disrupts the 
chromosomal DNA in these tissues, resulting in corrupt and short sequencing 
reads from that DNA. This hence generates sequences with various artefacts 
that cannot be distinguished from heterozygosity. This current study described 
a cheap and scalable in-house method that allowed the extraction and 
sequencing of high-quality DNA from long-term formalin-fixed materials. It was 
previously reported that reliable sequencing data could only be obtained from 
tissues that had been fixed in formalin for no longer than one day (Einaga et 
al., 2017). However, this study proved that it was possible to extract DNA and 
generate a reliable sequencing data from tissues fixed for up to 2 years using 
the improved method. Using Next Generation Sequencing (NGS) with the 
GATK best practice pipeline, described in chapter 4, generated high specificity 
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for detecting variants in DNA sequencing, with moderate sensitivity. However, 
using Sanger sequencing generated unreliable data that cannot be used to 
discover new rare variants, but it remains useful to confirm identified variants. 
Altogether, both NGS and Sanger sequencing demonstrated variable degree 
of accuracy for detecting variants in DNA extracted from formalin-fixed tissues, 
and hence it would not be recommended to use archival tissues except to 
check for variants that were previously identified in fresh tissues.  
The genetic aetiology of HLHS has been supported with a growing body of 
evidence throughout the years (Shokeir, 1974, Hinton et al., 2008). To date, 
there are three suggested transmission patterns of HLHS: autosomal 
recessive, autosomal dominant and polygenic inheritance. Since there are 
three ventricular subgroups of HLHS described in this study, it may be that 
there are different aetiologies for different HLHS subgroups. Therefore, in this 
study, evaluation of the HLHS-implicated genes was carried out in respect to 
their potential functions and expression during heart development, in the 
specific structures that are affected in HLHS. The analysed genes in this study 
included Gja1, Nkx2.5, Notch1-4, Hand1, Foxc2, Ets1, Pcdha9, Sap130, and 
Rbfox2. There were some genes that demonstrated broad expression and did 
not appear to be good candidates for causing the very specific and 
reproducible phenotypes seen in HLHS. In contrast, other genes showed 
specific expression to the regions affected by HLHS. Further, these genes 
could be linked to a potential subgroup of HLHS, based on the precise 
ventricular and valve phenotypes seen in each group. Further investigation is 
needed to gather additional evidence for an association between these genes 
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and a particular subgroup of HLHS. Even though numerous reports have 
implicated some of these genes in HLHS, identification of specific genes or 
variants remains challenging. This can be explained by the low prevalence of 
HLHS, which meant that several genetic studies pooled HLHS cases with 
other phenotypically related (and sometimes unrelated) heart malformations 
and this hence raises questions about relevance of these genes to HLHS. 
Also, from the current study, it is well-recognised that HLHS has various 
subgroups that could be caused by different genes, suggesting that it might be 
a good idea to analyse the subgroups separately. For example, a study carried 
out by Zuffardi group (2012), which used a defined-group of HLHS based on 
Tchervenkov et al. 2006 classification of HLHS, identified most of the HLHS-
implicated genes (Iascone et al., 2012). Hence, further subgrouping of HLHS 
could lead to identify the specific gene(s) for the desired HLHS subgroup.   
Altogether, the current study highlighted the potential importance of using a 
unique subgroup of HLHS in order to find the causative genes for HLHS. 
Therefore, future work will involve using a well-defined, carefully phenotyped 
and homogeneous subgroup of HLHS, ideally the slit-like ventricular group of 
HLHS (SLV-HLHS). This is because the SLV-HLHS group showed atresia or 
absence of both mitral and aortic valves as well as a highly uniform slit-like 
ventricular cavity, suggesting that all the HLHS regions are equally affected. 
Hence, speculation about the causative gene(s) for the SLV-HLHS group 
suggests that they might influence the remodelling of the valves, together with 
left ventricular growth, if each region is affected primarily, or just the valves if 
this is a sequence with the ventricular phenotype secondary to the valve 
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defects. Therefore, collecting samples from patients with the SLV-HLHS and 
performing exome sequencing on these sample will allow the identification of 
genes that are specific for this subgroup. In order to filter the data and home 
in on likely relevant genes, one strategy would be to generate a list of specific 
genes (from RNaseq at relevant stages of development, for examples when 
the valves are remodelling) that are only found in the HLHS-affected cardiac 
regions, from normal human embryonic heart. These regions would include 
the mitral valve, aortic valve and left ventricle, collected from human embryonic 
heart at CS14, CS17 and CS22, equivalent to the mouse embryonic stages of 
E10.5, E13.5 and E15.5 respectively. Filtering the exome patient data 
according to the RNAseq data of the normal heart regions will allow 
identification of genes that are variant in the patients and expressed in the 
regions of interest. This could provide a useful approach to identify the gene(s) 
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In summary, the aims of the current thesis were to establish on morphological 
grounds, using archival specimens, whether it was possible to devise an 
alternative way of classifying HLHS, which could be related to how the 
phenotypes seen in HLHS develop, that might be useful for genomic studies. 
As archived hearts were used to develop this new classification, it was then 
desirable to establish an improved method to extract high quality DNA with 
reliable and reproducible sequence information, from formalin-fixed tissues, so 
that the archived hearts with HLHS could themselves be used for genomic 
studies. Finally, as it was concluded that DNA obtained from formalin-fixed 
studies was best suited to confirming genes implicated from other methods, 
rather than for primary gene detection, the expression patterns of genes 
previously implicated in HLHS were examined, taking into account their 
localisation to both the valves and the ventricular chambers.  
Analysis of the HLHS archival collection demonstrated three distinctive 
ventricular subgroups of HLHS including slit-like ventricle, thick-walled 
ventricle and miniaturised ventricle. The proposed ventricular-based 
classification of HLHS in this study not only provided easy and firm approach 
to subgroup HLHS, but also facilitated the identification of causative genes for 
different HLHS subgroup through linking each HLHS subgroup to its possible 
origins of defect.  
It was also hypothesised that it would be possible to extract high quality DNA 
with reliable and reproducible sequence information from archival formalin 
fixed tissues and this would eventually be useful for identifying causative 
genes of specific HLHS subgroup by using the archival specimens. In fact, it 
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was possible to extract DNA from tissue fixed in formalin and carry out PCR 
using the proposed method in chapter 4. This proposed method allowed to 
generate high quality DNA from tissues fixed in formalin for up to two years. 
Since elevated quantity of DNA was obtained from the two-year tissues, it was 
speculated that it was possible to obtain DNA from tissues that were fixed in 
formalin for longer than two years. However, using the formalin extracted DNA 
to perform next generation sequencing (NGS) led to generate high specificity 
with moderate sensitivity sequencing reads. Whereas, with Sanger 
sequencing, unreliable reads that could not be possible to separate formalin 
artefacts from, for example, heterozygosity were obtained. Thus, both NGS 
and Sanger sequencing demonstrated variable degree of accuracy for 
detecting variants in DNA extracted from formalin-fixed tissues, and hence it 
would not be recommended to use archival tissues except to check for variants 
that were previously identified in fresh tissues 
Finally, it was hypothesised that the implicated HLHS genes showed 
expression patterns that reflected their potential functions during heart 
development, and this therefore would allow linking these genes to HLHS 
subgroups. Although some HLHS-implicated genes, including Gja1 and 
Sap130, showed very broad expression patterns, and thus it was hard to 
associate them with the HLHS phenotypes, other genes showed specific 
expression to the affected regions of HLHS. It was speculated that Notch3, 
Hand1, Foxc2, and Pcdha9 would be more likely to correlate with, based on 
their expression patterns, the abnormalities associated with various subgroups 
of HLHS. 
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Together, these data suggest that HLHS is a well-recognised defect that 
composes of various distinctive subgroups. These HLHS subgroups can be 
caused by different genes and therefore they have to be analysed separately 
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Table 8.1: The reported frequency of HLHS occurring over the last 40 years. 
 




Phenotypes Comment Reference 
Birmingham, UK ?? 0.03%   Not indicated  Barron et. al, 
2009 
Malta  1977-1994   0.4 % classical HLHS 
0.6% HLHS variants 





USA 1979-1988 0.016-0.036% 





Not indicated National Center for 
Health Statistics. 
Fruitman, 2000 
Bohemia 1980  1.4–3.8% stenotic and atretic mitral 
and aortic valves 




1981-1982  3.8% Not indicated No phenotype was given Goldmuntz, 2003 
California, USA 1995 and 
1999 
 2-3% No phenotype was given Hospital discharge 
database 
Gordon et. al, 
2008 




Reller et. al, 2008 
Cincinnati, USA 
 
2004-2006 0.02% of 
HLHS  
 
2% of HLHS associated 
with CVM 
Atresia and stenosis of 
left-side valves with 
intact atrial septum. 






Hinton et. al., 
2007 




Table 8.2: List of HLHS hearts used in the study including the measurements performed. 





































83-101 slit-like no no absent absent Slit-like 1.17 5   24 42 3 13.4 6 10.72 AA/MA 
6032-92 slit-like no no absent absent slit like 3.1 5.8   25.3 34.6 4 15.4 8.6 8.6 AA/MA 
66-183 slit-like no no absent absent slit-like 4.33 5.46   28.14 38 2.7 14.6 2.5 8.6 AA/MA 
67-153 slit-like no no absent absent slit like 2.2 2.6 - 18.2 32.8 1.5 13.8 - - AA/MA 
68-100 slit-like no no absent absent slit like  5 3.8 - 31 39 2.54 13.3 7.4 8.1 AA/MA 
70-132 slit-like no no absent absent Slit-like  3.26 7.6   35 48 4.68 17 7.4 6.5 AA/MA 
76-71 slit-like no no absent absent Slit-like 3 4.9 - 26.05 33.7 3.9 16.7 4.08 12.9 AA/MA 
79-39 slit-like no no absent absent slit-like 1.53 3.9   28.8 34.9 4.1 13.97 - - AA/MA 
79-73 slit-like no no absent absent slit like 1.95 3   29 36 2.9 16 1.8 10.7 AA/MA 
79-76 slit-like no no absent absent slit like 4.25 7.6   24.5 31.6 4.3 15 6.9 12.2 AA/MA 
74-106 slit-like no no small  absent slit-like 2.2 4.5 - 25.3 30.5 3.3 13.1 2 14 AA/MA 
4-94 slit-like no no absent absent  slit-like 3.8 4.9 - 30.5 38.4 5.2 17.8 5 13.8 AA/MA 
57-149 slit-like no no absent absent slit-like 2.4 3.4 - 24 29.5 2.1 13.3 4.8 7 AA/MA 
59-317 slit-like no no absent absent slit-like 2.6 4.2 - 22 36 1.9 12 - - AA/MA 
60-4 slit-like no no normal absent  slit-like 2.4 3.8 - 18 25 2.1 12.9 1.4 5.5 AA/MA 
62-261 slit-like no no absent absent slit-like 3.5 4.8 - 27 34 2.8 14.7 10 12.5 AA/MA 
69-140 slit-like no no absent bicupsid slit-like 4.1 6.9 - 25 36 4.7 15.6 - - AA/MA 




70-75 slit-like no no absent absent slit-like 3.6 3.6 - 22 32 1.86 14.4 3.4 11.5 AA/MA 
73-10 slit-like no no absent absnet slit-like 2.5 4.2 - 23.1 27 3.9 14.9 5.7 6.3 AA/MA 
68-159 Thick walled ventricle yes yes Image absent small 6.5 4.5 1.9 23.5 37.2 4.7 13.5 3 10.6 AA/MS 
68-190 Thick walled ventricle yes yes normal absent Small 12.4 4.3 1.7 26 34 5.3 13.7 4.7 6.7 AA/MS 
69-148 Thick walled 
ventricle 
yes no normal absent small 5.3 6.2 1 20.2 38 3 16.3 7.2 6.8 
AA/MS 
69-89 Thick walled ventricle yes yes normal absent moderate  8.35 4.2 1.2 22 33 6.6 12.59 6 12.2 AA/MS 
71-119 Thick walled ventricle yes yes Image Dysplastic moderate  7.5 6.1 2.1 25 33 4.2 13 1.4 11.9 AA/MS 
77-09 Thick walled ventricle yes yes normal absent small 7.1 7.17 1 16 33 6.5 14.4 5.6 12.3 AA/MS 
77-55 Thick walled ventricle yes yes normal absent small 6.8 4 0.1 21 37 5.9 12.2 1.2 6.8 AA/MS 
77-70 Thick walled ventricle yes yes normal not opened small  9.74 4.8 1.81 27 35.3 6.7 13.15 4.5 4.5 AA/MS 
79-111 Thick walled ventricle yes yes normal absent small 4.6 3.25 26.8 33.3 43   - - - AA/MS 
79-51 Thick walled ventricle yes yes normal unicuspid small 4.37 4.4 0.5 18.09 32 7.23 12.2 2.4 10.5 AA/MS 
79-89 
Thick walled 
ventricle yes yes normal unicuspid small 11.3 7 1.7 22 41 9.85 16.4 5.3 12.4 AA/MS 
80-42 Thick walled ventricle yes yes normal absent small 11.8 5.9 0.3 23.7 41.3 6 16 6 15 AA/MS 
84-06 Thick walled ventricle yes yes normal absent small 4.8 5 0.9 28.4 49 6.1 13.6 4.1 12.6 AA/MS 
55-186 Thick walled ventricle yes yes normal  absent small 9.8 4.6 1 24.5 34 3.7 14.6 - - AA/MS 
62-300 Thick walled ventricle yes yes normal absent small 7.5 4.7 1.8 26 37 5.7 14.2 3.6 10.7 AA/MS 
62-32 Thick walled ventricle yes yes normal absent small 6.2 3.2 0.9 17.9 29.6 4.7 12.4 - - AA/MS 
64-106 Thick walled ventricle yes yes normal absent small 9.7 4.5 2.8 22.6 31.5 6.1 12.5 - - AA/MS 
66-216 Thick walled ventricle yes yes normal absent small 9.3 3.3 1.6 23.3 37.9 5.5 16.8 - - AA/MS 
67-144 
Thick walled 
ventricle yes yes normal with nodules absnet small 6.9 5.1 1.1 19.8 31 3 13 3.6 9.5 AA/MS 






ventricle yes yes normal absent small 6 5.2 1 24 35 4.35 17.1 3.5 12.9 AA/MS 
70-11 Thick walled ventricle yes yes normal absent small 7.7 4.9 1.9 24.6 33.7 2.8 14.1 5.3 8.2 AA/MS 
70-31 Thick walled ventricle yes yes normal  absent small 6.6 3.7 0.9 20.7 31.9 3.3 15.3 3.3 11.3 AA/MS 
72-143 Thick walled ventricle yes yes normal absent small 11 6.9 1 23.7 33.2 3.8 16.7 1.4 13 AA/MS 
74-92 Thick walled ventricle yes yes normal absent small 9.8 5.4 0.9 28 34.3 2.4 12.5 1.5 8.2 AA/MS 
75-8 Thick walled 
ventricle 
yes yes normal absent small 6.1 3.7 0.8 19.4 30.5 4.5 13.4 1.7 13.5 
AA/MS 
75-96 Thick walled ventricle yes yes normal dysplastic absent small 6.4 5.7 1.3 26.6 37.7 5.4 15.1 1.9 6.6 AA/MS 
76-111 Thick walled ventricle yes yes normal absent Small 8.2 4.6 - 24.7 32.8 4.4 13.2 1.88 9.9 AA/MS 
77-25 Thick walled ventricle yes yes dysplastic  absent small 7.3 4.6 2.3 19.8 37.4 4.7 11.7 5.5 6.6 AA/MS 
56-188 Thick walled ventricle yes yes dysplastic absent small 4.5 3.4 0.85 18.2 29 3.6 13.1 - - AA/MS 
62-362 Thick walled ventricle yes yes dysplastic absent small 8.5 5.2 1.6 28.2 38.8 5 17.4 14 13.5 AA/MS 
50-273 Thick walled ventricle yes yes dysplastic absent small 7.3 3.4 1.1 24 33.2 5.7 14.1 - - AA/MS 
60-354 Thick walled ventricle yes yes dysplastic absent moderate 8 4.3 1.5 20 27 8.9 15 3.3 9.6 AA/MS 
79-124 Thick walled 
ventricle 
no no normal absent small 3.45 3.05 - 22.5 30.9 4.18 14.3 5.9 5.9 
AA/MS 
8-91 Thick walled ventricle no yes dysplastic absent small 6.2 4.7 - 29.37 37 5.7 12.4 2 12 AA/MS 
80-85 Thick walled ventricle no yes normal  absent small 8.2 4 - 31 36 4.2 14.3 0.1 13 AA/MS 
71-68 Thick walled ventricle yes yes normal  small small 6.8 5.4 1.4 25 38 6.7 14.6 1.6 12 AS/MS 
74-66 Thick walled ventricle yes yes normal small Small 7.7 5 2 26.4 37.3 4.3 11.7 4 15 AS/MS 
75-81 Thick walled ventricle yes yes normal normal moderate 7.3 5.9 1 33 39 5.6 13 2 2 AS/MS 
84-81 Thick walled ventricle yes yes normal bicuspid moderate 6 5.1 2 32 36.5 8.5 13.9 18 26 AS/MS 






ventricle yes yes normal bicuspid small  5.3 6.9 1.5 24.8 33 6.5 13.6 - - AS/MS 
-26 Thick walled ventricle yes yes normal dysplastic moderate 6.1 3.8 2.2 25 33.8 7.2 16.2 10.1 11 AS/MS 
42-77 Thick walled ventricle yes yes normal dysplastic (bicuspid) small 6.2 5.1 1.2 25 37.4 3.2 10.9 - - AS/MS 
49-260 Thick walled ventricle yes yes normal dysplastic small 3.8 2.7 1.2 14.9 33 3.4 10.4 4.8 8.8 AS/MS 
82-59 Thick walled ventricle yes yes small small small 4.5 6.9 0.8 23 40.1 5.4 10.7 4.6 9.6 AS/MS 
42-109 Thick walled 
ventricle 
yes yes dysplastic normal dysplastic moderate 5.3 5.4 1.7 30 42 8.9 15.2 3.3 15.2 
AS/MS 
80-55 Thick walled ventricle no no normal dysplastic small 6.9 5.4 - 26 41 5.9 16.8 13.8 13.8 AS/MS 
59-14 Thick walled ventricle no yes normal with nodules bicupsid moderate 9.9 6.9 ? 34 42 9.9 14.5 0.9 14.1 AS/MS 
71-170 Thick walled ventricle yes yes normal normal moderate 3.4 6.3 1.3 23 30 8 13.3 9 17 AS/MS 
73-132 Thick walled ventricle yes  yes normal normal small  6.9 4.4 2.5 23 34 7.2 12.2 4 4 AS/MS 
73-57 Thick walled ventricle yes yes normal normal small 4.5 5 0.8 26.4 37.5 7.35 14.9 2 12 AS/MS 
74-105 Thick walled ventricle yes yes normal normal small 8 3.3 4.8 30.4 42.3 8.4 12.1 3.1 15 AS/MS 
74-109 Thick walled ventricle yes yes normal normal large 7.2 4.4 2 27.7 33.5 7.8 13 1.5 8.4 AS/MS 
63-136 Thick walled 
ventricle 
yes no normal normal well-
formed 
8.4 5.6 2.7 40 40 9.3 18 6.3 17.6 
AS/MS 
63-113 Thick walled ventricle yes yes normal normal small 7.7 3.8 1.8 24 34 5.5 13.1 1.3 8.5 AS/MS 
67-187 Miniaturised ventricle no no normal normal 
well-
formed 4.5 4.35 - 26 32.5 4.9 13.3 - - AS/MS 
69-35 Miniaturised ventricle no yes normal normal small  4.7 5.3 - 31 36 7.7 12.2 6.5 9.5 AS/MS 
75-48 Miniaturised ventricle no no normal normal large 3.5 3.3 - 38 45.5 7.7 13.7 6.8 14 AS/MS 
75-90 Miniaturised ventricle no small normal normal Small 4.7 4.9 - 26 31 4.7 14.5 6.5 6 AS/MS 




4.9 5.6 - 21 27.6 6.4 13.1 2 11.4 
AS/MS 
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